
<html lang="en"     class="pb-page"  data-request-id="c0dffe61-8528-409d-9a7b-bf014179c976"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm900166t;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2009.52.issue-15;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="9-(Arenethenyl)purines as Dual Src/Abl Kinase Inhibitors Targeting the Inactive Conformation: Design, Synthesis, and Biological Evaluation" /></meta><meta name="dc.Creator" content="Wei-Sheng  Huang" /></meta><meta name="dc.Creator" content="Xiaotian  Zhu" /></meta><meta name="dc.Creator" content="Yihan  Wang" /></meta><meta name="dc.Creator" content="Mohammad  Azam" /></meta><meta name="dc.Creator" content="David  Wen" /></meta><meta name="dc.Creator" content="Raji  Sundaramoorthi" /></meta><meta name="dc.Creator" content="R. Mathew  Thomas" /></meta><meta name="dc.Creator" content="Shuangying  Liu" /></meta><meta name="dc.Creator" content="Geetha  Banda" /></meta><meta name="dc.Creator" content="Scott P.  Lentini" /></meta><meta name="dc.Creator" content="Sasmita  Das" /></meta><meta name="dc.Creator" content="Qihong  Xu" /></meta><meta name="dc.Creator" content="Jeff  Keats" /></meta><meta name="dc.Creator" content="Frank  Wang" /></meta><meta name="dc.Creator" content="Scott  Wardwell" /></meta><meta name="dc.Creator" content="Yaoyu  Ning" /></meta><meta name="dc.Creator" content="Joseph T.  Snodgrass" /></meta><meta name="dc.Creator" content="Marc I.  Broudy" /></meta><meta name="dc.Creator" content="Karin  Russian" /></meta><meta name="dc.Creator" content="George Q.  Daley" /></meta><meta name="dc.Creator" content="John  Iuliucci" /></meta><meta name="dc.Creator" content="David C.  Dalgarno" /></meta><meta name="dc.Creator" content="Tim  Clackson" /></meta><meta name="dc.Creator" content="Tomi K.  Sawyer" /></meta><meta name="dc.Creator" content="William C.  Shakespeare" /></meta><meta name="dc.Description" content="A novel series of potent dual Src/Abl kinase inhibitors based on a 9-(arenethenyl)purine core has been identified. Unlike traditional dual Src/Abl inhibitors targeting the active enzyme conformatio..." /></meta><meta name="Description" content="A novel series of potent dual Src/Abl kinase inhibitors based on a 9-(arenethenyl)purine core has been identified. Unlike traditional dual Src/Abl inhibitors targeting the active enzyme conformatio..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 2, 2009" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm900166t" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2009 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm900166t" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm900166t" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm900166t" /></link>
        
    
    

<title>9-(Arenethenyl)purines as Dual Src/Abl Kinase Inhibitors Targeting the Inactive Conformation: Design, Synthesis, and Biological Evaluation | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm900166t" /></meta><meta property="og:title" content="9-(Arenethenyl)purines as Dual Src/Abl Kinase Inhibitors Targeting the Inactive Conformation: Design, Synthesis, and Biological Evaluation" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0001.jpeg" /></meta><meta property="og:description" content="A novel series of potent dual Src/Abl kinase inhibitors based on a 9-(arenethenyl)purine core has been identified. Unlike traditional dual Src/Abl inhibitors targeting the active enzyme conformation, these inhibitors bind to the inactive, DFG-out conformation of both kinases. Extensive SAR studies led to the discovery of potent and orally bioavailable inhibitors, some of which demonstrated in vivo efficacy. Once-daily oral administration of inhibitor 9i (AP24226) significantly prolonged the survival of mice injected intravenously with wild type Bcr-Abl expressing Ba/F3 cells at a dose of 10 mg/kg. In a separate model, oral administration of 9i to mice bearing subcutaneous xenografts of Src Y527F expressing NIH 3T3 cells elicited dose-dependent tumor shrinkage with complete tumor regression observed at the highest dose. Notably, several inhibitors (e.g., 14a, AP24163) exhibited modest cellular potency (IC50 = 300−400 nM) against the Bcr-Abl mutant T315I, a variant resistant to all currently marketed therapies for chronic myeloid leukemia." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm900166t"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm900166t">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm900166t&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm900166t&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm900166t&amp;href=/doi/10.1021/jm900166t" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2009</span><span class="cit-fg-volume">, 52</span><span class="cit-fg-issue">, 15</span><span class="cit-fg-pageRange">, 4743-4756</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/52/15" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm9002654" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm900261f" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">9-(Arenethenyl)purines as Dual Src/Abl Kinase Inhibitors Targeting the Inactive Conformation: Design, Synthesis, and Biological Evaluation</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wei-Sheng++Huang">Wei-Sheng Huang</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiaotian++Zhu">Xiaotian Zhu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yihan++Wang">Yihan Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mohammad++Azam">Mohammad Azam</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David++Wen">David Wen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Raji++Sundaramoorthi">Raji Sundaramoorthi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=R.+Mathew++Thomas">R. Mathew Thomas</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shuangying++Liu">Shuangying Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Geetha++Banda">Geetha Banda</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Scott+P.++Lentini">Scott P. Lentini</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sasmita++Das">Sasmita Das</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qihong++Xu">Qihong Xu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeff++Keats">Jeff Keats</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Frank++Wang">Frank Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Scott++Wardwell">Scott Wardwell</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yaoyu++Ning">Yaoyu Ning</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joseph+T.++Snodgrass">Joseph T. Snodgrass</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marc+I.++Broudy">Marc I. Broudy</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Karin++Russian">Karin Russian</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=George+Q.++Daley">George Q. Daley</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John++Iuliucci">John Iuliucci</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David+C.++Dalgarno">David C. Dalgarno</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tim++Clackson">Tim Clackson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tomi+K.++Sawyer">Tomi K. Sawyer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=William+C.++Shakespeare">William C. Shakespeare</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Division of Hematology/Oncology, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, The Children’s Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115</span></div><div class="corresp-info"><strong>*</strong>To whom correspondence should be addressed. Phone: 617-621-2341. Fax: 617-494-8144. E-mail: <a href="/cdn-cgi/l/email-protection#681f0d01451b000d060f46001d09060f28091a01090c460b0705"><span class="__cf_email__" data-cfemail="1f687a76326c777a717831776a7e71785f7e6d767e7b317c7072">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm900166t&amp;href=/doi/10.1021%2Fjm900166t" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2009</span></span><span class="cit-volume">, 52</span><span class="cit-issue">, 15</span><span class="cit-pageRange">, 4743–4756</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 2, 2009</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>9 February 2009</li><li><span class="item_label"><b>Published</b> online</span>2 July 2009</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 August 2009</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm900166t" title="DOI URL">https://doi.org/10.1021/jm900166t</a></div><div class="article_header-article-copyright"><strong>Copyright © 2009 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4743%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DWei-Sheng%2BHuang%252C%2BXiaotian%2BZhu%252C%2BYihan%2BWang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D52%26issueNum%3D15%26contentID%3Djm900166t%26title%3D9-%2528Arenethenyl%2529purines%2Bas%2BDual%2BSrc%252FAbl%2BKinase%2BInhibitors%2BTargeting%2Bthe%2BInactive%2BConformation%253A%2BDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4756%26publicationDate%3DAugust%2B2009">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm900166t"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3642</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">35</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm900166t" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;9-(Arenethenyl)purines as Dual Src/Abl Kinase Inhibitors Targeting the Inactive Conformation: Design, Synthesis, and Biological Evaluation&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Wei-Sheng&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Xiaotian&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Yihan&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Mohammad&quot;,&quot;last_name&quot;:&quot;Azam&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Wen&quot;},{&quot;first_name&quot;:&quot;Raji&quot;,&quot;last_name&quot;:&quot;Sundaramoorthi&quot;},{&quot;first_name&quot;:&quot;R.&quot;,&quot;last_name&quot;:&quot;Mathew Thomas&quot;},{&quot;first_name&quot;:&quot;Shuangying&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Geetha&quot;,&quot;last_name&quot;:&quot;Banda&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;P. Lentini&quot;},{&quot;first_name&quot;:&quot;Sasmita&quot;,&quot;last_name&quot;:&quot;Das&quot;},{&quot;first_name&quot;:&quot;Qihong&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Jeff&quot;,&quot;last_name&quot;:&quot;Keats&quot;},{&quot;first_name&quot;:&quot;Frank&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;Wardwell&quot;},{&quot;first_name&quot;:&quot;Yaoyu&quot;,&quot;last_name&quot;:&quot;Ning&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;T. Snodgrass&quot;},{&quot;first_name&quot;:&quot;Marc&quot;,&quot;last_name&quot;:&quot;I. Broudy&quot;},{&quot;first_name&quot;:&quot;Karin&quot;,&quot;last_name&quot;:&quot;Russian&quot;},{&quot;first_name&quot;:&quot;George&quot;,&quot;last_name&quot;:&quot;Q. Daley&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;Iuliucci&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;C. Dalgarno&quot;},{&quot;first_name&quot;:&quot;Tim&quot;,&quot;last_name&quot;:&quot;Clackson&quot;},{&quot;first_name&quot;:&quot;Tomi&quot;,&quot;last_name&quot;:&quot;K. Sawyer&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;C. Shakespeare&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2009&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;02&quot;,&quot;issue&quot;:&quot;15&quot;,&quot;volume&quot;:&quot;52&quot;,&quot;pages&quot;:&quot;4743-4756&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm900166t&quot;},&quot;abstract&quot;:&quot;A novel series of potent dual Src/Abl kinase inhibitors based on a 9-(arenethenyl)purine core has been identified. Unlike traditional dual Src/Abl inhibitors targeting the active enzyme conformation, these inhibitors bind to the inactive, DFG-out conformation of both kinases. Extensive SAR studies led to the discovery of potent and orally bioavailable inhibitors, some of which demonstrated in vivo efficacy. Once-daily oral administration of inhibitor 9i (AP24226) significantly prolonged the survival of mice injected intravenously with wild type Bcr-Abl expressing Ba/F3 cells at a dose of 10 mg/kg. In a separate model, oral administration of 9i to mice bearing subcutaneous xenografts of Src Y527F expressing NIH 3T3 cells elicited dose-dependent tumor shrinkage with complete tumor regression observed at the highest dose. Notably, several inhibitors (e.g., 14a, AP24163) exhibited modest cellular potency (IC50 = 300−400 nM) against the Bcr-Abl mutant T315I, a variant resistant to all currently marketed therapies &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm900166t&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm900166t" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm900166t&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm900166t" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm900166t&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm900166t" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm900166t&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm900166t&amp;href=/doi/10.1021/jm900166t" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm900166t" /></input><a href="/doi/pdf/10.1021/jm900166t" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm900166t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm900166t%26sid%3Dliteratum%253Aachs%26pmid%3D19572547%26genre%3Darticle%26aulast%3DHuang%26date%3D2009%26atitle%3D9-%2528Arenethenyl%2529purines%2Bas%2BDual%2BSrc%252FAbl%2BKinase%2BInhibitors%2BTargeting%2Bthe%2BInactive%2BConformation%253A%2BDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D52%26issue%3D15%26spage%3D4743%26epage%3D4756%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292529" title="Aromatic compounds">Aromatic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=291026" title="Conformation">Conformation</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/52/15" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900166t&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A novel series of potent dual Src/Abl kinase inhibitors based on a 9-(arenethenyl)purine core has been identified. Unlike traditional dual Src/Abl inhibitors targeting the active enzyme conformation, these inhibitors bind to the inactive, DFG-out conformation of both kinases. Extensive SAR studies led to the discovery of potent and orally bioavailable inhibitors, some of which demonstrated in vivo efficacy. Once-daily oral administration of inhibitor <b>9i</b> (AP24226) significantly prolonged the survival of mice injected intravenously with wild type Bcr-Abl expressing Ba/F3 cells at a dose of 10 mg/kg. In a separate model, oral administration of <b>9i</b> to mice bearing subcutaneous xenografts of Src Y527F expressing NIH 3T3 cells elicited dose-dependent tumor shrinkage with complete tumor regression observed at the highest dose. Notably, several inhibitors (e.g., <b>14a</b>, AP24163) exhibited modest cellular potency (IC<sub>50</sub> = 300−400 nM) against the Bcr-Abl mutant T315I, a variant resistant to all currently marketed therapies for chronic myeloid leukemia.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68615" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68615" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Chronic myeloid leukemia (CML<a class="ref internalNav" href="#fn1" aria-label="a">a</a><div class="NLM_fn" id="fn1">a<p class="last">Abbreviations: CML, chronic myeloid leukemia; Bcr-Abl, breakpoint cluster region-abelson; Ph+ ALL, Philadelphia chromosome-positive acute lymphoblastic leukemia; Src/Abl, sarcoma /abelson; SFK, Src family kinases; B-ALL, B-cell acute lymphoblastic leukemia; Arg, Abl-related gene; EGFR, epidermal growth factor receptor; Lck, leukocyte-specific protein tyrosine kinase; c-Kit, cytokine receptor; PDGF, platelet-derived growth factor; P-loop: phosphate binding loop; ATP, adenosine-5′-triphosphate; DFG, aspartic acid-phenylalanine-glycine; VEGFR, vascular endothelial growth factor receptor; MAP, mitogen-activated protein; KDR, kinase insert domain receptor; PK, pharmacokinetic; WT, wild type.</p></div>) is characterized by a reciprocal translocation between chromosome 9 and 22, resulting in the short Philadelphia (Ph) chromosome<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> carrying the Bcr-Abl (Breakpoint cluster region−Abelson leukemia) oncogene.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> This oncogene encodes the chimeric Bcr-Abl fusion protein, which incorporates an activated Abl tyrosine kinase domain and is responsible for the initial phase of CML.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> In 2001, imatinib, a potent Bcr-Abl inhibitor, was approved for the treatment of CML.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Despite its tremendous clinical success, imatinib is relatively ineffective against advanced phases of CML and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Mutations in the kinase domain of Bcr-Abl are the major mechanism of acquired imatinib resistance.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> To date, at least 50 different point mutations that encode distinct single amino acid substitutions have been identified in CML patients who are resistant to imatinib. Most mutants are effectively inhibited with second-generation inhibitors dasatinib and nilotinib, although neither compound inhibits the T315I mutant, which represents ∼15−20% of all clinically observed mutants. Currently, there are no approved pharmaceutical therapies for CML patients harboring this mutation, and development of T315I targeted inhibitors addresses a significant unmet medical need.</div><div class="NLM_p">Although the most widely accepted mechanism for imatinib resistance is the presence of kinase domain mutations, several studies have provided a rationale for the use of dual Src/Abl kinase inhibitors to overcome imatinib resistance.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> For example, overexpression of Src family kinases (SFK) has recently been implicated in Bcr-Abl mediated leukemogenesis, particularly the induction of B-cell acute lymphoblastic leukemia (B-ALL), and also in CML disease progression.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Beyond CML, a recent study demonstrated endogenous Abl kinases (c-Abl and Arg) are activated by deregulated EGFR and Src kinases, driving invasion of aggressive breast cancer cells<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and further highlighting the potential expanded utility of dual Src/Abl inhibitors to this solid tumor indication.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Moreover, Src activation or overexpression itself has been demonstrated in a variety of human tumor types, including colon, breast, pancreas, lung, liver, brain, and bladder cancers.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Taken together, dual Src/Abl kinase inhibitors, targeting either kinase independently or simultaneously, possess significant therapeutic potential for the treatment of both solid and hematologic malignancies. In 2006, dasatinib, a potent dual Src/Abl inhibitor, was approved for the treatment of adults in all phase of CML with resistance or intolerance to imatinib,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and there are now multiple dual Src/Abl kinase inhibitors in clinical trials for the treatment of breast cancer, pancreatic cancer, and other solid tumors.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">Imatinib is a relatively selective kinase inhibitor. Prior to a recent study demonstrating modest Lck inhibition (IC<sub>50</sub> = 160 nM),<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> imatinib was found to inhibit only three kinases: Bcr-Abl, c-Kit, and the PDGF receptor.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The high degree of kinase selectivity exhibited by imatinib is, to a large extent, attributed to its binding to the inactive conformation of Abl. In this conformation, the glycine rich P-loop folds down over the ATP binding site and the activation loop adopts a conformation in which it occludes substrate binding and disrupts the ATP binding site, blocking the catalytic activity of the enzyme.<a onclick="showRef(event, 'cit15a'); return false;" href="javascript:void(0);" class="ref cit15a">(15a)</a> This binding mode induces changes in the orientation of the conserved Asp-Phe-Gly (DFG)-motif at the base of the activation loop in which the phenylalanine residue moves more than 10 Å from its position in the active conformation; the inactive conformation is therefore also termed the “DFG-out” conformation. The DFG-out conformation creates an additional hydrophobic pocket adjacent to the ATP pocket. The amino acids surrounding this pocket are less conserved relative to those in the ATP binding pocket, which may explain why inhibitors bound to this conformation of the protein usually exhibit more focused kinase selectivity.<a onclick="showRef(event, 'cit15b'); return false;" href="javascript:void(0);" class="ref cit15b">(15b)</a> The chemical structure of imatinib and several other inhibitors targeting the DFG-out conformation of Abl and other important kinases are depicted in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative kinase inhibitors targeting the DFG-out conformation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900166t&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Previously, we have described <b>1</b> (AP23464, Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) as a purine-based, ATP-competitive, dual Src/Abl inhibitor that potently inhibits Src, wild type Bcr-Abl and a panel of Bcr-Abl mutants (except T315I) with subnanomolar potencies.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> To further probe the purine core as a template for potent dual Src/Abl inhibitors, alternate 2-atom linkers between the template and a pendant hydrophobic substituent were explored. On the basis of this concept, two parallel programs were established targeting the “DFG-in” and “DFG-out” conformations of both proteins. Recently, we have reported progress on the “DFG-in” targeted inhibitors highlighting an N-9 vinyl linkage in a series of stable, synthetically accessible purine based dual Src/Abl inhibitors.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Herein we describe our work based on the same template but targeting the “DFG-out” conformation of both proteins.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of DFG-out dual Src/Abl inhibitors based on <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900166t&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Inhibitor Design</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33527" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33527" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To transform <b>1</b> into a compound targeting the DFG-out conformations of Src and Abl, we initially used Abl as the primary target and proposed molecules <b>2</b> and <b>3a</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>), with the <i>N</i><sup>9</sup>-hydroxyphenethyl moiety being replaced by a privileged DFG-out targeting structural fragment, diarylamide.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Crystal structures of several “DFG-out” bound inhibitors have revealed that the amide functional group forms crucial hydrogen bonds with the protein and that the aryl groups fill adjacent hydrophobic pockets. Compound <b>3a</b> shares the 9-(arenethenyl)purine scaffold that was initially designed for our “DFG-in” dual Src/Abl inhibitor series and can also be viewed as conformationally restricted analogue of <b>2</b>. To investigate the molecular interactions between these inhibitors and Abl kinase, both compounds were docked into an Abl model based on the DFG-out conformation to which imatinib binds (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1iep">1iep</a>). Side chains around the ligand site were allowed to relax by using induced fit protocol in the Schrodinger modeling package.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The docked structure reveals that inhibitor <b>2</b> forms four hydrogen bonds with the protein. Two H-bonds are formed between the kinase hinge region and N-7 of purine core and methylamino group at C-1, respectively. The amide group of compound <b>2</b> forms two additional H-bonds with the side chain of Glu286 in the αC-helix and main chain of Asp381 in the DFG motif, respectively. The trifluoromethylphenyl moiety (B ring) fills a hydrophobic pocket that is only available in the DFG-out conformation. Extensive van der Waals (vdw) interactions are observed between the trifluoromethyl group and a small pocket formed by residue Ile293, Leu298, Leu354, and Val379. These vdw contacts between the trifluoromethyl group and the protein have been highlighted in the design of other DFG-out kinase inhibitors such as Abl inhibitors nilotinib, NS-187 (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>),<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and the dual Raf-KDR inhibitor sorafenib. Compound <b>3a</b> is predicted to bind to Abl in an identical mode to that of <b>2</b>, except that the olefinic proton (β to purine N-9) can potentially form a nonclassic hydrogen bond with the OH group of the Thr315 gatekeeper residue (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). Overall, inhibitors <b>2</b> and <b>3a</b> were predicted to interact with Abl in the DFG-out, inactive conformation, analogously to imatinib and nilotinib. The cyclopentyl group at purine C-2 in <b>1</b>, which was orientated toward the ribose-binding pocket of the ATP site,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> was not accommodated in a DFG-out targeted inhibitor due to clashes with residues located in the glycine-rich P-loop (such as Leu248 and Tyr 253). In fact, the docking model suggested that the space therein was too tight to tolerate a group/atom larger than a proton. As such, our DFG-out targeted dual Src/Abl inhibitors would bear substituents at the 6,9-positions on the purine template as opposed to the traditional 2,6,9-trisubstitution.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Model of designed inhibitor <b>3a</b> bound to Abl kinase</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900166t&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemical Synthesis</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85813" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85813" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of 3-(Trifluoromethyl)benzamides <b>3</b><sup>a</sup></div><p class="last"></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900166t&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) RNH<sub>2</sub>, THF, rt, 5 h; (b) 2.5 mol % Pd(OAc)<sub>2</sub>, 5 mol % P(<i>o</i>-tol)<sub>3</sub>, 120 mol % (<i>i</i>-Pr)<sub>2</sub>NEt, DMF, 100 °C, 15 h; (c) 3-CF<sub>3</sub>C<sub>6</sub>H<sub>4</sub>CO<sub>2</sub>H, EDCI, HOBt, THF, rt, overnight; (d) 2 equiv ArNH<sub>2</sub>, 10 mol % Pd<sub>2</sub>(dba)<sub>3</sub>, 15 mol % PhP(c-hexyl)<sub>2</sub>, 1.5 equiv K<sub>3</sub>PO<sub>4</sub>, μW, 150 °C, 5 or 10 min.</p></p></figure><div class="NLM_p">We postulated that inhibitor <b>2</b> could be easily accessed by simple hydrogenation of <b>3a</b>, and so the synthesis of the latter compound became our primary objective. The synthetic approach to 9-(arenethenyl)purine <b>3</b> described in the literature is based on the Horner−Wadsworth−Emmons (HWE) reaction of <i>N</i><sup>9</sup>-(phosphorylmethyl)purine and substituted benzaldehydes.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> This method was employed in the initial phase of our “DFG-in” inhibitor program but presented several challenges in the preparation of “DFG-out” targeted compounds because the corresponding elaborated benzaldehyde could only be made via a lengthy chemical transformation sequence. Other inconveniences included a multistep synthesis of the requisite HWE reagent and the separation of <i>Z</i>- and <i>E</i>-isomeric products. To circumvent these problems, we have developed an efficient synthesis of <b>3</b> based on a Heck reaction of 9-vinylpurines and aryl halides.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> As shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>, 6-chloro-9-vinylpurine (<b>4</b>), prepared by direct vinylation of commercially available 6-chloropurine with excessive vinyl acetate in the presence of catalytic amount of sulfuric acid and mercury acetate,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> underwent S<sub>N</sub>Ar displacement by aliphatic amines or palladium-catalyzed <i>N</i>-arylation with aryl amines to yield 6-(aryl/alkyl)amino-9-vinylpurines <b>5</b>. Subsequent Heck reaction of <b>5</b> and iodobenzamide <b>6</b>, which was prepared by a standard condensation of requisite acid and aniline, furnished <b>3</b> in high yields and exclusively as the <i>E</i>-isomers. Inhibitors <b>3a</b>, <b>3b</b>, <b>3g</b>, and <b>3h</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) were prepared in this manner, and subsequent hydrogenation of <b>3a</b> furnished <b>2</b> quantitatively.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Assay Results of Inhibitors <b>2</b> and <b>3</b> (IC<sub>50</sub> in nM)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0014.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table single-image" border="0"><colgroup><col /></col></colgroup><tbody><tr valign="top"><td><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0015.gif" alt="" id="fx2" /></img></td></tr></tbody></table></div></div><div class="NLM_p">Inhibitors <b>3c</b>, <b>3d</b>, <b>3e</b>, and <b>3f</b> were synthesized in the reverse order by first introducing the <i>N</i><sup>9</sup>-arenethenyl moiety onto the purine template followed by installation of the arylamino group at C-6. Thus, Heck reaction of <b>4</b> with <b>6</b> generated a common intermediate <b>7</b>, which underwent palladium-catalyzed <i>N</i>-arylation with various aryl amines to furnish the targeted compounds.</div><div class="NLM_p">As depicted in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>, the reverse amides <b>9</b> and the urea analogue <b>11</b> were prepared from a similar Heck coupling of <b>5b</b> with iodobenzamides <b>8</b> and <i>N</i>,<i>N</i>′-diarylurea <b>10</b>, respectively. The precursors <b>8</b> were assembled by coupling 3-iodo-4-methylbenzoyl chloride with a variety of aryl amines and <b>10</b> was made from the addition of 3-iodo-4-methylaniline to 3-(trifluoromethyl)phenyl isocyanate.</div><div class="NLM_p">Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a> illustrates the preparation of inhibitors that bear further substitution on C-3′′ of the B ring. For the synthesis of inhibitors <b>14</b>, the imidazole rings were coupled via copper-catalyzed <i>N</i>-arylations with 3-bromo-5-(trifluoromethyl)aniline in the presence of a bidentate ligand.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> For the preparation of <b>17</b>, morpholine and 4-methylpiperazine were also introduced in the first step of the reaction sequence but via straightforward S<sub>N</sub>Ar displacement. It is noteworthy that protection of the free amino group was unnecessary under both conditions. However, an excess of the nucleophiles was required to drive the S<sub>N</sub>Ar reaction to completion. Subsequent amide bond formation and Heck coupling furnished <b>14</b> and <b>17</b>.</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Reverse Amides <b>9</b> and Urea <b>11</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900166t&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) SOCl<sub>2</sub>, reflux, 1 h, (ii) ArNH<sub>2</sub>, (<i>i</i>-Pr)<sub>2</sub>NEt, cat. DMAP, THF, rt, 2 h; (b) 2.5 mol % Pd(OAc)<sub>2</sub>, 5 mol % P(<i>o</i>-tol)<sub>3</sub>, 120 mol % (<i>i</i>-Pr)<sub>2</sub>NEt, DMF, 100 °C, 15 h; (c) 3-CF<sub>3</sub>C<sub>6</sub>H<sub>4</sub>NCO, CH<sub>2</sub>Cl<sub>2</sub>, rt, 4 h.</p></p></figure><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Analogues <b>14</b> and <b>17</b> Bearing Additional B Ring Substitutions<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900166t&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) imidazole or 4-methylimidazole, 15 mol % 8-hydroxyquinoline, 15 mol % CuI, 110 mol % K<sub>2</sub>CO<sub>3</sub>, DMSO, 120 °C, 15 h; (b) 3-iodo-4-methylbenzoyl chloride, (<i>i</i>-Pr)<sub>2</sub>NEt, THF, rt, 2 h; (c) 2.5 mol % Pd(OAc)<sub>2</sub>, 5 mol % P(<i>o</i>-tol)<sub>3</sub>, 120 mol % (<i>i</i>-Pr)<sub>2</sub>NEt, DMF, 100 °C, 15 h; (d) 4 equiv morpholine or 4-methylpiperazine, 2 equiv CsOH·H<sub>2</sub>O, DMSO, 120 °C, 4 h.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Structure−Activity Relationship (SAR)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58714" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58714" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In vitro biological evaluation of the inhibitors included measuring their kinase inhibitory activity against both Src and Abl and their cellular activity associated with Bcr-Abl inhibition using both K562 (a human derived CML cell line expressing wild-type (WT) Bcr-Abl) and Ba/F3 cells transfected with wild-type Bcr-Abl. In general, potency in both cellular assays was comparable and consistent with SAR trends observed from the enzymatic assays. Inhibition of parental, nontransfected Ba/F3 cells was used as a control. Additionally, pharmacokinetic properties for active compounds were evaluated in rats to help guide series selection.</div><div class="NLM_p">The prototype inhibitor <b>3a</b> demonstrated kinase IC<sub>50</sub>s of 52 and 25 nM against Src and Abl, respectively, which validated our initial inhibitor design and original docking model. Moreover, when <b>3a</b> was tested in cells, it was remarkably potent against both cell lines without any effect on the parental control at concentrations up to 10 μM (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Reduction of <b>3a</b> to <b>2</b> resulted in decreased kinase and cellular activity, suggesting the more rigid double bond may introduce bias toward the preferred binding conformation. Interaction of the olefinic proton with the threonine gatekeeper residue via a pseudo hydrogen bond, as mentioned in our inhibitor design, could also have contributed to the enhanced potency of <b>3a</b>. Preliminary pharmacokinetic assessment of compound <b>3a</b> suggested it was cleared rapidly after being dosed orally in rats (vide infra). Previously, we have disclosed that the enamine-like <i>N</i><sup>9</sup>-(phenethenyl) moiety in the context of DFG-in targeted dual Src/Abl inhibitors is stable in vivo. For example, AP24149 (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>, compound <b>10a</b> from reference <a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">22</a>) demonstrated oral bioavailability of approximately 20% in rats. Therefore, we speculated that the methylamino group at purine C-6 might be responsible for the poor oral bioavailability because the <i>N</i>-phenyl 3-trifluoromethyl-benzamide moiety has been highlighted in other orally bioavailable DFG-out targeted inhibitors.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> To test this hypothesis, we substituted the methyl group with a cyclopropyl ring (<b>3b</b>), which is metabolically more stable and therefore less susceptible to rapid <i>N</i>-dealkylation. The preference for a cyclopropyl group was also partially due to the small change in molecular weight relative to <b>3a</b>. Gratifyingly, compound <b>3b</b> displayed satisfactory pharmacokinetics with high exposure and good oral bioavailability (<i>F</i> = 40%, Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>) while maintaining target kinase potency and cellular activity.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Orally bioavailable “DFG-in” <i>N</i><sup>9</sup>-(arenethenyl)purine.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900166t&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Encouraged by these data demonstrating that larger, lipophilic molecules like <b>3b</b> can be orally bioavailable, we focused on improving both the kinase and cellular potency through further SAR exploration at C-6 on the purine template. As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>, several arylamines increased kinase activity while an alkyl derivative (<b>3h</b>) demonstrated reduced potency. This suggested the aryl rings might be engaged in hydrophobic or π stacking interactions with residues lining the hinge region. An exception was pyridine-2-ylamine (<b>3c</b>), which reduced kinase potency by about 50%. A tentative explanation for this observation is that the lone pair electrons on the 2-pyridyl N and those from N-1 on the purine template are repulsed, disrupting the coplanarity that contributes to optimal binding. In the case of the 3-pyridyl (<b>3d</b>) or 4-pyridyl (<b>3e</b>) derivatives, such electron repulsions do not exist. Instead, a nonclassical hydrogen bond between N-1 on purine template and the C-2′ aromatic proton on the pyridine ring might help stabilize the preferred coplanar conformation and hence, increase the kinase activity of <b>3d</b> and <b>3e</b>.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> It is noteworthy that both compounds show dramatic increases in cellular potency with IC<sub>50</sub>s for inhibition of K562 cells in the single digit nM range. Introduction of a (4-dimethylphosphinoyl)-phenyl moiety, one of the key molecular recognition elements responsible for the excellent potency observed with <b>1</b>, greatly improved potency in this series as well. Compound <b>3g</b> potently inhibited Src and Abl with IC<sub>50</sub>s of 3.8 and 5.7 nM, respectively, and inhibited the proliferation of both cell lines in the single digit nM range. Additionally, this compound demonstrated excellent selectivity relative to the control cell line. Unfortunately, despite their increased kinase and cellular potencies, inhibitors <b>3d</b>, <b>3e</b>, and <b>3g</b> failed to demonstrate satisfactory preliminary pharmacokinetics. Therefore, in further optimization, we focused on inhibitors bearing a cyclopropylamine at C-6 of purine template.</div><div class="NLM_p">Next, we briefly explored the reversed amide (<b>9</b>) and ureido (<b>11</b>) linkages connecting both pendent aryl rings at N-9 on the purine template (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Both linkers modeled well and were predicted to form the requisite hydrogen bonds to the protein. Compound <b>9a</b>, which bears the same amide linkage as nilotinib, was found to be slightly more potent than <b>3b</b> that has a “imatinib-like” amide. Urea <b>11</b> displayed a marked decrease in potency against Src kinase but almost no change relative to Abl, which may reflect different activation loop conformations adopted by the inactive forms of both Src and Abl. Nevertheless, molecule <b>11</b> demonstrated poor cellular activity in K562 cells (IC<sub>50</sub> > 1 μM) and was not pursued further.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vitro Assay Results of Inhibitors <b>9</b> and <b>11</b> (IC<sub>50</sub> in nM)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0016.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table single-image" border="0"><colgroup><col /></col></colgroup><tbody><tr valign="top"><td><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0017.gif" alt="" id="fx4" /></img></td></tr></tbody></table></div></div><div class="NLM_p">With the amide linkage optimized, we explored SAR on the pendent B-ring in the DFG binding pocket. Simple halogenation at either the ortho or the para position (<b>9b</b> and <b>9c</b>) slightly reduced potency relative to <b>9a</b>. Next we explored the possibility of replacing the trifluoromethyl group with reduced molecular weight and/or smaller hydrophobic substituents. <i>tert</i>-Butyl group substitution (<b>9d</b>) retained potency relative to <b>9a</b>, while the isopropyl analogue (<b>9e</b>) exhibited a 3−6 fold decrease depending upon the enzyme. This could be rationalized by the larger volume of the <i>tert</i>-butyl group relative to isopropyl and the consequential increased van der Waals contact in the well-defined hydrophobic pocket. Nevertheless, the <i>tert</i>-butyl derivative (<b>9d</b>) had a higher cLogP<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> relative to <b>9a</b> (6.76 vs 6.24, respectively), which we viewed as undesirable. To counterbalance this, we explored incorporating heteroatoms through several commercially available five-membered heteroaryls bearing <i>tert</i>-butyl substituents. Gratifyingly, isoxazole analogue <b>9g</b> (cLogP = 5.29) was found to retain potency relative to <b>9a</b> against both target kinases. Despite this, both <b>9d</b> and <b>9g</b> exhibited less desirable rat pharmacokinetics (vide infra) relative to <b>9a</b> and this series was abandoned. Further work to reduce the lipophilicity of <b>9a</b> through heteroatom incorporation ultimately led to the discovery of <b>9i</b> (cLogP = 5.32), which not only maintained enzymatic and cell-based potency but also demonstrated increased exposure and was essentially 100% orally bioavailable.</div><div class="NLM_p">The then-recent structural disclosure of nilotinib and its increased potency relative to imatinib prompted us to make several compounds based on this modified B ring (<b>14a</b>, <b>14b</b>) and, more generally, analogues in which alternative heterocyclic rings were installed at the C-3′′ position (<b>17</b>) (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a> and Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Inhibitors <b>14a</b> and <b>14b</b> retained Src and Abl potency relative to <b>9i</b>, while <b>17</b> displayed a slight decrease in potency, but overall, the impact of substitutions meta to the trifluoromethyl appeared to be minor.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro Assay Results of Inhibitors <b>14</b> and <b>17</b> (IC<sub>50</sub> in nM)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="center" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top"><th align="center">compd</th><th align="left">Src kinase</th><th align="left">Abl kinase</th><th align="left">K562</th><th align="center">WT Abl (Ba/F3)</th><th align="center">parental (Ba/F3)</th></tr></thead><tbody><tr valign="top"><td align="center"><b>14a</b></td><td align="left">7.6 (<i>n</i> = 8)</td><td align="left">25 (<i>n</i> = 8)</td><td align="left">4.3 (<i>n</i> = 7)</td><td align="center">7.3 (<i>n</i> = 6)</td><td align="center">6455 (<i>n</i> = 6)</td></tr><tr valign="top"><td align="center"><b>14b</b></td><td align="left">8.0 (<i>n</i> = 1)</td><td align="left">13 (<i>n</i> = 1)</td><td align="left">5.4 (<i>n</i> = 3)</td><td align="center">4.2 (<i>n</i> = 3)</td><td align="center">7120 (<i>n</i> = 2)</td></tr><tr valign="top"><td align="center"><b>17a</b></td><td align="left">33 (<i>n</i> = 1)</td><td align="left">72 (<i>n</i> = 1)</td><td align="left">17 (<i>n</i> = 3)</td><td align="center">10 (<i>n</i> = 3)</td><td align="center">2525 (<i>n</i> = 1)</td></tr><tr valign="top"><td align="center"><b>17b</b></td><td align="left">41 (<i>n</i> = 1)</td><td align="left">24 (<i>n</i> = 1)</td><td align="left">14 (<i>n</i> = 3)</td><td align="center">11 (<i>n</i> = 3)</td><td align="center">543 (<i>n</i> = 1)</td></tr></tbody></table></div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Understanding Dual Src/Abl Activities</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26301" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26301" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Many inhibitors (e.g., dasatinib,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> bosutinib,<a onclick="showRef(event, 'cit13a'); return false;" href="javascript:void(0);" class="ref cit13a">(13a)</a> and AZD0530;<a onclick="showRef(event, 'cit13b'); return false;" href="javascript:void(0);" class="ref cit13b">(13b)</a> Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>), initially designed and synthesized for Src inhibition, were subsequently found to possess potent Abl inhibitory activity as well. This is not unexpected because of the high sequence homology between Src and Abl and their similar active DFG-in conformations. However, DFG-out Abl inhibitors do not necessarily possess potent Src inhibitory activity. It has been reported that neither imatinib nor nilotinib inhibits Src. The structural basis for Src inactivity of these potent DFG-out Abl binders is still not fully understood.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> It is generally believed that Abl can easily adopt a DFG-out conformation, whereas Src appears to pay a high intrinsic energetic penalty to adopt such a binding mode, which makes it challenging to design a potent DFG-out inhibitor against both Abl and Src.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> To better understand why our DFG-out Abl inhibitors also possess strong affinity for Src, we docked <b>9i</b> into the DFG-out conformation of Src kinase. Because of the lack of a DFG-out Src/ligand cocrystal at the time and the very close resemblance of Lck and Src kinases, we built the DFG-out Src model based on a published DFG-out structure of Lck (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2og8">2og8</a>).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> As shown in this model (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>), <b>9i</b> makes two H-bonds with the Src hinge region through purine N-7 and the cyclopropyl amine. Two additional H-bonds are formed from the amide group of <b>9i</b> to the DFG backbone and Glu310 of α helix C, respectively. Notice that the H-bonding pattern in Src is essentially identical to that predicted in the Abl model. Also, as in the Abl model, the methylphenyl group of <b>9i</b> binds to the selective hydrophobic pocket located behind the gatekeeper residue, while the (trifluoromethyl)pyridyl group binds to a hydrophobic pocket, which is typically occupied by Phe405 of Src in the DFG-in conformation. The similarity in H-bonding and van der Waals (vdw) interactions of <b>9i</b> with Src and Abl observed in these models could explain the dual activities of <b>9i</b> and other related inhibitors in this chemical series against Src and Abl.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Representative dual Src/Abl kinase inhibitors targeting the “DFG-in” conformations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900166t&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although the overall binding modes are similar, structural differences in loop conformations and ligand interactions are present in the docking models of Abl and Src. The largest difference resides in the conformation of the Gly-rich loops. The Gly-rich loop in Abl appears to be more flexible than that in Src based on a number of reported crystal structures of Abl and Src;<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33, 34)</a> this loop is collapsed around bound inhibitors in Abl and makes numerous contacts with them. In contrast, the Gly-rich loop in Src adopts an extended conformation and makes minimal contacts with the inhibitor, as seen in our model and other reported crystal structures of Src (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3el7">3el7</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3el8">3el8</a>) and its homologue Lck.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33, 34)</a> The loop conformational variation is contributed by the difference in amino acid sequence of the Gly-rich loops, especially Phe 278 in Src and Tyr253 in Abl, as well as their neighboring residues. The additional interactions of the Gly-rich loop with inhibitors make this class of compounds less sensitive to chemical modifications in terms of binding affinity to Abl. One modification introduced to <b>9i</b> was the removal of the C-6 substituent, leading to the loss of the hydrogen bond donor to the hinge region, as exemplified by inhibitors <b>18a</b> and <b>18b</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). Comparative kinase inhibition data indicated that the modification had little effect on Abl potency but had a much larger impact on Src. In fact, as shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>, compound <b>18a</b> is 10-fold less potent than <b>14a</b>, while <b>18b</b> is 45 times less potent than <b>9i</b> in the Src kinase assay. Interestingly, the same hydrogen bond donor to the hinge region is also absent in imatinib and nilotinib, both of which have minimal activities against Src. Taken together, structural differences in Abl and Src do exist despite the overall similarity and these differences can lead to Abl or Src specific inhibitors targeting the DFG-out conformation. Particularly, in this 9-(arenethenyl)purine series of DFG-out inhibitors, it appears that the Src inhibitors are more dependent on the formation of two H-bonds to the hinge region to gain potency, whereas Abl inhibitors bearing a single H-bond acceptor to the hinge region can achieve the same degree of potency due to additional interactions with the Gly-rich loop.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Impact of Additional H-Bond with Hinge on Potency (IC<sub>50</sub> in nM)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0018.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top"><th align="center">compd</th><th align="center" char=".">Src kinase</th><th align="center">Abl kinase</th><th align="center">WT Abl (Ba/F3)</th></tr></thead><tbody><tr valign="top"><td align="left"><b>14a</b></td><td align="char" char=".">8</td><td align="center">25</td><td align="center">9</td></tr><tr valign="top"><td align="left"><b>18a</b></td><td align="char" char=".">84</td><td align="center">48</td><td align="center">7</td></tr><tr valign="top"><td align="left"><b>9i</b></td><td align="char" char=".">7</td><td align="center">20</td><td align="center">6</td></tr><tr valign="top"><td align="left"><b>18b</b></td><td align="char" char=".">307</td><td align="center">38</td><td align="center">5</td></tr></tbody></table></div></div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Model of compound <b>9i</b> bound to Abl (left) and Src (right).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900166t&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Pharmacokinetics of Selected Compounds</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82588" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82588" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">During this program, potent inhibitors were continually evaluated for their pharmacokinetic (PK) properties immediately following the assessment of their in vitro activity (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). We observed that the introduction of certain functionalities consistently resulted in poor pharmacokinetics. Such examples included heteroarylamines (<b>3d</b>, <b>3e</b>) and certain 4-substituted anilines (e.g., <b>3g</b>) at C-6 on the purine core. To the contrary, compounds incorporating a 6-cyclopropylamine at the same position usually displayed favorable PK profiles (<b>3b</b>, <b>9g</b>, <b>9i</b>, <b>14a</b>). Both <b>9i</b> and <b>14a</b> exhibited low rates of clearance and high oral exposure. As a prerequisite to evaluating both compounds in in vivo efficacy models, PK parameters for both were determined orally in mice at three different doses; excellent dose proportionality was observed for both compounds (data not shown).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Mean Pharmacokinetic Parameters Following Intravenous (iv) or Oral Dosing (po) in CD Rats or Mice <a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="" /></col><col align="char" char="" /></col><col align="char" char="" /></col><col align="center" /></col><col align="char" char="" /></col><col align="char" char="" /></col><col align="char" char="" /></col><col align="char" char="" /></col></colgroup><thead><tr valign="top" class="rowsep1"><th class="rowsep1" align="center"> </th><th class="rowsep1" colspan="3" align="center">iv</th><th class="rowsep1" colspan="4" align="center">po</th></tr><tr valign="top" class="rowsep1"><th class="rowsep1" align="char">compd</th><th class="rowsep1" align="char">CL (L/h/ kg)</th><th class="rowsep1" align="char"><i>V</i><sub>d</sub> (L/kg)</th><th class="rowsep1" align="center"><i>t</i><sub>1/2</sub> (h)</th><th class="rowsep1" align="char">AUC<sub>0−24 h</sub> (ng·h/mL)</th><th class="rowsep1" align="char"><i>C</i><sub>max</sub> (ng/mL)</th><th class="rowsep1" align="char"><i>t</i><sub>max</sub> (h)</th><th class="rowsep1" align="char"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="rowsep0"><td class="rowsep0" align="char"><b>3a</b></td><td class="rowsep0" align="char">0.38</td><td class="rowsep0" align="char" char=".">1.60</td><td class="rowsep0" align="center">2.95</td><td class="rowsep0" align="char">N/C<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></td><td class="rowsep0" align="char">N/C</td><td class="rowsep0" align="char">N/C</td><td class="rowsep0" align="char">N/C</td></tr><tr valign="top" class="rowsep0"><td class="rowsep0" align="char"><b>3b</b></td><td class="rowsep0" align="char">0.19<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="rowsep0" align="char" char=".">1.08</td><td class="rowsep0" align="char" char=".">4.0</td><td class="rowsep0" align="char">32151<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="rowsep0" align="char">2613</td><td class="rowsep0" align="char">1.0</td><td class="rowsep0" align="char">40</td></tr><tr valign="top" class="rowsep0"><td class="rowsep0" align="char"><b>3d</b></td><td class="rowsep0" align="char">0.49<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="rowsep0" align="char" char=".">1.70</td><td class="rowsep0" align="char" char=".">2.4</td><td class="rowsep0" align="char">3311<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="rowsep0" align="char">387</td><td class="rowsep0" align="char">2.0</td><td class="rowsep0" align="char">11</td></tr><tr valign="top" class="rowsep0"><td class="rowsep0" align="char"><b>3e</b></td><td class="rowsep0" align="char">0.96<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="rowsep0" align="char" char=".">9.01</td><td class="rowsep0" align="char" char=".">6.7</td><td class="rowsep0" align="char">N/C</td><td class="rowsep0" align="char">483</td><td class="rowsep0" align="char">6.0</td><td class="rowsep0" align="char">N/C</td></tr><tr valign="top" class="rowsep0"><td class="rowsep0" align="char"><b>3g</b></td><td class="rowsep0" align="char">0.79<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="rowsep0" align="char" char=".">3.54</td><td class="rowsep0" align="char" char=".">3.1</td><td class="rowsep0" align="char">146<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="rowsep0" align="char">63</td><td class="rowsep0" align="char">1.0</td><td class="rowsep0" align="char">0.8</td></tr><tr valign="top" class="rowsep0"><td class="rowsep0" align="char"><b>9d</b></td><td class="rowsep0" align="char">1.79<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="rowsep0" align="char" char=".">5.31</td><td class="rowsep0" align="char" char=".">2.1</td><td class="rowsep0" align="char">297<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="rowsep0" align="char">100</td><td class="rowsep0" align="char">1.0</td><td class="rowsep0" align="char">3.5</td></tr><tr valign="top" class="rowsep0"><td class="rowsep0" align="char"><b>9g</b></td><td class="rowsep0" align="char">0.90<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="rowsep0" align="char" char=".">4.87</td><td class="rowsep0" align="char" char=".">3.7</td><td class="rowsep0" align="char">7540<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="rowsep0" align="char">1040</td><td class="rowsep0" align="char">1.0</td><td class="rowsep0" align="char">45</td></tr><tr valign="top" class="rowsep0"><td class="rowsep0" align="char"><b>9i</b></td><td class="rowsep0" align="char">0.04<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="rowsep0" align="char" char=".">0.34</td><td class="rowsep0" align="char" char=".">5.7</td><td class="rowsep0" align="char">428459<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="rowsep0" align="char">23525</td><td class="rowsep0" align="char">2.0</td><td class="rowsep0" align="char">116</td></tr><tr valign="top" class="rowsep0"><td class="rowsep0" align="char"><b>14a</b></td><td class="rowsep0" align="char">0.06<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="rowsep0" align="char" char=".">0.78</td><td class="rowsep0" align="char" char=".">8.3</td><td class="rowsep0" align="char">17249<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="rowsep0" align="char">1753</td><td class="rowsep0" align="char">2.0</td><td class="rowsep0" align="char">7</td></tr><tr valign="top" class="rowsep0"><td class="rowsep0" align="char"><b>9i</b></td><td class="rowsep0" align="char"> </td><td class="rowsep0" align="char"> </td><td class="rowsep0" align="center"> </td><td class="rowsep0" align="char">21195<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="rowsep0" align="char">3097</td><td class="rowsep0" align="char">2.0</td><td class="rowsep0" align="char"> </td></tr><tr valign="top"><td align="char"><b>14a</b></td><td align="char"> </td><td align="char"> </td><td align="center"> </td><td align="char">6927<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td align="char">1020</td><td align="char">1.0</td><td align="char"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last"><i>n</i> = 3 animals per study.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Dosed iv in rats at 5 mg/kg as a solution in 50% DMA, 45% PEG-400, and 5% Tween-80.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">Dosed po in rats at 15 mg/kg as a solution 15% DMA, 15% TPGS, 5% Tween-80, 25% PEG-400, and 40% water.</p></div><div class="footnote" id="t5fn4"><sup>d</sup><p class="last">Dosed po in mice at 10 mg/kg as a solution in 15% DMA, 15% TPGS, 5% Tween-80, 25% PEG-400, and 40% water.</p></div><div class="footnote" id="t5fn5"><sup>e</sup><p class="last">N/C = not calculated.</p></div></div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">In Vivo Efficacy</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00227" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00227" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The excellent in vitro kinase and cellular potency coupled with desirable pharmacokinetics of inhibitor <b>9i</b> prompted us to evaluate its antitumor activity in vivo in two well-established mouse efficacy models. In the first model, Ba/F3 cells expressing wild-type Bcr-Abl were injected into the tail vein of SCID mice. After 3 days, the animals were dosed orally with <b>9i</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>) at 10 mg/kg once daily for 19 consecutive days. In the control group, median survival was approximately 20 days with noted splenomegaly at autopsy. In the <b>9i</b> treated animals, median survival was approximately 35 days, representing a 75% increase in overall survival relative to control. For comparison, similar efficacy was observed in nilotinib treated animals at an oral dose of 75 mg/kg/day. In the second efficacy model, to evaluate Src inhibitory activity, subcutaneous tumors were established with NIH 3T3 cells transfected with constitutively activated Src Y527F. Daily oral administration of <b>9i</b> elicited dose-dependent tumor shrinkage with complete tumor growth inhibition observed at the highest dose (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>).</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. In vivo efficacy of <b>9i</b> in a Ba/F3 WT Bcr-Abl survival model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900166t&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. In vivo efficacy of <b>9i</b> in a Src Y527F mouse tumor model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900166t&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Compound <b>14</b> Inhibits Bcr-Abl Mutant T315I</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00163" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00163" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To determine whether any of our compounds possessed activity against the refractory T315I mutant,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> we screened several compounds in an Abl-T315I kinase assay and ultimately in Ba/F3 cells transfected with Bcr-Abl T315I. Interestingly, two inhibitors bearing imidazole appendages on the B ring, <b>14a</b> and <b>14b</b>, demonstrated modest kinase inhibition and inhibited the proliferation of such Ba/F3 cells with IC<sub>50</sub>s between 300 and 400 nM (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). Moreover, inhibition of cell proliferation by <b>14a</b> directly correlated with decreased cellular phosphorylation of pBcr-Abl (data not shown, see ref <a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">35</a>) and the IC<sub>50</sub> for inhibition of the nontransfected parental Ba/F3 control was greater than 6 μM. Inhibitors bearing other ring systems (<b>17</b>) or without substitution at the C-3′′ position (<b>9i</b>) were either less effective or completely inactive against this mutation. Previously, we observed that compounds bearing these substitutions gave rise to only minor changes in potency against wild type Abl. The model of <b>14a</b> docked into T315I Abl kinase demonstrates that the 4-methylimidazole group fills a shallow pocket formed by Glu228, Glu282, Val289, Asp381, and Phe359 (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>). This additional interaction with the protein appears to contribute significantly to its activity against T315I. It is noteworthy that inhibitor <b>14a</b> shares an identical structural fragment with nilotinib but that the latter is completely ineffective against Abl T315I. When nilotinib is docked into the model of Abl kinase with the T315I mutation, there is an obvious steric clash between the amino group on the pyrimidine ring and the larger isoleucine residue. Such a clash is not observed between the less sterically demanding double bond linkage in <b>14a</b>, which may explain its increased activity against this important clinical mutation.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Inhibition of Bcr-Abl Mutant T315I (IC<sub>50</sub> in nM)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top"><th align="left"> </th><th align="left"><b>14a</b></th><th align="left"><b>14b</b></th><th align="left"><b>17a</b></th><th align="left"><b>17b</b></th><th align="left"><b>9i</b></th></tr></thead><tbody><tr valign="top"><td align="left">T315I kinase</td><td align="left">478</td><td align="left">542</td><td align="left">>5000</td><td align="left">1818</td><td align="left">14412</td></tr><tr valign="top"><td align="left">T315I (Ba/F3)</td><td align="left">422</td><td align="left">298</td><td align="left">nd</td><td align="left">nd</td><td align="left">2746</td></tr></tbody></table></div></div><figure id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Model of compound <b>14a</b> bound to Abl T315I.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900166t&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">To further characterize the activity of <b>14a</b>, we also determined the antiproliferation activity against a broader panel of Ba/F3 cells expressing clinically relevant Bcr-Abl mutants: L248R, G250E, Q252H, Y253H, and E255K. Relative to T315I-expressing cells, these cell lines were more potently inhibited with IC<sub>50</sub>s of 64, 63, 42, 44, and 24 nM, respectively, which is comparable or superior to the potency of nilotinib against the same mutations.<a onclick="showRef(event, 'cit16a'); return false;" href="javascript:void(0);" class="ref cit16a">(16a)</a></div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21261" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21261" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Through our program of structure guided drug design, we have identified a novel series of purine-based compounds that potently inhibit Src and Abl by specifically targeting the inactive conformation of both proteins. Extensive SAR revealed structural features contributing to high potency. Several key ligand−protein interactions responsible for potency against both kinases include a hydrogen bond between the hinge region and N-7 on the purine core, hydrogen bonds between the amide group and the Glu residue in the αC-helix and Asp residue in the DFG motif, respectively, and hydrophobic interaction between the trifluoromethylphenyl and the proteins. The NH at C-6 on the purine template was identified as critical for achieving high potency against Src through a well-defined hydrogen bond with a hinge residue. Compounds bearing cyclopropylamine at C-6 on the purine core were found to display highly desirable pharmacokinetics in general. Once-daily oral administration of inhibitor <b>9i</b> (AP24226)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> at 10 mg/kg significantly prolonged the survival of mice injected intravenously with wild type Bcr-Abl expressing Ba/F3 cells, with potency comparable to nilotinib when dosed at 75 mg/kg. Furthermore, <b>9i</b> also elicited dose-dependent tumor shrinkage in a Src Y527F mouse tumor model at oral doses ranging from 10 to 100 mg/kg. Inhibitor <b>14a</b> (AP24163),<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> an alternative member of this novel series, not only potently inhibits both Src and Abl but also displays clear cellular potency against a number of clinically identified Bcr-Abl mutants including the highly refractory T315I mutation. Its modest cellular potency (IC<sub>50</sub> = 420 nM) against T315I is encouraging given the insensitivity of this mutant to all currently marketed first- and second-generation Bcr-Abl inhibitors.</div></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35154" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35154" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec10_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Chemistry</h3><div class="NLM_p last">All reagents and solvents were used as received. <sup>1</sup>H NMR (300.1 MHz), <sup>19</sup>F NMR (282.4 MHz), and <sup>31</sup>P NMR (121.5 MHz) spectra were recorded on a Bruker ARX300 spectrometer, using TMS as internal standard and CFCl<sub>3</sub> or 85% H<sub>3</sub>PO<sub>4</sub> as external standard, respectively. MS spectra were recorded on a Waters Micromass ZQ spectrometer. Elemental analyses were performed by Robertson Microlit Laboratories in Madison, NJ. HPLC was performed on an Agilent 1100 HPLC system. The purity of all SAR compounds was determined to be ≥95% by reverse phase HPLC (C-18 column, MeCN/H<sub>2</sub>O with 0.1% CF<sub>3</sub>CO<sub>2</sub>H as the mobile phase), and certain compounds were further checked for their purity via combustion analysis.</div></div><div id="sec10_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Procedure for the Preparation of 6-(Alkylamino)-9-vinylpurines 5; <i>N</i>-methyl-9-vinyl-9<i>H</i>-purin-6-amine (<b>5a</b>), Method A</h3><div class="NLM_p last">6-Chloro-9-vinylpurine<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a>(0.54 g, 3 mmol) was added to the solution of methylamine (7.5 mL, 15 mmol, 2.0 M in THF) in THF (5 mL), and the mixture was stirred for 5 h at rt. Water was added to dissolve the white precipitate (methylamine hydrochloride). The aqueous layer was extracted with ethyl acetate, and the combined organic layers were dried over sodium sulfate, concentrated on a rotavap, and then subjected to silica gel column chromatography (5% methanol/methylene chloride), yielding the desired product as white solid in 75% yield. <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 3.11 (s, 3H), 5.18 (dd, <i>J</i> = 9.2, 1.3 Hz, 1H), 5.97 (dd, <i>J</i> = 16.0, 1.3 Hz, 1H), 7.28 (dd, <i>J</i> = 16.0, 9.2 Hz, 1H), 8.28 (s, 1H), 8.32 (s, 1H).</div></div><div id="sec10_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> <i>N</i>-Cyclopropyl-9-vinyl-9<i>H</i>-purin-6-amine (<b>5b</b>)</h3><div class="NLM_p last">Method A; yield: 92%. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 0.60 (m, 2H), 0.87 (m, 2H), 3.00 (m, 1H), 5.08 (dd, <i>J</i> = 9.1, 1.4 Hz, 1H), 5.80 (dd, <i>J</i> = 16.0, 1.4 Hz, 1H), 6.39 (br, 1H), 7.20 (dd, <i>J</i> = 16.0, 9.1 Hz, 1H), 7.94 (s, 1H), 8.45 (s, 1H).</div></div><div id="sec10_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> <i>N</i>-(4-(Dimethylphosphoryl)phenyl)-9-vinyl-9<i>H</i>-purin-6-amine (<b>5g</b>)</h3><div class="NLM_p last">A mixture of 6-chloro-9-vinylpurine (0.18 g, 1 mmol), 4-dimethylphosphinylaniline (0.17 g, 1 mmol), and pyridine hydrochloride (0.11 g, 1 mmol) was dissolved in 2-ethoxyethanol (2 mL). The resulting solution was heated at 160 °C for 10 min under microwave irradiation. The mixture was concentrated to dryness on a rotavap. EtOAc and aq NaHCO<sub>3</sub> were added. The aqueous layer was extracted with ethyl acetate, and the combined organic layers were dried over sodium sulfate, concentrated on a rotavap, and then subjected to silica gel column chromatography (eluent: 10% methanol/methylene chloride), yielding the desired product in 56% yield. <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 1.70 (d, <i>J</i> = 13.2 Hz, 3H), 1.81 (d, <i>J</i> = 13.3 Hz, 3H), 5.23 (d, <i>J</i> = 9.2 Hz, 1H), 6.07 (d, <i>J</i> = 16.0 Hz, 1H), 7.34 (dd, <i>J</i> = 16.0, 9.1 Hz, 1H), 7.33 (m, 2H), 7.79 (m, 2H), 8.46 (s, 1H), 8.50 (s, 1H).</div></div><div id="sec10_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> <i>N</i>-(3-(<i>N</i>′,<i>N</i>′-Dimethylamino)propyl)-9-vinyl-9<i>H</i>-purin-6-amine (<b>5h</b>)</h3><div class="NLM_p last">Method A; yield: 95%. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.00 (m, 2H), 2.44 (s, 6H), 2.67 (m, 2H), 3.80 (m, 2H), 5.15 (dd, <i>J</i> = 9.1, 1.4 Hz, 1H), 5.85 (dd, <i>J</i> = 16.0, 1.4 Hz, 1H), 6.63 (br, 1H), 7.23 (dd, <i>J</i> = 16.0, 9.1 Hz, 1H), 7.97 (s, 1H), 8.41 (s, 1H).</div></div><div id="sec10_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> <i>N</i>-(3-Iodo-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>6</b>)</h3><div class="NLM_p last">A solution of 3-iodo-4-methylaniline (1.22 g, 5.25 mmol), 3-(trifluoromethyl)benzoic acid (0.95 g, 5 mmol), HOBt (0.68 g, 5 mmol), and EDCI (1.05 g, 5.5 mmol) in THF (20 mL) was stirred overnight at rt. Water was added, and the aqueous layer was extracted with dichloromethane. The combined organic layers were dried over sodium sulfate, concentrated on a rotavap, and then subjected to silica gel column chromatography (3:1 hexane/ethyl acetate), yielding the desired product as white solid in 83% yield. <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 2.40 (s, 3H), 7.27 (d, <i>J</i> = 8.3 Hz, 1H), 7.62 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H), 7.71 (dd, <i>J</i> = 7.8, 7.8 Hz, 1H), 7.87 (d, <i>J</i> = 7.9 Hz, 1H), 8.18 (d, <i>J</i> = 7.9 Hz, 1H), 8.25 (d, <i>J</i> = 7.9 Hz, 1H), 8.26 (dd, <i>J</i> = 7.9, 2.1 Hz, 1H).</div></div><div id="sec10_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> General Procedure for the Heck Reaction of 9-Vinylpurines and Aryl Iodides; (<i>E</i>)-<i>N</i>-(4-Methyl-3-(2-(6-(methylamino)-9<i>H</i>-purin-9-yl)vinyl)phenyl)-3-(trifluoromethyl)-benzamide (<b>3a</b>), Method B</h3><div class="NLM_p last">A solution of 9-vinylpurine <b>5a</b> (1 mmol), aryl iodide <b>6</b> (1.1 mmol), Pd(OAc)<sub>2</sub> (11.2 mg, 0.05 mmol), and P(<i>o</i>-tol)<sub>3</sub> (30.4 mg, 0.1 mmol) in DMF (3 mL) was degassed with bubbling N<sub>2</sub> for 10 min. (<i>i</i>-Pr)<sub>2</sub>NEt (0.52 mL, 3 mmol) was added under N<sub>2</sub>, The resulting solution was stirred at 110 °C for 15 h. Water was added, and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated on a rotavap, and then subjected to silica gel column chromatography (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>), yielding the desired product as white powder in 82% yield; mp 201 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.42 (d, <i>J</i> = 7.9 Hz, 3H), 3.24 (s, 3H), 5.87 (s, 1H), 7.20 (d, <i>J</i> = 8.2 Hz, 1H), 7.48 (d, <i>J</i> = 14.5 Hz, 1H), 7.52 (dd, <i>J</i> = 7.1, 2.0 Hz, 1H), 7.59 (d, <i>J</i> = 14.5 Hz, 1H), 7.65 (d, <i>J</i> = 7.8 Hz, 1H), 7.81 (d, <i>J</i> = 8.2 Hz, 1H), 7.84 (d, <i>J</i> = 1.9 Hz, 1H), 8.02 (s, 1H), 8.11 (d, <i>J</i> = 7.8 Hz, 1H), 8.18 (s, 2H), 8.48 (s, 1H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): δ −61.92. MS [M + H]<sup>+</sup> 453.3.</div></div><div id="sec10_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> (<i>E</i>)-<i>N</i>-(4-Methyl-3-(2-(6-(cyclopropylamino)-9<i>H</i>-purin-9-yl)vinyl)-phenyl)-3-(trifluoromethyl)benzamide (<b>3b</b>)</h3><div class="NLM_p last">Method B: This compound was made from <b>5b</b> and <b>6</b> in 56% yield. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 0.67 (m, 2H), 0.77 (m, 2H), 2.42 (s, 3H), 3.24 (m, 1H), 7.37 (d, <i>J</i> = 8.4 Hz, 1H), 7.68 (dd, <i>J</i> = 8.1, 1.9 Hz, 1H), 7.73 (s, 1H), 7.81 (d, <i>J</i> = 7.2 Hz, 1H), 7.82 (d, <i>J</i> = 14.5 Hz, 1H), 8.00 (d, <i>J</i> = 7.1 Hz, 1H), 8.07 (d, <i>J</i> = 2.0 Hz, 2H), 8.30 − 8.38 (m, 3H), 8.74 (s, 1H), 10.47 (s, 1H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): δ −57.17. MS [M + H]<sup>+</sup> 479.1. Anal. calcd for (C<sub>25</sub>H<sub>21</sub>F<sub>3</sub>N<sub>6</sub>O·0.07CH<sub>2</sub>Cl<sub>2</sub>): C, H, N.</div></div><div id="sec10_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (<i>E</i>)-<i>N</i>-(3-(2-(6-(4-(Dimethylphosphoryl)phenylamino)-9<i>H</i>-purin-9-yl)-vinyl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>3g</b>)</h3><div class="NLM_p last">Method B: This compound was made from <b>5g</b> and <b>6</b> in 47% yield. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 1.65 (d, <i>J</i> = 13.2 Hz, 6H), 2.44 (s, 3H), 7.29 (d, <i>J</i> = 8.2 Hz, 1H), 7.69 (dd, <i>J</i> = 7.2, 1.9 Hz, 1H), 7.73−7.87 (m, 3H), 7.78 (d, <i>J</i> = 14.8 Hz, 1H), 7.90 (d, <i>J</i> = 14.7 Hz, 1H), 8.00 (d, <i>J</i> = 7.8 Hz, 1H), 8.11 (m, 1H), 8.14 (d, <i>J</i> = 2.0 Hz, 1H), 8.17 (d, <i>J</i> = 2.0 Hz, 1H), 8.32 (d, <i>J</i> = 8.2 Hz, 1H), 8.36 (s, 1H), 8.60 (s, 1H), 8.97 (s, 1H), 10.29 (s, 1H), 10.49 (s, 1H). <sup>19</sup>F NMR (DMSO-<i>d</i><sub>6</sub>): δ −57.17. <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>): δ 36.77. MS [M + H]<sup>+</sup> 591.4. Anal. calcd for (C<sub>30</sub>H<sub>26</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub>P·0.25CH<sub>2</sub>Cl<sub>2</sub>): C, H, N.</div></div><div id="sec10_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (<i>E</i>)-<i>N</i>-(4-Methyl-3-(2-(6-(3-(<i>N</i>′,<i>N</i>′-dimethylamino)propylamino)-9<i>H</i>-purin-9-yl)vinyl)phenyl)-3-(trifluoromethyl)benzamide (<b>3h</b>)</h3><div class="NLM_p last">Method B: This compound was made from <b>5h</b> and <b>6</b> in 45% yield. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.74 (tt, <i>J</i> = 6.6, 6.6 Hz, 2H), 2.16 (s, 6H), 2.32 (s, 3H), 2.34 (t, <i>J</i> = 6.7 Hz, 2H), 3.64 (m, 2H), 6.75 (t, <i>J</i> = 5.3 Hz, 1H), 7.00 (d, <i>J</i> = 8.3 Hz, 1H), 7.21 (d, <i>J</i> = 17.5 Hz, 1H), 7.34 (d, <i>J</i> = 17.6 Hz, 1H), 7.39 (dd, <i>J</i> = 8.2, 2.1 Hz, 1H), 7.46 (d, <i>J</i> = 7.8 Hz, 1H), 7.59 − 7.65 (m, 2H), 7.85 (s, 1H), 7.94 (d, <i>J</i> = 2.9 Hz, 1H), 8.09 (s, 1H), 8.31 (s, 1H), 8.68 (s, 1H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): δ −63.45. MS [M + H]<sup>+</sup> 524.4. Anal. calcd for (C<sub>27</sub>H<sub>28</sub>F<sub>3</sub>N<sub>7</sub>O): C, H, N.</div></div><div id="sec10_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> <i>N</i>-(4-Methyl-3-(2-(6-(methylamino)-9<i>H</i>-purin-9-yl)ethyl)phenyl)-3-(trifluoromethyl)-benzamide (<b>2</b>)</h3><div class="NLM_p last">To a solution of <b>3a</b> (0.10 g) in MeOH was added a catalytic amount of 10% palladium on carbon. The resulting mixture was hydrogenated under 50 psi H<sub>2</sub> for 48 h, at which point HPLC indicated completion. The catalyst was removed by filtration, and the filtrate was concentrated on a rotavap and further dried under vacuum, giving the desired product in quantitative yield. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.13 (d, <i>J</i> = 7.3 Hz, 3H), 3.21 (t, <i>J</i> = 7.1 Hz, 2H), 3.30 (s, 3H), 4.47 (t, <i>J</i> = 7.1 Hz, 2H), 7.17 (d, <i>J</i> = 8.2 Hz, 1H), 7.37 (d, <i>J</i> = 7.5 Hz, 1H), 7.48 (s, 1H), 7.55 (s, 1H), 7.65 (dd, <i>J</i> = 7.8, 7.7 Hz, 1H), 7.81 (s, 1H), 7.85 (d, <i>J</i> = 7.5 Hz, 1H), 8.08 (d, <i>J</i> = 7.9 Hz, 1H), 8.13 (s, 1H), 8.33 (s, 1H). MS [M + H]<sup>+</sup> 455.3.</div></div><div id="sec10_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (<i>E</i>)-<i>N</i>-(3-(2-(6-Chloro-9<i>H</i>-purin-9-yl)vinyl)-4-methylphenyl)-3-(trifluoromethyl)-benzamide (<b>7</b>)</h3><div class="NLM_p last">Method B: 29% yield. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.42 (s, 3H), 7.28 (d, <i>J</i> = 8.3 Hz, 1H), 7.67 (dd, <i>J</i> = 8.2, 2.1 Hz, 1H), 7.77 (d, <i>J</i> = 14.7 Hz, 1H), 7.80 (dd, <i>J</i> = 7.9, 7.8 Hz, 1H), 7.92 (d, <i>J</i> = 14.7 Hz, 1H), 8.00 (d, <i>J</i> = 7.9 Hz, 1H), 8.12 (d, <i>J</i> = 2.0 Hz, 1H), 8.30 (d, <i>J</i> = 8.0 Hz, 1H), 8.34 (s, 1H), 8.92 (s, 1H), 9.24 (s, 1H), 10.49 (s, 1H). MS [M − H]<sup>+</sup> 455.6.</div></div><div id="sec10_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> General Procedure for the Preparation of <b>3</b> from Pd-Catalyzed Amination of <b>7</b> with Arylamines; (<i>E</i>)-<i>N</i>-(4-Methyl-3-(2-(6-(pyridine-2-yl-amino)-9<i>H</i>-purin-9-yl)vinyl)phenyl)-3-(trifluoromethyl)-benzamide (<b>3c</b>), Method C</h3><div class="NLM_p last">A mixture of compound <b>7</b> (46 mg, 0.1 mmol), 2-aminopyridine (22 mg, 0.2 mmol), dicyclohexylphenylphosphine (11 mg, 0.03 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (18 mg, 0.02 mmol), and K<sub>3</sub>PO<sub>4</sub> (32 mg, 0.15 mmol) was charged in a microwave reaction tube and then degassed via three cycles of vacuum−Ar refilling. Anhydrous DMF (1 mL) was added, and the resulting solution was heated under microwave at 150 °C for 5 min. After cooling to rt, the reaction mixture was filtered and subjected to a silica gel column chromatography (5−10% methanol/methylene chloride), giving the desired product as white solid in 36% yield. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.41 (s, 3H), 7.03 (dd, <i>J</i> = 6.1, 5.9 Hz, 1H), 7.19 (d, <i>J</i> = 6.8 Hz, 1H), 7.49 (s, 1H), 7.52 (d, <i>J</i> = 8.2 Hz, 1H), 7.61−7.69 (m, 2H), 7.76−7.83 (m, 2H), 7.89 (s, 1H), 8.13−8.19 (m, 4H), 8.34 (d, <i>J</i> = 3.7 Hz, 1H), 8.66 (s, 1H), 8.68 (m, 1H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): δ −63.49. MS [M]<sup>+</sup> 515.1.</div></div><div id="sec10_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> (<i>E</i>)-<i>N</i>-(4-Methyl-3-(2-(6-(pyrid-3-yl-amino)-9<i>H</i>-purin-9-yl)vinyl)phenyl)-3-(trifluoromethyl)-benzamide (<b>3d</b>)</h3><div class="NLM_p last">Method C: purified by reverse phase prep-HPLC (MeCN/H<sub>2</sub>O, 0.1% TFA) as TFA salt. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.43 (s, 3H), 7.28 (d, <i>J</i> = 8.3 Hz, 1H), 7.66−7.70 (m, 2H), 7.74 (s, 1H), 7.79 (s, 1H), 7.83 (d, <i>J</i> = 7.9 Hz, 1H), 7.87−7.94 (m, 1H), 8.00 (d, <i>J</i> = 8.0 Hz, 1H), 8.12 (d, <i>J</i> = 1.9 Hz, 1H), 8.30−8.35 (m, 2H), 8.42 (d, <i>J</i> = 5.0 Hz, 1H), 8.63 (s, 1H), 9.00 (s, 1H), 9.35 (d, <i>J</i> = 2.2 Hz, 1H), 10.49 (s, 1H), 10.61 (s, 1H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): δ −57.09, −70.31. MS [M]<sup>+</sup> 515.4.</div></div><div id="sec10_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> (<i>E</i>)-<i>N</i>-(4-Methyl-3-(2-(6-(pyrid-4-yl-amino)-9<i>H</i>-purin-9-yl)vinyl)phenyl)-3-(trifluoromethyl)-benzamide (<b>3e</b>)</h3><div class="NLM_p last">Method C: purified by reverse phase prep-HPLC (MeCN/H<sub>2</sub>O, 0.1% TFA) as TFA salt. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.44 (s, 3H), 7.30 (d, <i>J</i> = 8.2 Hz, 1H), 7.66 (d, <i>J</i> = 7.7 Hz, 1H), 7.77 − 7.84 (m, 2H), 7.94 (d, <i>J</i> = 14.8 Hz, 1H), 8.00 (d, <i>J</i> = 7.7 Hz, 1H), 8.16 (s, 1H), 8.31 (d, <i>J</i> = 8.2 Hz, 1H), 8.35 (s, 1H), 8.58 (d, <i>J</i> = 6.9 Hz, 2H), 8.70 (d, <i>J</i> = 6.9 Hz, 2H), 8.86 (s, 1H), 9.17 (s, 1H), 10.50 (s, 1H), 11.70 (s, 1H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): δ −57.09, −69.99. MS [M]<sup>+</sup> 515.6.</div></div><div id="sec10_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> (<i>E</i>)-<i>N</i>-(4-Methyl-3-(2-(6-(pyrimid-4-yl-amino)-9<i>H</i>-purin-9-yl)-vinyl)-phenyl)-3-(trifluoromethyl)-benzamide (<b>3f</b>)</h3><div class="NLM_p last">Method C: purified by reverse phase prep-HPLC (MeCN/H<sub>2</sub>O, 0.1% TFA) as TFA salt. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.27 (s, 3H), 7.25 (d, <i>J</i> = 8.3 Hz, 1H), 7.69 (dd, <i>J</i> = 7.9, 1.9 Hz, 1H), 7.70 (d, <i>J</i> = 15.0 Hz, 1H), 7.76 (d, <i>J</i> = 15.5 Hz, 1H), 7.78 (s, 1H), 7.82 (d, <i>J</i> = 7.8 Hz, 1H), 7.98 (d, <i>J</i> = 7.7 Hz, 1H), 8.05 (d, <i>J</i> = 1.9 Hz, 1H), 8.23 (d, <i>J</i> = 5.8 Hz, 1H), 8.32 (d, <i>J</i> = 8.1 Hz, 1H), 8.34 (d, <i>J</i> = 5.6 Hz, 1H), 8.36 (d, <i>J</i> = 6.2 Hz, 1H), 8.60 (s, 1H), 8.66 (s, 1H), 10.49 (s, 1H). <sup>19</sup>F NMR (CDCl<sub>3</sub>): δ −57.16. MS [M]<sup>+</sup> 516.7. Anal. calcd for (C<sub>26</sub>H<sub>19</sub>F<sub>3</sub>N<sub>8</sub>O·0.6CF<sub>3</sub>CO<sub>2</sub>H): C, H, N.</div></div><div id="sec10_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> General Procedure for the Preparation of 3-Iodo-4-methylbenzamides <b>8</b>; 3-Iodo-4-methyl-<i>N</i>-(4-(trifluoromethyl)pyridin-2-yl)benzamide (<b>8i</b>), Method D</h3><div class="NLM_p last">3-Iodo-4-methylbenzoic acid (2.62 g, 10 mmol) was refluxed in SOCl<sub>2</sub> (10 mL) for 1 h. The volatile components were removed on a rotavap, and the residue was dissolved in benzene (10 mL), concentrated to dryness on a rotavap, and further dried under vacuum. The resulting acyl chloride was added to a solution of 2-amino-4-(trifluoromethyl)pyridine (1.65 g, 10.2 mmol), <i>N</i>,<i>N</i>-diisopropylethylamine (1.56 g, 12 mmol), and a catalytic amount of DMAP in THF (20 mL). After stirring at rt for 2 h, the reaction was quenched with water. EtOAc was added, and the layers were separated. The combined organic layers were concentrated to dryness, giving a mixture of desired product (major) and bis-acylated byproduct; the latter is slightly less polar (TLC) but difficult to separate by column chromatography. The product mixture was then dissolved in THF (30 mL) and stirred with 4 N aq NaOH (30 mL) at 50 °C for 15 min. Extraction with EtOAc followed by concentration of combined organic layers gave the desired product, which was pure by NMR and used in next step without purification. Yield: 95%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.45 (s, 3H), 7.48 (d, <i>J</i> = 8.1 Hz, 1H), 7.54 (dd, <i>J</i> = 5.1, 1.9 Hz, 1H), 7.97 (dd, <i>J</i> = 7.9, 1.8 Hz, 1H), 8.49 (d, <i>J</i> = 1.8 Hz, 1H), 8.51 (m, 1H), 8.68 (d, <i>J</i> = 5.1 Hz, 1H), 11.33 (s, 1H). MS [M + H]<sup>+</sup> 407.0.</div></div><div id="sec10_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> <i>N</i>-(3-(<i>tert</i>-Butyl)phenyl)-3-iodo-4-methylbenzamide (<b>8d</b>)</h3><div class="NLM_p last">Method D. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 1.29 (s, 9H), 2.45 (s, 3H), 7.14 (dtt, <i>J</i> = 7.9, 1.8, 1.0 Hz, 1H), 7.09 (dd, <i>J</i> = 7.9, 7.9 Hz, 1H), 7.48 (d, <i>J</i> = 8.1 Hz, 1H), 7.66 (dtt, <i>J</i> = 8.0, 1.9, 1.0 Hz, 1H), 7.75 (dd, <i>J</i> = 1.9, 1.8 Hz, 1H), 7.91 (dd, <i>J</i> = 7.9, 1.8 Hz, 1H), 8.41 (d, <i>J</i> = 1.8 Hz, 1H), 10.16 (s, 1H).</div></div><div id="sec10_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> <i>N</i>-(3-(<i>iso</i>-Propyl)phenyl)-3-iodo-4-methylbenzamide (<b>8e</b>)</h3><div class="NLM_p last">Method D. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 1.22 (d, <i>J</i> = 6.9 Hz, 6H), 2.44 (s, 3H), 2.88 (septet, <i>J</i> = 6.9 Hz, 1H), 6.99 (d, <i>J</i> = 7.7 Hz, 1H), 7.26 (dd, <i>J</i> = 7.8, 7.7 Hz, 1H), 7.48 (d, <i>J</i> = 8.0 Hz, 1H), 7.61 − 7.63 (m, 2H), 7.91 (dd, <i>J</i> = 7.9, 1.8 Hz, 1H), 8.41 (d, <i>J</i> = 1.8 Hz, 1H), 10.16 (s, 1H).</div></div><div id="sec10_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> <i>N</i>-(5-(<i>tert</i>-Butyl)-1<i>H</i>-oxazo-3-yl)-3-iodo-4-methylbenzamide (<b>8g</b>)</h3><div class="NLM_p last">Method D. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.39 (s, 9Η), 2.52 (s, 3H), 6.84 (s, 1H), 7.37 (d, <i>J</i> = 7.9 Hz, 1H), 7.84 (dd, <i>J</i> = 7.9, 1.7 Hz, 1H), 8.40 (d, <i>J</i> = 1.7 Hz, 1H), 9.36 (s, 1H).</div></div><div id="sec10_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> <i>N</i>-(1-Methyl-3-(<i>tert</i>-butyl)-1<i>H</i>-pyrazo-5-yl)-3-iodo-4-methylbenzamide (<b>8h</b>)</h3><div class="NLM_p last">Method D. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 1.23 (s, 9Η), 2.45 (s, 3H), 3.61 (s, 3H), 6.09 (s, 1H), 7.49 (d, <i>J</i> = 8.1 Hz, 1H), 7.89 (dd, <i>J</i> = 7.9, 1.7 Hz, 1H), 8.39 (d, <i>J</i> = 1.7 Hz, 1H), 10.24 (s, 1H).</div></div><div id="sec10_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> (<i>E</i>)-3-(2-(6-(Cyclopropylamino)-9<i>H</i>-purin-9-yl)vinyl)-4-methyl-<i>N</i>-(3-(trifluoromethyl)phenyl)benzamide (<b>9a</b>)</h3><div class="NLM_p last">Method B. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 0.71 (m, 2H), 0.97 (m, 2H), 2.50 (s, 3H), 3.13 (m, 1H), 7.34 (d, <i>J</i> = 7.9 Hz, 1H), 7.41 (d, <i>J</i> = 8.0 Hz, 1H), 7.48 (d, <i>J</i> = 8.0 Hz, 1H), 7.55 (d, <i>J</i> = 16.0 Hz, 1H), 7.62 (s, 1H), 7.66 (s, 1H), 7.73 (dd, <i>J</i> = 7.9, 1.8 Hz, 1H), 7.93 (d, <i>J</i> = 8.2 Hz, 1H), 8.01 (s, 1H), 8.07 (m, 2H), 8.23 (s, 1H), 8.50 (s, 1H). Anal. calcd for (C<sub>25</sub>H<sub>21</sub>F<sub>3</sub>N<sub>6</sub>O·0.02CH<sub>2</sub>Cl<sub>2</sub>): C, H, N.</div></div><div id="sec10_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (<i>E</i>)-3-(2-(6-(Cyclopropylamino)-9<i>H</i>-purin-9-yl)vinyl)-4-methyl-<i>N</i>-(2-fluoro-5-(trifluoromethyl)phenyl)benzamide (<b>9b</b>)</h3><div class="NLM_p last">Method B; purified by reverse phase prep-HPLC (MeCN/H<sub>2</sub>O, 0.1% TFA) as TFA salt. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 0.72 (m, 2H), 0.82 (m, 2H), 2.51 (s, 3H), 2.98 (m, 1H), 7.44 (d, <i>J</i> = 8.1 Hz, 1H), 7.58 (dd, <i>J</i> = 9.6, 9.2 Hz, 1H), 7.68 (m, 1H), 7.85 (dd, <i>J</i> = 7.9, 1.8 Hz, 1H), 7.90 (d, <i>J</i> = 10.0 Hz, 1H), 7.94 (d, <i>J</i> = 14.7 Hz, 1H), 7.85 (dd, <i>J</i> = 7.9, 1.8 Hz, 1H), 8.11 (dd, <i>J</i> = 6.7, 1.9 Hz, 1H), 8.29 (d, <i>J</i> = 1.5 Hz, 1H), 8.46 (s, 1H), 8.80 (s, 1H), 10.43 (s, 1H). MS [M + H]<sup>+</sup> 496.7. Anal. calcd for (C<sub>25</sub>H<sub>20</sub>F<sub>4</sub>N<sub>6</sub>O·1.7CF<sub>3</sub>CO<sub>2</sub>H): C, H, N.</div></div><div id="sec10_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (<i>E</i>)-3-(2-(6-(Cyclopropylamino)-9<i>H</i>-purin-9-yl)vinyl)-4-methyl-<i>N</i>-(4-chloro-3-(trifluoromethyl)phenyl)benzamide (<b>9c</b>)</h3><div class="NLM_p last">Method B; purified by reverse phase prep-HPLC (MeCN/H<sub>2</sub>O, 0.1% TFA) as TFA salt. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 0.71 (m, 2H), 0.81 (m, 2H), 2.51 (s, 3H), 3.04 (m, 1H), 7.45 (d, <i>J</i> = 8.1 Hz, 1H), 7.45 (d, <i>J</i> = 8.1 Hz, 1H), 7.85 (dd, <i>J</i> = 7.9, 1.8 Hz, 1H), 7.90 (d, <i>J</i> = 3.2 Hz, 2H), 8.15 (dd, <i>J</i> = 8.6, 2.4 Hz, 1H), 8.25 (d, <i>J</i> = 1.6 Hz, 1H), 8.38 (d, <i>J</i> = 2.5 Hz, 1H), 8.46 (s, 1H), 8.76 (s, 1H), 10.67 (s, 1H). MS [M + H]<sup>+</sup> 512.7. Anal. calcd for (C<sub>25</sub>H<sub>20</sub>ClF<sub>3</sub>N<sub>6</sub>O·1.4CF<sub>3</sub>CO<sub>2</sub>H): C, H, N.</div></div><div id="sec10_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> (<i>E</i>)-3-(2-(6-(Cyclopropylamino)-9<i>H</i>-purin-9-yl)vinyl)-4-methyl-<i>N</i>-(3-(<i>tert</i>-butyl)phenyl)benzamide (<b>9d</b>)</h3><div class="NLM_p last">Method B; purified by reverse phase prep-HPLC (MeCN/H<sub>2</sub>O, 0.1% TFA) as TFA salt. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 0.71 (m, 2H), 0.81 (m, 2H), 1.31 (s, 9H), 2.51 (s, 3H), 3.06 (m, 1H), 7.15 (m, 1H), 7.29 (dd, <i>J</i> = 7.9, 7.9 Hz, 1H), 7.42 (d, <i>J</i> = 8.0 Hz, 1H), 7.69 (m, 1H), 7.79 (dd, <i>J</i> = 1.9, 1.9 Hz, 1H), 7.84 (dd, <i>J</i> = 7.6, 1.7 Hz, 1H), 7.91 (d, <i>J</i> = 3.8 Hz, 2H), 8.24 (d, <i>J</i> = 1.4 Hz, 1H), 8.45 (s, 1H), 8.75 (s, 1H), 10.21 (s, 1H). MS [M + H]<sup>+</sup> 466.7. Anal. calcd for (C<sub>28</sub>H<sub>30</sub>N<sub>6</sub>O·1.2CF<sub>3</sub>CO<sub>2</sub>H): C, H, N.</div></div><div id="sec10_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> (<i>E</i>)-3-(2-(6-(Cyclopropylamino)-9<i>H</i>-purin-9-yl)vinyl)-4-methyl-<i>N</i>-(3-(<i>iso</i>-propyl)phenyl)benzamide (<b>9e</b>)</h3><div class="NLM_p last">Method B; purified by reverse phase prep-HPLC (MeCN/H<sub>2</sub>O, 0.1% TFA) as TFA salt. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 0.71 (m, 2H), 0.80 (m, 2H), 1.23 (d, <i>J</i> = 6.9 Hz, 6H), 2.51 (s, 3H), 2.89 (septet, <i>J</i> = 6.9 Hz, 1H), 3.06 (m, 1H), 7.00 (d, <i>J</i> = 7.6 Hz, 1H), 7.28 (dt, <i>J</i> = 2.5, 7.8 Hz, 1H), 7.42 (d, <i>J</i> = 8.0 Hz, 1H), 7.65 (m, 2H), 7.83 (dd, <i>J</i> = 2.0, 1.7 Hz, 1H), 7.90(s, 1H), 7.92 (s, 1H), 8.24 (d, <i>J</i> = 1.5 Hz, 1H), 8.45 (s, 1H), 8.75 (s, 1H), 10.21 (s, 1H). MS [M + H]<sup>+</sup> 452.7.</div></div><div id="sec10_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> (<i>E</i>)-3-(2-(6-(Cyclopropylamino)-9<i>H</i>-purin-9-yl)vinyl)-4-methyl-<i>N</i>-(5-(<i>tert</i>-butyl)thiazo-2-yl)benzamide (<b>9f</b>)</h3><div class="NLM_p last">Method B. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 0.70 (m, 2H), 0.89 (m, 2H), 1.31 (s, 9H), 2.53 (s, 3H), 3.09 (m, 1H), 6.01 (s, 1H), 6.61 (s, 1H), 7.38 (d, <i>J</i> = 8.0 Hz, 1H), 7.61 (d, <i>J</i> = 14.6 Hz, 1H), 7.78 (d, <i>J</i> = 14.9 Hz, 1H), 7.82 (dd, <i>J</i> = 8.0, 1.9 Hz, 1H), 8.06 (s, 1H), 8.17 (d, <i>J</i> = 1.6 Hz, 1H), 8.56 (s, 1H). Anal. calcd for (C<sub>25</sub>H<sub>27</sub>N<sub>7</sub>OS): C, H, N.</div></div><div id="sec10_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> (<i>E</i>)-3-(2-(6-(Cyclopropylamino)-9<i>H</i>-purin-9-yl)vinyl)-4-methyl-<i>N</i>-(5-(<i>tert</i>-butyl)oxazo-3-yl)benzamide (<b>9g</b>)</h3><div class="NLM_p last">Method B. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 0.75 (m, 2H), 0.98 (m, 2H), 1.39 (s, 9H), 2.52 (s, 3H), 3.15 (m, 1H), 6.62 (br, 1H), 6.88 (s, 1H), 7.27−7.52 (m, 2H), 7.66 (m, 1H), 8.00 (m, 1H), 8.05 (d, <i>J</i> = 18.8 Hz, 1H), 8.49 (s, 1H), 9.31 (s, 1H).</div></div><div id="sec10_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> (<i>E</i>)-3-(2-(6-(Cyclopropylamino)-9<i>H</i>-purin-9-yl)vinyl)-4-methyl-<i>N</i>-(1-methyl-3-(<i>tert</i>-butyl)pyrazo-5-yl)benzamide (<b>9h</b>)</h3><div class="NLM_p last">Method B; purified by reverse phase prep-HPLC (MeCN/H<sub>2</sub>O, 0.1% TFA) as TFA salt. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 0.71 (m, 2H), 0.80 (m, 2H), 1.27 (s, 9H), 2.51 (s, 3H), 3.06 (m, 1H), 3.64 (s, 3H), 6.11 (s, 1H), 7.43 (d, <i>J</i> = 8.0 Hz, 1H), 7.82 (dd, <i>J</i> = 8.0, 1.6 Hz, 1H), 7.84 (d, <i>J</i> = 14.8 Hz, 1H), 7.89 (d, <i>J</i> = 10.4 Hz, 1H), 7.93 (d, <i>J</i> = 14.7 Hz, 1H), 8.26 (s, 1H), 8.44 (s, 1H), 8.78 (s, 1H), 10.29 (s, 1H). MS [M + H]<sup>+</sup> 470.7. Anal. calcd for (C<sub>26</sub>H<sub>30</sub>N<sub>8</sub>O·2CF<sub>3</sub>CO<sub>2</sub>H): C, H, N.</div></div><div id="sec10_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> (<i>E</i>)-3-(2-(6-(Cyclopropylamino)-9<i>H</i>-purin-9-yl)vinyl)-4-methyl-<i>N</i>-(4-(trifluoromethyl)pyridin-2-yl)benzamide (<b>9i</b>)</h3><div class="NLM_p last">Method B; 82% yield, white solid, mp 232 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 11.44 (s, 1Η), 8.72 (s, 1H), 8.69 (s, 1H), 8.59 (s, 1H), 8.38 (m, 2H), 8.05 (m, 1H), 8.03 (d, 1H, <i>J</i> = 14.7 Hz), 7.87 (d, 1H, <i>J</i> = 7.9 Hz), 7.81 (d, 1H, <i>J</i> = 14.7 Hz), 7.55 (d, 1H, <i>J</i> = 4.1 Hz), 7.42 (d, 1H, <i>J</i> = 8.0 Hz), 3.09 (m, 1H), 2.43 (s, 3H), 0.74 (m, 2H), 0.66 (m, 2H). MS [M + H]<sup>+</sup> 480.0 Anal. calcd for (C<sub>24</sub>H<sub>20</sub>F<sub>3</sub>N<sub>7</sub>O): C, H, N.</div></div><div id="sec10_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> <i>N</i>-(3-Iodo-4-methylphenyl)-<i>N</i>′-(3-(trifluoromethyl)phenyl)urea (<b>10</b>)</h3><div class="NLM_p last">A mixture of 3-(trifluoromethyl)phenylisocyanate (1.03 g, 5.5 mmol) and 3-iodo-4-methylaniline (1.17 g, 5 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was stirred at rt for 4 h. Filtration gave pure product as white solid, 98% yield. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 2.31 (s, 3H), 7.22−7.33 (m, 3H), 7.48−7.59 (m, 2H), 8.00 (s, 1H), 8.09 (d, <i>J</i> = 2.0 Hz, 1H), 8.80 (s, 1H), 9.03 (s, 1H).</div></div><div id="sec10_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> (<i>E</i>)-1-(3-(2-(6-(Cyclopropylamino)-9<i>H</i>-purin-9-yl)vinyl)-4-methylphenyl)-3-(3-(trifluoromethyl)phenyl)urea (<b>11</b>)</h3><div class="NLM_p last">Method B. <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 0.67 (m, 2H), 0.89 (m, 2H), 2.39 (s, 3H), 2.98 (m, 1H), 7.12−7.33 (m, 3H), 7.46 (m, 1H), 7.58−7.80 (m, 4H), 7.93 (s, 1H), 8.37 (s, 1H), 8.44 (s, 1H).</div></div><div id="sec10_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> (<i>E</i>)-3-(2-(6-(Cyclopropylamino)-9<i>H</i>-purin-9-yl)vinyl)-4-methyl-<i>N</i>-(3-(4-methyl-1-imidazol-1-yl)-5-(trifluoromethyl)phenyl)benzamide (<b>14a</b>)</h3><div class="NLM_p last">Method B. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 0.66 (m, 2H), 0.74 (m, 2H), 2.19 (s, 3H), 2.50 (s, 3H), 3.29 (m, 1H), 7.45 (d, <i>J</i> = 8.1 Hz, 1H), 7.50 (s, 1H), 7.74 (s, 1H), 7.86 (dd, <i>J</i> = 7.9, 1.6 Hz, 1H), 7.90 (d, <i>J</i> = 1.3 Hz, 2H), 8.16−8.21 (m, 2H), 8.27 (d, <i>J</i> = 1.3 Hz, 1H), 8.33−8.39 (m, 2H), 8.67 (s, 1H), 10.71 (s, 1H). MS [M + H]<sup>+</sup> 558.8. Anal. calcd for (C<sub>29</sub>H<sub>25</sub>F<sub>3</sub>N<sub>8</sub>O·0.09CH<sub>2</sub>Cl<sub>2</sub>): C, H, N.</div></div><div id="sec10_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 3-Iodo-4-methyl-<i>N</i>-[3-(imidazol-1-yl)-5-(trifluoromethyl)phenyl]-benzamide (<b>13b</b>)</h3><div class="NLM_p last">Prepared via our previously reported procedure for the synthesis of <b>13a</b>.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): 2.47 (s, 3H), 7.28 (s, 1H), 7.59 (d, <i>J</i> = 8.0 Hz, 1H), 7.84 (s, 2H), 7.95 (d, <i>J</i> = 7.9 Hz, 1H), 8.22 (s, 1H), 8.33 (s, 1H), 8.36 (s, 1H), 8.50 (s, 1H), 10.71 (s, 1H).</div></div><div id="sec10_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> (<i>E</i>)-3-(2-(6-(Cyclopropylamino)-9<i>H</i>-purin-9-yl)vinyl)-4-methyl-<i>N</i>-(3-(1<i>H</i>-imidazol-1-yl)-5-(trifluoromethyl)phenyl)benzamide (<b>14b</b>)</h3><div class="NLM_p last">Method B. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): 0.67 (m, 2H), 0.76 (m, 2H), 2.50 (s, 3H), 3.67 (m, 1H), 7.44 (d, <i>J</i> = 8.0 Hz, 2H), 7.84−7.92 (m, 4H), 8.06 (d, <i>J</i> = 8.1 Hz, 2H), 8.26 (s, 1H), 8.29 (d, <i>J</i> = 16.8 Hz, 2H), 8.39 (s, 1H), 8.67 (s, 1H), 10.62 (s, 1H). MS [M + H]<sup>+</sup> 545.1.</div></div><div id="sec10_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 5-(4-Morpholinyl)-3-(trifluoromethyl)benzenamine (<b>15a</b>)</h3><div class="NLM_p last">A suspension of 3-bromo-5-(trifluoromethyl)aniline (3.0 g, 12.5 mmol), <i>N</i>-methylpiperazine (5.55 g, 50 mmol), and CsOH monohydrate (4.20 g, 25 mmol) in DMSO (48 mL) was heated at 120 °C in a sealed tube for 4 h. DMSO was then removed under vacuum. The residue was suspended in CH<sub>2</sub>Cl<sub>2</sub>, and the inorganic salts were filtered off. The filtrate was concentrated on rotavap and then subjected to silica gel column chromatography (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>), yielding the desired product as pale-yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 3.23 (m. 4H), 3.92 (m, 4H), 6.35 (s, 1H), 6.45 (s, 1H), 6.56 (s, 1H).</div></div><div id="sec10_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 3-(4-Methyl-1-piperazinyl)-5-(trifluoromethyl)benzenamine (<b>15b</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.34 (s, 3H), 2.65 (m, 4H), 3.30 (m, 4H), 3.79 (br, 2H), 6.31 (s, 1H), 6.39 (s, 1H), 6.51 (s, 1H).</div></div><div id="sec10_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> 3-Iodo-4-methyl-<i>N</i>-[3-(morpholin-4-yl)-5-(trifluoromethyl)phenyl]-benzamide (<b>16a</b>)</h3><div class="NLM_p last">Method D. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): 3.21 (m, 4H), 3.78 (m, 4H), 7.01 (s, 1H), 7.50 (d, <i>J</i> = 8.0 Hz, 1H), 7.67 (s, 1H), 7.69 (s, 1H), 7.98 (d, <i>J</i> = 7.9 Hz, 1H), 8.41 (s, 1H), 10.31 (s, 1H).</div></div><div id="sec10_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 3-Iodo-4-methyl-<i>N</i>-[3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)-phenyl]benzamide (<b>16b</b>)</h3><div class="NLM_p last">Method D. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): 2.23 (s, 3H), 2.46 (s, 3H), 2.50 (m, 4H), 3.27 (m, 4H), 6.97 (s, 1H), 7.54 (d, <i>J</i> = 8.0 Hz, 1H), 7.64 (s, 1H), 7.66 (s, 1H), 7.94 (d, <i>J</i> = 7.9 Hz, 1H), 8.33 (s, 1H), 10.29 (s, 1H).</div></div><div id="sec10_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> (<i>E</i>)-3-(2-(6-(Cyclopropylamino)-9<i>H</i>-purin-9-yl)vinyl)-4-methyl-<i>N</i>-[3-(morpholin-4-yl)-5-(trifluoromethyl)phenyl]benzamide (<b>17a</b>)</h3><div class="NLM_p last">Method B. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): 0.67 (m, 2H), 0.73 (m, 2H), 2.49 (s, 3H), 3.14 (m, 1H), 3.21 (t, <i>J</i> = 4.6 Hz, 2H), 3.77 (t, <i>J</i> = 4.6 Hz, 2H), 6.98 (s, 1H), 7.43 (d, <i>J</i> = 8.0 Hz, 1H), 7.70 (m, 2H), 7.83 (d, <i>J</i> = 7.71, 1H), 7.91 (s, 1H), 7.93 (d, <i>J</i> = 15.5 Hz, 1H), 8.05 (d, <i>J</i> = 3.5 Hz, 1H), 8.24 (s, 1H), 8.39 (s, 1H), 8.66 (s, 1H), 10.39 (s, 1H). MS [M + H]<sup>+</sup> 564.1. Anal. calcd for (C<sub>29</sub>H<sub>28</sub>F<sub>3</sub>N<sub>7</sub>O<sub>2</sub>): C, H, N.</div></div><div id="sec10_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> (<i>E</i>)-3-(2-(6-(Cyclopropylamino)-9<i>H</i>-purin-9-yl)vinyl)-4-methyl-<i>N</i>-[3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)phenyl]benzamide (<b>17b</b>)</h3><div class="NLM_p last">Method B. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): 0.68 (m, 2H), 0.77 (m, 2H), 2.36 (s, 3H), 2.50 (s, 3H), 2.60 (m, 4H), 3.25 (m, 4H), 4.05 (m, 1H), 7.01 (s, 1H), 7.42 (d, <i>J</i> = 8.1 Hz, 1H), 7.86 (d, <i>J</i> = 14.8 Hz, 1H), 7.81 − 7.91 (m, 4H), 8.04 (br, 1H), 8.24 (s, 1H), 8.38 (s, 1H), 8.66 (s, 1H), 10.57 (s, 1H). MS [M + H]<sup>+</sup> 577.1.</div></div><div id="sec10_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> (<i>E</i>)-3-(2-(Purin-9-yl)vinyl)-4-methyl-<i>N</i>-(3-(4-methyl-1-imidazol-1-yl)-5-(trifluoromethyl)phenyl)benzamide (<b>18a</b>)</h3><div class="NLM_p last">Method B. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): 2.19 (s, 3H), 2.50 (s, 3H), 7.49 (d, <i>J</i> = 8.3 Hz, 1H), 7.50 (s, 1H), 7.75 (s, 1H), 7.89 (d, <i>J</i> = 7.9 Hz, 1H), 8.02 (d, <i>J</i> = 3.1 Hz, 2H), 8.19 (d, <i>J</i> = 17.1 Hz, 2H), 8.32 (d, <i>J</i> = 6.8 Hz, 2H), 9.11 (s, 2H), 9.29 (s, 1H), 10.72 (s, 1H). MS [M + H]<sup>+</sup> 503.9. Anal. calcd for (C<sub>26</sub>H<sub>20</sub>F<sub>3</sub>N<sub>7</sub>O): C, H, N.</div></div><div id="sec10_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> (<i>E</i>)-3-(2-(Purin-9-yl)vinyl)-4-methyl-<i>N</i>-(4-(trifluoromethyl)pyridin-2-yl)benzamide (<b>18b</b>)</h3><div class="NLM_p last">Method B. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): 2.73 (s, 1.5H), 2.89 (s, 1.5H), 7.43 (d, <i>J</i> = 8.0 Hz, 1H), 7.54 (d, <i>J</i> = 4.3 Hz, 1H), 7.88−7.94 (m, 2H), 8.13 (d, <i>J</i> = 14.7 Hz, 1H), 8.40 (s, 1H), 8.59 (s, 1H), 8.70 (d, <i>J</i> = 4.7 Hz, 1H), 9.10 (s, 1H), 9.14 (s, 1H), 9.28 (s, 1H), 11.41 (s, 1H). MS [M + H]<sup>+</sup> 424.9. Anal. calcd for (C<sub>21</sub>H<sub>15</sub>F<sub>3</sub>N<sub>6</sub>O·0.15CH<sub>2</sub>Cl<sub>2</sub>): C, H, N.</div></div><div id="sec10_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Modeling Studies</h3><div class="NLM_p last">The binding site model used for Abl docking was based on the X-ray coordinates of Abl bound with an imatinib derivative, PDB-ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1fpu">1fpu</a>. Protein side chains within a 5 Å radius of the bound ligand were allowed to relax to optimize binding interactions using the Induced Fit protocol in the Schrodinger package.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The binding site model used for Src docking was based on a homology model of Src built from the crystal structure of Lck bound with a DFG-out inhibitor (2og8)<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> using Prime in the Schrodinger package. Docking studies were performed with Glide in the Schrodinger modeling package.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The solution with the best docking score was chosen and used for analysis.</div></div><div id="sec10_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Wild Type Abl, Abl T315I, and Src LANCE Assay</h3><div class="NLM_p last">Inhibition of wild type Abl, Abl T315I, or Src activity was measured in a homogeneous time-resolved fluorescence resonance energy transfer (TR-FRET) assay using purified human wild-type Abl kinase (Panvera), Abl T315I (Upstate Biotechnology Inc.), or partially purified human Src (Upstate Biotechnology Inc.), and biotinylated phosphokinase substrate peptides: Biotin-EKKMAAEAIYAAPFAK-NH<sub>2</sub> (Quality Controlled Biochemicals) for wild type Abl and Abl T315I, and Biotin-KVEKIGEGTYGVVYK-NH<sub>2</sub> (Pierce) for Src. The kinase reactions were carried out in complete LANCE kinase buffer (LKB) and consisted of 20 mM NaHEPES pH 7.4, 0.1 mg/mL BSA, 1 mM ATP, 10 mM MgCl<sub>2</sub>, and 0.41 mM DTT in round-bottom black 96-well Microfluor plates (Dynex Technologies Inc.) preblocked with 1% BSA in PBS at 4 °C overnight. For the kinase reaction, compound dilutions were incubated with wild type Abl or Abl T315I (40 pM) or Src (165 pM) and their substrate peptide (50 nM) 1 h for Abl T315I or 2 h for Abl at room temperature, or 2 h at 37 °C for Src, in a total volume of 0.1 mL LKB. The kinase reaction was terminated by addition of 0.05 mL of a kill/detection solution containing 15 μM of a potent ARIAD kinase inhibitor, 6 nM europium-labeled antiphosphotyrosine mAb PT66 and 60 nM allophycocyanin-labeled streptavidin (LANCE reagents from Perkin-Elmer Inc.). Assay plates were incubated at room temperature in the dark for 20 min prior to reading fluorescence at 615 and 665 nm on a Victor2 V plate reader (Perkin-Elmer). Positive and negative controls and a standard curve for phosphorylated peptide were included on each plate. Data values were transferred to an Excel spreadsheet and IC<sub>50</sub>s were calculated from the fluorescence at 665 nm by interpolation between the averaged duplicate well data on 3-fold serial dilutions of test inhibitor.</div></div><div id="sec10_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Proliferation Assay</h3><div class="NLM_p last">K562 human wild-type Bcr-Abl CML cell line and murine pro-B Ba/F3 cell line stably transfected with constructs expressing full-length wild-type Bcr-Abl or Bcr-Abl with various kinase domain point mutations (T315I, L248R, G250E, Q252H, Y253H, and E255K) were used in the cell proliferation assays. The parental Ba/F3 cell line was used as control. K562 cell line was obtained from the American Type Culture Collection (ATCC) and maintained in Iscove’s modified Dulbecco’s medium with 10% FBS. Ba/F3 cell lines were kindly provided by Brian J. Druker (Howard Hughes Medical Institute, Oregon Health and Science University, Portland, OR) and were maintained in RPMI 1640 growth medium with 10% FBS except the parental Ba/F3 cell line, which was maintained in the same medium supplemented with 10 ng/mL IL-3. All cells were incubated at 37 °C in 5% CO<sub>2</sub>. After the compounds were incubated with the cells for 3 days, the number of viable cells in each well in 96-well plate was measured using an MTS assay (Promega). MTS reagent was added to all wells and then the plates were returned to the incubator at 37 °C for 2 h. The absorbance in each well was then measured at 490 nm using a Wallac Victor<sup>2</sup>V plate reader. The IC<sub>50</sub> was calculated by determining the concentration of compound required to decrease the MTS signal by 50% in best-fit curves using Microsoft XLfit software and comparing with baseline, the DMSO control, as 0% inhibition.</div></div><div id="sec10_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Pharmacokinetics (PK) and in Vivo Efficacy</h3><div class="NLM_p">All in vivo experiments were conducted in accordance with ARIAD Pharmaceuticals, Inc. Institutional Animal Care and Use Committee (IACUC) guidelines. Unless otherwise stated, all animals were obtained from Charles River Laboratories (Wilmington, MA). Rats were housed two per cage and mice were housed five per cage, were in micro isolator caging, and were offered food and water ad libitum unless otherwise stated.</div><div id="sec10_47_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> PK Studies</h4><div class="NLM_p">Oral and intravenous pharmacokinetic testing was performed on CD rats. For oral dosing, the rats were fasted overnight and received food 2 h post dosing. Each rat was dosed according to each individual body weight measured just prior to dose administration. The dosing levels and volumes were set at 15 mg/kg and 4 mL for po administration and 5 mg/kg and 2 mL for iv administration. Blood was collected into microcentrifuge tubes containing a small amount of 5 mM EDTA from the retro orbital plexus of each rat at prescribed time points, the tubes were centrifuged, and plasma was isolated for LC-MS analysis.</div><div class="NLM_p last">As a prerequisite to evaluating in vivo efficacy, some compounds were subjected to oral pharmacokinetic testing on mice. The animals were not fasted and were dosed at a fixed volume of 10 mL and three different levels (10, 30, and 100 mg/kg) for the purpose of observing dose response. Blood was collected from three mice at each time point via exsanguination.</div></div><div id="sec10_47_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> In Vivo Efficacy Studies</h4><div class="NLM_p last">(1) Ba/F3 WT Bcr-Abl survival model: Ba/F3 cell line expressing wild type Bcr-Abl was kindly provided by Brian J. Druker (Howard Hughes Medical Institute, Oregon Health and Science University, Portland, OR). Eight to ten week old female CB17 SCID mice were injected intravenously with 1 × 10<sup>6</sup> cells per mouse on day zero and randomly selected into groups (<i>n</i> = 10). Treatments began on day three after cell injection and were administered daily for up to 21 consecutive days. Mice were observed twice daily during the week and once daily during the weekend. Animals were euthanized via CO<sub>2</sub> asphyxiation when they became moribund according to the company IACUC guidelines. Mice dead of disease were verified showing splenomegaly at necropsy. Percent survival refers to the percentage of mice remaining “on-study” at the end of the day. (2) Src Y527F mouse tumor model: A c-Src Y527F overexpressing cell line was established from NIH3T3 mouse fibroblasts transformed with a mutant chicken Src (Y527F). It was kindly provided by Dr. David Shalloway at Cornell University. Eight to ten week old female CD-1 nude mice were injected subcutaneously with 2 × 10<sup>6</sup> cells per mouse and were randomly selected into treatment groups (<i>n</i> = 10) when the average tumor size was ∼200 mm<sup>3</sup> (day zero). Treatments were administered orally for 21 consecutive days. Subcutaneous tumors were measured 2 or 3 times weekly. Tumor volume (in mm<sup>3</sup>) was calculated using the formula (<i>L</i> × <i>W</i><sup>2</sup>)/2. When a tumor reached 10% of the body weight of the host, the animal was euthanized via CO<sub>2</sub> asphyxiation.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="si1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i69"><a href="/doi/suppl/10.1021/jm900166t">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65265" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65265" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Combustion analysis of certain tested compounds. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm900166t/suppl_file/jm900166t_si_001.pdf">jm900166t_si_001.pdf (19.58 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm900166t" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71578" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71578" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei-Sheng Huang</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f1869498dc8299949f96df9984909f96b19083989095df929e9c"><span class="__cf_email__" data-cfemail="3641535f1b455e535851185e435758517657445f57521855595b">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaotian Zhu</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yihan Wang</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mohammad Azam</span> - <span class="hlFld-Affiliation affiliation">Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Division of Hematology/Oncology, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, The Children’s Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Wen</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Raji Sundaramoorthi</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">R. Mathew Thomas</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuangying Liu</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Geetha Banda</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott P. Lentini</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sasmita Das</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qihong Xu</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeff Keats</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Frank Wang</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott Wardwell</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yaoyu Ning</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph T. Snodgrass</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marc I. Broudy</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karin Russian</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">George Q. Daley</span> - <span class="hlFld-Affiliation affiliation">Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Division of Hematology/Oncology, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, The Children’s Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John Iuliucci</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David C. Dalgarno</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tim Clackson</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tomi K. Sawyer</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William C. Shakespeare</span> - <span class="hlFld-Affiliation affiliation">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i70">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86524" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86524" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 36 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Nowell, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hungerford, D. A.</span><span> </span><span class="NLM_article-title">A minute chromosome in chronic granulocytic leukemia</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1960</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">1497</span><span class="NLM_x">–</span> <span class="NLM_lpage">1501</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=1960&pages=1497-1501&author=P.+C.+Nowellauthor=D.+A.+Hungerford&title=A+minute+chromosome+in+chronic+granulocytic+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNowell%26aufirst%3DP.%2BC.%26aulast%3DHungerford%26aufirst%3DD.%2BA.%26atitle%3DA%2520minute%2520chromosome%2520in%2520chronic%2520granulocytic%2520leukemia%26jtitle%3DScience%26date%3D1960%26volume%3D132%26spage%3D1497%26epage%3D1501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rowley, J. D.</span><span> </span><span class="NLM_article-title">A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">243</span><span class="NLM_x">, </span> <span class="NLM_fpage">290</span><span class="NLM_x">–</span> <span class="NLM_lpage">293</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=243&publication_year=1973&pages=290-293&author=J.+D.+Rowley&title=A+new+consistent+chromosomal+abnormality+in+chronic+myelogenous+leukemia+identified+by+quinacrine+fluorescence+and+Giemsa+staining"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRowley%26aufirst%3DJ.%2BD.%26atitle%3DA%2520new%2520consistent%2520chromosomal%2520abnormality%2520in%2520chronic%2520myelogenous%2520leukemia%2520identified%2520by%2520quinacrine%2520fluorescence%2520and%2520Giemsa%2520staining%26jtitle%3DNature%26date%3D1973%26volume%3D243%26spage%3D290%26epage%3D293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Groffen, J</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephenson, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heisterkamp, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Klein, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartram, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosveld, G.</span><span> </span><span class="NLM_article-title">Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">93</span><span class="NLM_x">–</span> <span class="NLM_lpage">99</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1984&pages=93-99&author=J+Groffenauthor=J.+R.+Stephensonauthor=N.+Heisterkampauthor=A.+de+Kleinauthor=C.+R.+Bartramauthor=G.+Grosveld&title=Philadelphia+chromosomal+breakpoints+are+clustered+within+a+limited+region%2C+bcr%2C+on+chromosome+22"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGroffen%26aufirst%3DJ%26aulast%3DStephenson%26aufirst%3DJ.%2BR.%26aulast%3DHeisterkamp%26aufirst%3DN.%26aulast%3Dde%2BKlein%26aufirst%3DA.%26aulast%3DBartram%26aufirst%3DC.%2BR.%26aulast%3DGrosveld%26aufirst%3DG.%26atitle%3DPhiladelphia%2520chromosomal%2520breakpoints%2520are%2520clustered%2520within%2520a%2520limited%2520region%252C%2520bcr%252C%2520on%2520chromosome%252022%26jtitle%3DCell%26date%3D1984%26volume%3D36%26spage%3D93%26epage%3D99" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lugo, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pendergast, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, O. N.</span><span> </span><span class="NLM_article-title">Tyrosine kinase activity and transformation potency of Bcr-Abl oncogene products</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">247</span><span class="NLM_x">, </span> <span class="NLM_fpage">1079</span><span class="NLM_x">–</span> <span class="NLM_lpage">1082</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=247&publication_year=1990&pages=1079-1082&author=T.+G.+Lugoauthor=A.+M.+Pendergastauthor=A.+J.+Mullerauthor=O.+N.+Witte&title=Tyrosine+kinase+activity+and+transformation+potency+of+Bcr-Abl+oncogene+products"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLugo%26aufirst%3DT.%2BG.%26aulast%3DPendergast%26aufirst%3DA.%2BM.%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DTyrosine%2520kinase%2520activity%2520and%2520transformation%2520potency%2520of%2520Bcr-Abl%2520oncogene%2520products%26jtitle%3DScience%26date%3D1990%26volume%3D247%26spage%3D1079%26epage%3D1082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Chronic myeloid leukemia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">340</span><span class="NLM_x">, </span> <span class="NLM_fpage">1330</span><span class="NLM_x">–</span> <span class="NLM_lpage">1340</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1056%2FNEJM199904293401706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=10219069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A280%3ADyaK1M3hvFOlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=1999&pages=1330-1340&author=C.+L.+Sawyers&title=Chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic myeloid leukemia</span></div><div class="casAuthors">Sawyers C L</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1330-40</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR38AD8e0PJ50HdcurJClFcfW6udTcc2eZ-4nVWy7SDwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M3hvFOlug%253D%253D&md5=45ce459ec092eda659cb1e20cb5c8604</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1056%2FNEJM199904293401706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199904293401706%26sid%3Dliteratum%253Aachs%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DChronic%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1999%26volume%3D340%26spage%3D1330%26epage%3D1340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matter, A.</span><span> </span><span class="NLM_article-title">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1038%2Fnrd839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=12120256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=493-502&author=R.+Capdevilleauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=A.+Matter&title=Glivec+%28STI571%2C+imatinib%29%2C+a+rationally+developed%2C+targeted+anticancer+drug"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span></div><div class="casAuthors">Capdeville, Renaud; Buchdunger, Elisabeth; Zimmermann, Juerg; Matter, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">493-502</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research.  Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery program was initiated with the aim of rationally developing targeted anticancer therapies.  Here, we describe how this program led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeI0HV4de6ObVg90H21EOLACvtfcHk0lge9wFW6kipQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D&md5=c8f6b7a66f74b64f0dedb5e641097acc</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrd839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd839%26sid%3Dliteratum%253Aachs%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26atitle%3DGlivec%2520%2528STI571%252C%2520imatinib%2529%252C%2520a%2520rationally%2520developed%252C%2520targeted%2520anticancer%2520drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D493%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochhaus, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukemia</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">356</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1038%2Fnrc2126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=17457302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksFSiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=345-356&author=E.+Weisbergauthor=P.+W.+Manleyauthor=S.+W.+Cowan-Jacobauthor=A.+Hochhausauthor=J.+D.+Griffin&title=Second+generation+inhibitors+of+BCR-ABL+for+the+treatment+of+imatinib-resistant+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukemia</span></div><div class="casAuthors">Weisberg, Ellen; Manley, Paul W.; Cowan-Jacob, Sandra W.; Hochhaus, Andreas; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">345-356</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Imatinib, a small-mol. ABL kinase inhibitor, is a highly effective therapy for early-phase chronic myeloid leukemia (CML), which has constitutively active ABL kinase activity owing to the expression of the BCR-ABL fusion protein.  However, there is a high relapse rate among advanced- and blast-crisis-phase patients owing to the development of mutations in the ABL kinase domain that cause drug resistance.  Several second-generation ABL kinase inhibitors have been or are being developed for the treatment of imatinib-resistant CML.  Here, we describe the mechanism of action of imatinib in CML, the structural basis of imatinib resistance, and the potential of second-generation BCR-ABL inhibitors to circumvent resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxlco2ZKndcbVg90H21EOLACvtfcHk0lge9wFW6kipQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksFSiu7o%253D&md5=36735dff94df075862a60b26d3f358e5</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc2126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2126%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DSecond%2520generation%2520inhibitors%2520of%2520BCR-ABL%2520for%2520the%2520treatment%2520of%2520imatinib-resistant%2520chronic%2520myeloid%2520leukemia%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D345%26epage%3D356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Overriding imatinib resistance with a novel Abl kinase inhibitor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">305</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">402</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1126%2Fscience.1099480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=15256671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1egtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2004&pages=399-402&author=N.+P.+Shahauthor=C.+Tranauthor=F.+Y.+Leeauthor=P.+Chenauthor=D.+Norrisauthor=C.+L.+Sawyers&title=Overriding+imatinib+resistance+with+a+novel+Abl+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor</span></div><div class="casAuthors">Shah, Neil P.; Tran, Chris; Lee, Francis Y.; Chen, Ping; Norris, Derek; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">305</span>
        (<span class="NLM_cas:issue">5682</span>),
    <span class="NLM_cas:pages">399-402</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Resistance to the ABL kinase inhibitor imatinib (STI571 or Gleevec) in chronic myeloid leukemia (CML) occurs through selection for tumor cells harboring BCR-ABL kinase domain point mutations that interfere with drug binding.  Crystallog. studies predict that most imatinib-resistant mutants should remain sensitive to inhibitors that bind ABL with less stringent conformational requirements.  BMS-354825 is an orally bioavailable ABL kinase inhibitor with two-log increased potency relative to imatinib that retains activity against 14 of 15 imatinib-resistant BCR-ABL mutants.  BMS-354825 prolongs survival of mice with BCR-ABL-driven disease and inhibits proliferation of BCR-ABL-pos. bone marrow progenitor cells from patients with imatinib-sensitive and imatinib-resistant CML.  These data illustrate how mol. insight into kinase inhibitor resistance can guide the design of second-generation targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0O0Lhe8nKCrVg90H21EOLACvtfcHk0lge9wFW6kipQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1egtrY%253D&md5=b3827c3419b4c6b57893b11fd68f1f96</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099480%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DTran%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DOverriding%2520imatinib%2520resistance%2520with%2520a%2520novel%2520Abl%2520kinase%2520inhibitor%26jtitle%3DScience%26date%3D2004%26volume%3D305%26spage%3D399%26epage%3D402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">O'Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffregen, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">4500</span><span class="NLM_x">–</span> <span class="NLM_lpage">4505</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=4500-4505&author=T.+O%27Hareauthor=D.+K.+Waltersauthor=E.+P.+Stoffregenauthor=T.+Jiaauthor=P.+W.+Manleyauthor=J.+Mestanauthor=S.+W.+Cowan-Jacobauthor=F.+Y.+Leeauthor=M.+C.+Heinrichauthor=M.+W.+N.+Deiningerauthor=B.+J.+Druker&title=In+vitro+activity+of+Bcr-Abl+inhibitors+AMN107+and+BMS-354825+against+clinically+relevant+imatinib-resistant+Abl+kinase+domain+mutants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%2527Hare%26aufirst%3DT.%26aulast%3DWalters%26aufirst%3DD.%2BK.%26aulast%3DStoffregen%26aufirst%3DE.%2BP.%26aulast%3DJia%26aufirst%3DT.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%2BN.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DIn%2520vitro%2520activity%2520of%2520Bcr-Abl%2520inhibitors%2520AMN107%2520and%2520BMS-354825%2520against%2520clinically%2520relevant%2520imatinib-resistant%2520Abl%2520kinase%2520domain%2520mutants%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D4500%26epage%3D4505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">O'Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W. N.</span><span> </span><span class="NLM_article-title">Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">2242</span><span class="NLM_x">–</span> <span class="NLM_lpage">2249</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=2242-2249&author=T.+O%27Hareauthor=C.+A.+Eideauthor=M.+W.+N.+Deininger&title=Bcr-Abl+kinase+domain+mutations%2C+drug+resistance%2C+and+the+road+to+a+cure+for+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%2527Hare%26aufirst%3DT.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%2BN.%26atitle%3DBcr-Abl%2520kinase%2520domain%2520mutations%252C%2520drug%2520resistance%252C%2520and%2520the%2520road%2520to%2520a%2520cure%2520for%2520chronic%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D2242%26epage%3D2249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">O'Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span> </span><span class="NLM_article-title">New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check</span> <span class="citation_source-journal">Exp. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">865</span><span class="NLM_x">–</span> <span class="NLM_lpage">878</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2008&pages=865-878&author=T.+O%27Hareauthor=C.+A.+Eideauthor=M.+W.+Deininger&title=New+Bcr-Abl+inhibitors+in+chronic+myeloid+leukemia%3A+keeping+resistance+in+check"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%2527Hare%26aufirst%3DT.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DNew%2520Bcr-Abl%2520inhibitors%2520in%2520chronic%2520myeloid%2520leukemia%253A%2520keeping%2520resistance%2520in%2520check%26jtitle%3DExp.%2520Opin.%2520Invest.%2520Drugs%26date%3D2008%26volume%3D17%26spage%3D865%26epage%3D878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Lee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voi, M.</span><span> </span><span class="NLM_article-title">Overcoming kinase resistance in chronic myeloid leukemia</span> <span class="citation_source-journal">Int. J. Biochem. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">334</span><span class="NLM_x">–</span> <span class="NLM_lpage">343</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1016%2Fj.biocel.2007.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=18401881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitVentrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2008&pages=334-343&author=F.+Leeauthor=A.+Fandiauthor=M.+Voi&title=Overcoming+kinase+resistance+in+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6eR"><div class="casContent"><span class="casTitleNuber">6e</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming kinase resistance in chronic myeloid leukemia</span></div><div class="casAuthors">Lee, Francis; Fandi, Abderrahim; Voi, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">334-343</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Imatinib is a small-mol. inhibitor of BCR-ABL tyrosine kinase activity, with proven efficacy and tolerability.  Despite imatinib's activity, the development of resistance, whether BCR-ABL dependent or independent, is a concern.  BCR-ABL-dependent resistance is commonly a result of mutations in the BCR-ABL gene, which can induce a structural predisposition towards the active conformation of the protein, resulting in a shift in the equil. of BCR-ABL from inactive, which imatinib binds, to active, which imatinib is unable to bind.  BCR-ABL gene amplification may play a role in the development of imatinib resistance in patients with CML.  There are a no. of BCR-ABL-independent mechanisms of imatinib resistance, including the efflux protein multidrug resistance protein-1, of which imatinib is a substrate.  Another mechanism may be the development of alternative pathways of disease progression, leading to less reliance on BCR-ABL; indeed, the SRC family tyrosine kinases LYN and HCK have been frequently implicated in treatment resistance and progression of CML.  Clearly, imatinib resistance requires the development of other treatment options.  Dasatinib, with increased binding potency (325-fold greater potency than imatinib for wild-type BCR-ABL), inhibition of both the active and inactive formation of BCR-ABL, and targeting of SRC family kinases, is the only agent approved for the treatment of patients with imatinib-resistant or -intolerant CML and Ph+ ALL.  Dasatinib is highly active in all phases of these diseases, and is active in the majority of imatinib-resistant mutations, with the exception of T315I.  The development of agents that effectively inhibit T315I mutations suggests that future treatment options will include combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJsI4yyauR8bVg90H21EOLACvtfcHk0lipg1KI5Q_8FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitVentrw%253D&md5=7662265f4fb1e2f7bac9bf14bd1e6ab1</span></div><a href="/servlet/linkout?suffix=cit6e&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2007.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2007.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DF.%26aulast%3DFandi%26aufirst%3DA.%26aulast%3DVoi%26aufirst%3DM.%26atitle%3DOvercoming%2520kinase%2520resistance%2520in%2520chronic%2520myeloid%2520leukemia%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2008%26volume%3D40%26spage%3D334%26epage%3D343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Tanaka, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, S.</span><span> </span><span class="NLM_article-title">Abl tyrosine kinase inhibitors for overriding Bcr-Abl/ T315I: from the second to third generation</span> <span class="citation_source-journal">Exp. Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1387</span><span class="NLM_x">–</span> <span class="NLM_lpage">1398</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1586%2F14737140.8.9.1387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=18759691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOhsrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1387-1398&author=R.+Tanakaauthor=S.+Kimura&title=Abl+tyrosine+kinase+inhibitors+for+overriding+Bcr-Abl%2F+T315I%3A+from+the+second+to+third+generation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6fR"><div class="casContent"><span class="casTitleNuber">6f</span><div class="casTitle"><span class="NLM_cas:atitle">Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation</span></div><div class="casAuthors">Tanaka, Ruriko; Kimura, Shinya</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1387-1398</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Treatment of chronic myeloid leukemia (CML) has changed drastically with the emergence of the Abl tyrosine kinase inhibitor (TKI), imatinib mesylate.  However, primary and secondary resistance have frequently been reported, particularly in patients with advanced-stage disease.  Point mutations within the Abl kinase domain that interfere with imatinib binding are the most crit. cause of imatinib resistance.  In order to override this resistance, several second generation ATP-competitive Abl TKIs including dasatinib, nilotinib, bosutinib and INNO-406 have been developed.  Despite promising clin. results from these novel Abl TKIs for most mutations, the frequently obsd. mutant T315I is not effectively targeted by any of these agents.  Thus, identification of novel agents and the development of new strategies for the effective treatment of CML patients with the T315I mutation are important and challenging tasks.  In this review, the current status of novel agents for CML treatment is overviewed as follows: pathogenesis and features of CML; imatinib and second-generation Abl TKIs; why Abl TKIs are not effective against T315I; and novel agents that may override the T315I mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHnGTn_O-afbVg90H21EOLACvtfcHk0lipg1KI5Q_8FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOhsrrO&md5=afe3c45934c38478967b259deddd2cb9</span></div><a href="/servlet/linkout?suffix=cit6f&amp;dbid=16384&amp;doi=10.1586%2F14737140.8.9.1387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.8.9.1387%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DR.%26aulast%3DKimura%26aufirst%3DS.%26atitle%3DAbl%2520tyrosine%2520kinase%2520inhibitors%2520for%2520overriding%2520Bcr-Abl%252F%2520T315I%253A%2520from%2520the%2520second%2520to%2520third%2520generation%26jtitle%3DExp.%2520Rev.%2520Anticancer%2520Ther.%26date%3D2008%26volume%3D8%26spage%3D1387%26epage%3D1398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Noronha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dneprovskaia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebansky, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohse, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPherson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palanki, M. S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pathak, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soll, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, B.</span><span> </span><span class="NLM_article-title">Inhibitors of ABL and the ABL- T315I mutation</span> <span class="citation_source-journal">Curr. Top. Med. Chem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">905</span><span class="NLM_x">–</span> <span class="NLM_lpage">921</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.2174%2F156802608784911635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=18673174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVantL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=905-921&author=G.+Noronhaauthor=J.+Caoauthor=C.+P.+Chowauthor=E.+Dneprovskaiaauthor=R.+M.+Fineauthor=J.+Hoodauthor=X.+Kangauthor=B.+Klebanskyauthor=D.+Lohseauthor=C.+C.+Makauthor=A.+McPhersonauthor=M.+S.+S.+Palankiauthor=V.+P.+Pathakauthor=J.+Renickauthor=R.+Sollauthor=B.+Zeng&title=Inhibitors+of+ABL+and+the+ABL-+T315I+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6gR"><div class="casContent"><span class="casTitleNuber">6g</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of ABL and the ABL-T315I mutation</span></div><div class="casAuthors">Noronha, Glenn; Cao, Jianguo; Chow, Chun P.; Dneprovskaia, Elena; Fine, Richard M.; Hood, John; Kang, Xinshan; Klebansky, Boris; Lohse, Dan; Mak, Chi Ching; McPherson, Andrew; Palanki, Moorthy S. S.; Pathak, Ved P.; Renick, Joel; Soll, Richard; Zeng, Binqi</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">905-921</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Chronic myelogenous leukemia (CML) is a hematol. stem cell disorder caused by increased and unregulated growth of myeloid cells in the bone marrow, and the accumulation of excessive white blood cells.  Abelson tyrosine kinase (ABL) is a non-receptor tyrosine kinase involved in cell growth and proliferation and is usually under tight control.  However, 95% of CML patients have the ABL gene from chromosome 9 fused with the breakpoint cluster (BCR) gene from chromosome 22, resulting in a short chromosome known as the Philadelphia chromosome.  This Philadelphia chromosome is responsible for the prodn. of BCR-ABL, a constitutively active tyrosine kinase that causes uncontrolled cellular proliferation.  An ABL inhibitor, imatinib, was approved by the FDA for the treatment of CML, and is currently used as first line therapy.  However, a high percentage of clin. relapse has been obsd. due to long term treatment with imatinib.  A majority of these relapsed patients have several point mutations at and around the ATP binding pocket of the ABL kinase domain in BCR-ABL.  To address the resistance of mutated BCR-ABL to imatinib, 2nd generation inhibitors such as dasatinib, and nilotinib were developed.  These compds. were approved for the treatment of CML patients who are resistant to imatinib.  All of the BCR-ABL mutants are inhibited by the 2nd generation inhibitors with the exception of the T3151 mutant.  Several 3rd generation inhibitors such as AP24534, VX-680 (MK-0457), PHA-739358, PPY-A, XL-228, SGX-70393, FTY720 and TG101113 are being developed to target the T3151 mutation.  The early results from these compds. are encouraging and it is anticipated that physicians will have addnl. drugs at their disposal for the treatment of patients with the mutated BCR-ABL-T315I.  The success of these inhibitors has greater implication not only in CML, but also in other diseases driven by kinases where the mutated gatekeeper residue plays a major role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCjbrW8rt8HbVg90H21EOLACvtfcHk0lipg1KI5Q_8FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVantL8%253D&md5=c61dc3941c9fd71ddd4ed02732e80998</span></div><a href="/servlet/linkout?suffix=cit6g&amp;dbid=16384&amp;doi=10.2174%2F156802608784911635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608784911635%26sid%3Dliteratum%253Aachs%26aulast%3DNoronha%26aufirst%3DG.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DChow%26aufirst%3DC.%2BP.%26aulast%3DDneprovskaia%26aufirst%3DE.%26aulast%3DFine%26aufirst%3DR.%2BM.%26aulast%3DHood%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DX.%26aulast%3DKlebansky%26aufirst%3DB.%26aulast%3DLohse%26aufirst%3DD.%26aulast%3DMak%26aufirst%3DC.%2BC.%26aulast%3DMcPherson%26aufirst%3DA.%26aulast%3DPalanki%26aufirst%3DM.%2BS.%2BS.%26aulast%3DPathak%26aufirst%3DV.%2BP.%26aulast%3DRenick%26aufirst%3DJ.%26aulast%3DSoll%26aufirst%3DR.%26aulast%3DZeng%26aufirst%3DB.%26atitle%3DInhibitors%2520of%2520ABL%2520and%2520the%2520ABL-%2520T315I%2520mutation%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem%26date%3D2008%26volume%3D8%26spage%3D905%26epage%3D921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Therapeutic options against BCR-ABL1 T315I -positive chronic myelogenous leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">4392</span><span class="NLM_x">–</span> <span class="NLM_lpage">4399</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6h&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1158%2F1078-0432.CCR-08-0117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6h&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=18628453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6h&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosFGit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=4392-4399&author=A.+Quintas-Cardamaauthor=J.+Cortes&title=Therapeutic+options+against+BCR-ABL1+T315I+-positive+chronic+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6hR"><div class="casContent"><span class="casTitleNuber">6h</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Cortes, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4392-4399</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Despite the efficacy of imatinib therapy in chronic myelogenous leukemia, the development of resistance continues to challenge the treatment of this disease.  Mutations within the kinase domain of BCR-ABL1 constitute the most frequent mechanism of resistance in patients with chronic myelogenous leukemia treated with imatinib or the second generation tyrosine kinase inhibitors nilotinib and dasatinib.  Of particular concern is the substitution of the threonine residue at the highly conserved gatekeeper residue 315 with a bulkier hydrophobic isoleucine amino acid.  This mutation causes steric hindrance precluding the access ATP-competitive inhibitors to the ATP-binding pocket.  To expedite the identification of strategies to override the resistance imposed by the T315I mutation, several strategies have been pursued, including the exploitation of BCR-ABL1 kinase sites distant from the ATP-binding pocket to cripple the kinase activity of the enzyme and inhibiting signaling pathways downstream from BCR-ABL1.  Recent insights gained regarding the structural biol. of T315I have led to the development of a variety of compds. against this mutant.  We herein summarize the most clin. promising anti-T315I therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplJ8bpmJXGkrVg90H21EOLACvtfcHk0lhAMbzkjfuR9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosFGit74%253D&md5=01688b0795daf1ca29c7ad4a98e3977b</span></div><a href="/servlet/linkout?suffix=cit6h&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0117%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DTherapeutic%2520options%2520against%2520BCR-ABL1%2520T315I%2520-positive%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D4392%26epage%3D4399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mahon, F.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayette, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagarde, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belloc, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turcq, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belanger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leroy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etienne, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roche, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquet, J.-M.</span><span> </span><span class="NLM_article-title">Evidence that resistance to nilotinib may be due to Bcr-Abl, Pgp, or Src kinase overexpression</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">9809</span><span class="NLM_x">–</span> <span class="NLM_lpage">9816</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1158%2F0008-5472.CAN-08-1008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=19047160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVegtbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9809-9816&author=F.-X.+Mahonauthor=S.+Hayetteauthor=V.+Lagardeauthor=F.+Bellocauthor=B.+Turcqauthor=F.+Nicoliniauthor=C.+Belangerauthor=P.+W.+Manleyauthor=C.+Leroyauthor=G.+Etienneauthor=S.+Rocheauthor=J.-M.+Pasquet&title=Evidence+that+resistance+to+nilotinib+may+be+due+to+Bcr-Abl%2C+Pgp%2C+or+Src+kinase+overexpression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression</span></div><div class="casAuthors">Mahon, Francois-Xavier; Hayette, Sandrine; Lagarde, Valerie; Belloc, Francis; Turcq, Beatrice; Nicolini, Franck; Belanger, Coralie; Manley, Paul W.; Leroy, Cedric; Etienne, Gabriel; Roche, Serge; Pasquet, Jean-Max</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9809-9816</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeting the tyrosine kinase activity of Bcr-Abl is an attractive therapeutic strategy in chronic myeloid leukemia (CML) and in Bcr-Abl-pos. acute lymphoblastic leukemia.  Whereas imatinib, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for CML, second-generation inhibitors of Bcr-Abl tyrosine kinase such as nilotinib or dasatinib have been developed for the treatment of imatinib-resistant or imatinib-intolerant disease.  In the current study, we generated nilotinib-resistant cell lines and investigated their mechanism of resistance.  Overexpression of BCR-ABL and multidrug resistance gene (MDR-1) were found among the investigated mechanisms.  We showed that nilotinib is a substrate of the multidrug resistance gene product, P-glycoprotein, using verapamil or PSC833 to block binding.  Up-regulated expression of p53/56 Lyn kinase, both at the mRNA and protein level, was found in one of the resistant cell lines and Lyn silencing by small interfering RNA restored sensitivity to nilotinib.  Moreover, failure of nilotinib treatment was accompanied by an increase of Lyn mRNA expression in patients with resistant CML.  Two Src kinase inhibitors (PP1 and PP2) partially removed resistance but did not significantly inhibit Bcr-Abl tyrosine kinase activity.  In contrast, dasatinib, a dual Bcr-Abl and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn.  Such mechanisms of resistance are close to those obsd. in imatinib-resistant cell lines and emphasize the crit. role of Lyn in nilotinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjFLZ5Im5NArVg90H21EOLACvtfcHk0lhAMbzkjfuR9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVegtbjK&md5=3a129d5e8e4fe09a82b9b10ab9995906</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1008%26sid%3Dliteratum%253Aachs%26aulast%3DMahon%26aufirst%3DF.-X.%26aulast%3DHayette%26aufirst%3DS.%26aulast%3DLagarde%26aufirst%3DV.%26aulast%3DBelloc%26aufirst%3DF.%26aulast%3DTurcq%26aufirst%3DB.%26aulast%3DNicolini%26aufirst%3DF.%26aulast%3DBelanger%26aufirst%3DC.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DLeroy%26aufirst%3DC.%26aulast%3DEtienne%26aufirst%3DG.%26aulast%3DRoche%26aufirst%3DS.%26aulast%3DPasquet%26aufirst%3DJ.-M.%26atitle%3DEvidence%2520that%2520resistance%2520to%2520nilotinib%2520may%2520be%2520due%2520to%2520Bcr-Abl%252C%2520Pgp%252C%2520or%2520Src%2520kinase%2520overexpression%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D9809%26epage%3D9816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schenone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manetti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botta, M.</span><span> </span><span class="NLM_article-title">Last findings on dual inhibitors of Abl and Src tyrosine-kinases</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">201</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=191-201&author=S.+Schenoneauthor=F.+Manettiauthor=M.+Botta&title=Last+findings+on+dual+inhibitors+of+Abl+and+Src+tyrosine-kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchenone%26aufirst%3DS.%26aulast%3DManetti%26aufirst%3DF.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DLast%2520findings%2520on%2520dual%2520inhibitors%2520of%2520Abl%2520and%2520Src%2520tyrosine-kinases%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D191%26epage%3D201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kantarjian, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Important therapeutic targets in chronic myelogenous leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1089</span><span class="NLM_x">–</span> <span class="NLM_lpage">1097</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1158%2F1078-0432.CCR-06-2147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=17317816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvF2hsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1089-1097&author=H.+M.+Kantarjianauthor=F.+Gilesauthor=A.+Quintas-Cardamaauthor=J.+Cortes&title=Important+therapeutic+targets+in+chronic+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">Important Therapeutic Targets in Chronic Myelogenous Leukemia</span></div><div class="casAuthors">Kantarjian, Hagop M.; Giles, Francis; Quintas-Cardama, Alfonso; Cortes, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1089-1097</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Review the state-of-art knowledge of the biol. and therapy of chronic myelogenous leukemia (CML).  Exptl. Design: A review of the literature was undertaken to summarize current information on the pathophysiol. of CML and to update data of imatinib mesylate therapy, mechanisms of resistance, and in vitro and clin. data with the new tyrosine kinase inhibitors.  Results: Imatinib, which targets the ABL kinase activity of BCR-ABL, has prolonged survival in CML.  Despite the efficacy of imatinib, some patients in chronic phase and more in advanced phases of CML develop resistance, frequently as a result of BCR-ABL tyrosine kinase domain mutants that impair imatinib binding but retain enzymic activity.  New tyrosine kinase inhibitors inhibit BCR-ABL more potently than imatinib and maintain activity against an array of imatinib-resistant BCR-ABL mutants.  The IC50 values of nilotinib and dasatinib are at least 10- to 100-fold lower for BCR-ABL compared with imatinib.  Phase I-II trials of nilotinib and dasatinib showed high activity in imatinib-resistant CML and Philadelphia chromosome-pos. ALL.  Dasatinib also inhibits members of the Src family of kinases (SFKs); nilotinib does not.  Whether SFKs have a crit. role in imatinib resistance or BCR-ABL-mediated oncogenesis is unresolved.  Agents that target signals downstream of BCR-ABL (e.g. Ras/Raf and phosphatidylinositol 3-kinase) are under investigation.  Conclusions: Understanding the pathophysiol. of CML and mechanisms of resistance has produced effective targeted strategies for imatinib-resistant CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6TUXDbtEOxrVg90H21EOLACvtfcHk0lhAMbzkjfuR9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvF2hsL4%253D&md5=a750a241b963ee917314b672103ca154</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-2147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-2147%26sid%3Dliteratum%253Aachs%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DImportant%2520therapeutic%2520targets%2520in%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D1089%26epage%3D1097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Martinelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soverini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccarani, M.</span><span> </span><span class="NLM_article-title">Dual tyrosine kinase inhibitors in chronic myeloid leukemia</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1872</span><span class="NLM_x">–</span> <span class="NLM_lpage">1879</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=1872-1879&author=G.+Martinelliauthor=S.+Soveriniauthor=G.+Rostiauthor=M.+Baccarani&title=Dual+tyrosine+kinase+inhibitors+in+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DSoverini%26aufirst%3DS.%26aulast%3DRosti%26aufirst%3DG.%26aulast%3DBaccarani%26aufirst%3DM.%26atitle%3DDual%2520tyrosine%2520kinase%2520inhibitors%2520in%2520chronic%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2005%26volume%3D19%26spage%3D1872%26epage%3D1879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelletier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Etten, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span> </span><span class="NLM_article-title">Requirement of Src kinases Lyn, Hck and Fgr for <i>BCR-ABL1</i>-induced B-lymphoblastic leukemia but not chronic myeloid leukemia</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">453</span><span class="NLM_x">–</span> <span class="NLM_lpage">461</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1038%2Fng1343" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=15098032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFSnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2004&pages=453-461&author=Y.+Huauthor=Y.+Liuauthor=S.+Pelletierauthor=E.+Buchdungerauthor=M.+Warmuthauthor=D.+Fabbroauthor=M.+Hallekauthor=R.+A.+Van+Ettenauthor=S.+Li&title=Requirement+of+Src+kinases+Lyn%2C+Hck+and+Fgr+for+BCR-ABL1-induced+B-lymphoblastic+leukemia+but+not+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia</span></div><div class="casAuthors">Hu, Yiguo; Liu, Yuhua; Pelletier, Shawn; Buchdunger, Elisabeth; Warmuth, Markus; Fabbro, Doriano; Hallek, Michael; Van Etten, Richard A.; Li, Shaoguang</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">453-461</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Abl kinase inhibitor imatinib mesylate is the preferred treatment for Philadelphia chromosome-pos. (Ph+) chronic myeloid leukemia (CML) in chronic phase but is much less effective in CML blast crisis or Ph+ B-cell acute lymphoblastic leukemia (B-ALL).  Here, we show that Bcr-Abl activated the Src kinases Lyn, Hck and Fgr in B-lymphoid cells.  BCR-ABL1 retrovirus-transduced marrow from mice lacking all three Src kinases efficiently induced CML but not B-ALL in recipients.  The kinase inhibitor CGP76030 impaired the proliferation of B-lymphoid cells expressing Bcr-Abl in vitro and prolonged survival of mice with B-ALL but not CML.  The combination of CGP76030 and imatinib was superior to imatinib alone in this regard.  The biochem. target of CGP76030 in leukemia cells was Src kinases, not Bcr-Abl.  These results implicate Src family kinases as therapeutic targets in Ph+ B-ALL and suggest that simultaneous inhibition of Src and Bcr-Abl kinases may benefit individuals with Ph+ acute leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsI4S1CAKINbVg90H21EOLACvtfcHk0lgDyqznNk3YzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFSnt74%253D&md5=9783ffa92e8aee107ee09d05e0d2fa76</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fng1343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng1343%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DPelletier%26aufirst%3DS.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DHallek%26aufirst%3DM.%26aulast%3DVan%2BEtten%26aufirst%3DR.%2BA.%26aulast%3DLi%26aufirst%3DS.%26atitle%3DRequirement%2520of%2520Src%2520kinases%2520Lyn%252C%2520Hck%2520and%2520Fgr%2520for%2520BCR-ABL1-induced%2520B-lymphoblastic%2520leukemia%2520but%2520not%2520chronic%2520myeloid%2520leukemia%26jtitle%3DNat.%2520Genet.%26date%3D2004%26volume%3D36%26spage%3D453%26epage%3D461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Srinivasan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plattner, R.</span><span> </span><span class="NLM_article-title">Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">5648</span><span class="NLM_x">–</span> <span class="NLM_lpage">5655</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=5648-5655&author=D.+Srinivasanauthor=R.+Plattner&title=Activation+of+Abl+tyrosine+kinases+promotes+invasion+of+aggressive+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSrinivasan%26aufirst%3DD.%26aulast%3DPlattner%26aufirst%3DR.%26atitle%3DActivation%2520of%2520Abl%2520tyrosine%2520kinases%2520promotes%2520invasion%2520of%2520aggressive%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D5648%26epage%3D5655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Srinivasan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plattner, R.</span><span> </span><span class="NLM_article-title">Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1095</span><span class="NLM_x">–</span> <span class="NLM_lpage">1105</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=1095-1105&author=D.+Srinivasanauthor=J.+T.+Simsauthor=R.+Plattner&title=Aggressive+breast+cancer+cells+are+dependent+on+activated+Abl+kinases+for+proliferation%2C+anchorage-independent+growth+and+survival"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSrinivasan%26aufirst%3DD.%26aulast%3DSims%26aufirst%3DJ.%2BT.%26aulast%3DPlattner%26aufirst%3DR.%26atitle%3DAggressive%2520breast%2520cancer%2520cells%2520are%2520dependent%2520on%2520activated%2520Abl%2520kinases%2520for%2520proliferation%252C%2520anchorage-independent%2520growth%2520and%2520survival%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D1095%26epage%3D1105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arlinghaus, R.</span><span> </span><span class="NLM_article-title">Activated c-Abl tyrosine kinase in malignant solid tumors</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4385</span><span class="NLM_x">–</span> <span class="NLM_lpage">4391</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=4385-4391&author=J.+Linauthor=R.+Arlinghaus&title=Activated+c-Abl+tyrosine+kinase+in+malignant+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DArlinghaus%26aufirst%3DR.%26atitle%3DActivated%2520c-Abl%2520tyrosine%2520kinase%2520in%2520malignant%2520solid%2520tumors%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D4385%26epage%3D4391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Park, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallick, G. E.</span><span> </span><span class="NLM_article-title">Regulation of angiogenesis and vascular permeability by Src family kinases: opportunities for therapeutic treatment of solid tumors</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1207</span><span class="NLM_x">–</span> <span class="NLM_lpage">1217</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1517%2F14728222.11.9.1207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=17845146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVWmsL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=1207-1217&author=S.+I.+Parkauthor=A.+N.+Shahauthor=J.+Zhangauthor=G.+E.+Gallick&title=Regulation+of+angiogenesis+and+vascular+permeability+by+Src+family+kinases%3A+opportunities+for+therapeutic+treatment+of+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of angiogenesis and vascular permeability by Src family kinases: opportunities for therapeutic treatment of solid tumors</span></div><div class="casAuthors">Park, Serk In; Shah, Ami N.; Zhang, Jing; Gallick, Gary E.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1207-1217</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Aberrant expression or activation of protein tyrosine kinases, including Src and related Src family kinases, is a common occurrence in many human cancers, resulting in deregulation of expression of numerous mediators of cellular functions, including pro-angiogenic mols.  In addn., Src activation regulates vascular permeability of endothelial cells.  How these processes contribute to tumor progression and metastasis are the subjects of this review.  As Src-selective inhibitors have entered clin. trials for a no. of solid tumors, further understanding of the roles of Src kinases in mediating tumor angiogenesis as well as modulating tumor/microenvironment interactions will provide insights into the best use of these inhibitors in treating patients afflicted with tumors in which Src is activated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqweA3eJZ8qArVg90H21EOLACvtfcHk0lgDyqznNk3YzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVWmsL3O&md5=55e9c22d88680d57d0699b628bf38681</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1517%2F14728222.11.9.1207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.11.9.1207%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%2BI.%26aulast%3DShah%26aufirst%3DA.%2BN.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DGallick%26aufirst%3DG.%2BE.%26atitle%3DRegulation%2520of%2520angiogenesis%2520and%2520vascular%2520permeability%2520by%2520Src%2520family%2520kinases%253A%2520opportunities%2520for%2520therapeutic%2520treatment%2520of%2520solid%2520tumors%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2007%26volume%3D11%26spage%3D1207%26epage%3D1217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Summy, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallick, G. E.</span><span> </span><span class="NLM_article-title">Treatment for advanced tumors: Src reclaims center stage</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1398</span><span class="NLM_x">–</span> <span class="NLM_lpage">1401</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1158%2F1078-0432.CCR-05-2692" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=16533761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD28XitVGmsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=1398-1401&author=J.+M.+Summyauthor=G.+E.+Gallick&title=Treatment+for+advanced+tumors%3A+Src+reclaims+center+stage"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment for advanced tumors: Src reclaims center stage</span></div><div class="casAuthors">Summy, Justin M.; Gallick, Gary E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1398-1401</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The recent advances in roles of Src in tumor progression and clin./translational advances are discussed.  Src activation in tumor cells indirectly regulates Src activity in endothelial cells.  Increased Src activity in the tumor cells increases VEGF expression, resulting in increased binding to VEGF expression, resulting in increased binding to VEGF receptors on endothelial cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2D4rtkj8O3LVg90H21EOLACvtfcHk0ljBk298uN4Bfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitVGmsr4%253D&md5=96eb5f53cf01bd47bc52e250b81e5c71</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-2692&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-2692%26sid%3Dliteratum%253Aachs%26aulast%3DSummy%26aufirst%3DJ.%2BM.%26aulast%3DGallick%26aufirst%3DG.%2BE.%26atitle%3DTreatment%2520for%2520advanced%2520tumors%253A%2520Src%2520reclaims%2520center%2520stage%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D1398%26epage%3D1401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Chen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, C. C.</span><span> </span><span class="NLM_article-title">Src tyrosine kinase as a chemotherapeutic target: is there a clinical case?</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">131</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=123-131&author=T.+Chenauthor=J.+A.+Georgeauthor=C.+C.+Taylor&title=Src+tyrosine+kinase+as+a+chemotherapeutic+target%3A+is+there+a+clinical+case%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DT.%26aulast%3DGeorge%26aufirst%3DJ.%2BA.%26aulast%3DTaylor%26aufirst%3DC.%2BC.%26atitle%3DSrc%2520tyrosine%2520kinase%2520as%2520a%2520chemotherapeutic%2520target%253A%2520is%2520there%2520a%2520clinical%2520case%253F%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2006%26volume%3D17%26spage%3D123%26epage%3D131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Alvarez, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J. E.</span><span> </span><span class="NLM_article-title">The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">1918</span><span class="NLM_x">–</span> <span class="NLM_lpage">1929</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2006&pages=1918-1929&author=R.+H.+Alvarezauthor=H.+M.+Kantarjianauthor=J.+E.+Cortes&title=The+role+of+Src+in+solid+and+hematologic+malignancies%3A+development+of+new-generation+Src+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarez%26aufirst%3DR.%2BH.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26atitle%3DThe%2520role%2520of%2520Src%2520in%2520solid%2520and%2520hematologic%2520malignancies%253A%2520development%2520of%2520new-generation%2520Src%2520inhibitors%26jtitle%3DCancer%26date%3D2006%26volume%3D107%26spage%3D1918%26epage%3D1929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Lesslie, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallick, G. E.</span><span> </span><span class="NLM_article-title">Src family kinases as regulators of angiogenesis: therapeutic implications</span> <span class="citation_source-journal">Curr. Cancer Ther. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">45</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11e&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.2174%2F1573394052952500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11e&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2MXislOjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2005&pages=45-50&author=D.+P.+Lesslieauthor=G.+E.+Gallick&title=Src+family+kinases+as+regulators+of+angiogenesis%3A+therapeutic+implications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11eR"><div class="casContent"><span class="casTitleNuber">11e</span><div class="casTitle"><span class="NLM_cas:atitle">Src family kinases as regulators of angiogenesis: Therapeutic implications</span></div><div class="casAuthors">Lesslie, Donald P.; Gallick, Gary E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Therapy Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-50</span>CODEN:
                <span class="NLM_cas:coden">CCTRCG</span>;
        ISSN:<span class="NLM_cas:issn">1573-3947</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Despite its discovery nearly a century ago, the functions of the Src family of protein tyrosine kinases (SFKs) remain incompletely understood.  While much has been learned regarding the functions of Src family kinases in the last few years, new roles for Src, particularly in promoting the progression of cancer towards the metastatic phenotype, continue to emerge.  SFKs, through their functions as kinases and adapter proteins in signaling complexes, regulate such diverse cellular events as proliferation, migration, cell cycle control, and apoptosis.  In tumor cells, the kinase activity of Src is frequently activated, with greater increases during progressive stages.  Likewise, resistance to chemotherapy also corresponds with Src kinase activity.  Thus, Src activation is predictive of poor prognosis in several tumors.  Recently, selective SFK inhibitors are showing promise in clin. trials in imatinib mesylate (Gleevec, Novartis) resistant chronic myelogenous leukemia.  However, in vitro studies have suggested that Src inhibitors may hold promise in the treatment of solid tumors such as colon and pancreatic cancer in which new therapeutic inhibitors are desperately needed.  This review will summarize briefly the structure and function of Src and the evidence for Src in promoting tumor progression and metastasis.  As recent work in this lab. and others has demonstrated that Src is a regulator of expression of diverse pro-angiogenic factors produced by tumor cells, and a regulator of the endothelial cells that respond to these factors, this review will focus on the role of Src in angiogenesis and potential roles of Src inhibitors as antiangiogenic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2ccgdPedHerVg90H21EOLACvtfcHk0ljBk298uN4Bfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXislOjtbY%253D&md5=35eb77f20a7bd572c4c1b584fcb74735</span></div><a href="/servlet/linkout?suffix=cit11e&amp;dbid=16384&amp;doi=10.2174%2F1573394052952500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1573394052952500%26sid%3Dliteratum%253Aachs%26aulast%3DLesslie%26aufirst%3DD.%2BP.%26aulast%3DGallick%26aufirst%3DG.%2BE.%26atitle%3DSrc%2520family%2520kinases%2520as%2520regulators%2520of%2520angiogenesis%253A%2520therapeutic%2520implications%26jtitle%3DCurr.%2520Cancer%2520Ther.%2520Rev.%26date%3D2005%26volume%3D1%26spage%3D45%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Tsygankov, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shore, S. K.</span><span> </span><span class="NLM_article-title">Src: regulation, role in human carcinogenesis and pharmacological inhibitors</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1745</span><span class="NLM_x">–</span> <span class="NLM_lpage">1756</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11f&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.2174%2F1381612043384457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11f&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=15180537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11f&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktV2gsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=1745-1756&author=A.+Y.+Tsygankovauthor=S.+K.+Shore&title=Src%3A+regulation%2C+role+in+human+carcinogenesis+and+pharmacological+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11fR"><div class="casContent"><span class="casTitleNuber">11f</span><div class="casTitle"><span class="NLM_cas:atitle">SRC: Regulation, role in human carcinogenesis and pharmacological inhibitors</span></div><div class="casAuthors">Tsygankov, A. Y.; Shore, S. K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1745-1756</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The cellular signaling machinery is a complex network of cross-talking proteins that enables dynamic communication between upstream causal factors and downstream effectors.  Non-receptor tyrosine kinases, including Src, are the intermediates of signal transfer, controlling pathways as diverse as cell growth, death, differentiation, migration, and genome maintenance.  When expressed as viral genes these proteins are potent carcinogens.  Furthermore, analogous genetic alterations are obsd., albeit not frequently, in human tumors.  In a variety of tumors including those derived from the colon and breast.  Src is either over expressed or constitutively active in a large percentage of patients.  Increased expression or activity of Src correlates with the stage and metastatic potential of some neoplasia.  The detailed knowledge of Src activation facilitates rational design of drugs that potentially interfere with either binding of ATP or substrate peptides.  Several existing inhibitors are available as lead compds. for further development of Src inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5-BohF8ENQbVg90H21EOLACvtfcHk0ljBk298uN4Bfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktV2gsbg%253D&md5=8e69eb379a1d9a73c51eae47a0d3a7d3</span></div><a href="/servlet/linkout?suffix=cit11f&amp;dbid=16384&amp;doi=10.2174%2F1381612043384457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612043384457%26sid%3Dliteratum%253Aachs%26aulast%3DTsygankov%26aufirst%3DA.%2BY.%26aulast%3DShore%26aufirst%3DS.%2BK.%26atitle%3DSrc%253A%2520regulation%252C%2520role%2520in%2520human%2520carcinogenesis%2520and%2520pharmacological%2520inhibitors%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2004%26volume%3D10%26spage%3D1745%26epage%3D1756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Yeatman, T. J.</span><span> </span><span class="NLM_article-title">A renaissance for Src</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">470</span><span class="NLM_x">–</span> <span class="NLM_lpage">480</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11g&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1038%2Fnrc1366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11g&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=15170449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11g&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVaisbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=470-480&author=T.+J.+Yeatman&title=A+renaissance+for+Src"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11gR"><div class="casContent"><span class="casTitleNuber">11g</span><div class="casTitle"><span class="NLM_cas:atitle">A renaissance for SRC</span></div><div class="casAuthors">Yeatman, Timothy J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">470-480</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  The c-SRC non-receptor tyrosine kinase is overexpressed and activated in a large no. of human malignancies and has been linked to the development of cancer and progression to distant metastases.  These observations have led to the recent targeting of c-SRC for the development of anticancer therapeutics, which show promise as a new avenue for cancer treatment.  Despite this, however, the precise functions of c-SRC in cancer remain unclear.  In addn. to increasing cell proliferation, a key role of c-SRC in cancer seems to be to promote invasion and motility, functions that might contribute to tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCGFL31NDP4LVg90H21EOLACvtfcHk0liqvgTkJ7MUmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVaisbo%253D&md5=e14e862826b2881721d0f6bb14356650</span></div><a href="/servlet/linkout?suffix=cit11g&amp;dbid=16384&amp;doi=10.1038%2Fnrc1366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1366%26sid%3Dliteratum%253Aachs%26aulast%3DYeatman%26aufirst%3DT.%2BJ.%26atitle%3DA%2520renaissance%2520for%2520Src%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D470%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaneda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelius, L. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doweyko, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairchild, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inigo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, M.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wityak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">6658</span><span class="NLM_x">–</span> <span class="NLM_lpage">6661</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049486a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=6658-6661&author=L.+J.+Lombardoauthor=F.+Y.+Leeauthor=P.+Chenauthor=D.+Norrisauthor=J.+C.+Barrishauthor=K.+Behniaauthor=S.+Castanedaauthor=L.+A.+M.+Corneliusauthor=J.+Dasauthor=A.+M.+Doweykoauthor=C.+Fairchildauthor=J.+T.+Huntauthor=I.+Inigoauthor=K.+Johnstonauthor=A.+Kamathauthor=D.+Kanauthor=H.+Kleiauthor=P.+Maratheauthor=S.+Pangauthor=R.+Petersonauthor=S.+Pittauthor=G.+L.+Schievenauthor=R.+J.+Schmidtauthor=J.+Tokarskiauthor=M.-L.+Wenauthor=J.+Wityakauthor=R.+M.+Borzilleri&title=Discovery+of+N-%282-chloro-6-methyl-phenyl%29-2-%286-%284-%282-hydroxyethyl%29-piperazin-1-yl%29-2-methylpyrimidin-4-ylamino%29thiazole-5-carboxamide+%28BMS-354825%29%2C+a+dual+Src%2FAbl+kinase+inhibitor+with+potent+antitumor+activity+in+preclinical+assays"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm049486a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049486a%26sid%3Dliteratum%253Aachs%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DBehnia%26aufirst%3DK.%26aulast%3DCastaneda%26aufirst%3DS.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%2BM.%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DFairchild%26aufirst%3DC.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DInigo%26aufirst%3DI.%26aulast%3DJohnston%26aufirst%3DK.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DKan%26aufirst%3DD.%26aulast%3DKlei%26aufirst%3DH.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DPang%26aufirst%3DS.%26aulast%3DPeterson%26aufirst%3DR.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DSchmidt%26aufirst%3DR.%2BJ.%26aulast%3DTokarski%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DM.-L.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%2520N-%25282-chloro-6-methyl-phenyl%2529-2-%25286-%25284-%25282-hydroxyethyl%2529-piperazin-1-yl%2529-2-methylpyrimidin-4-ylamino%2529thiazole-5-carboxamide%2520%2528BMS-354825%2529%252C%2520a%2520dual%2520Src%252FAbl%2520kinase%2520inhibitor%2520with%2520potent%2520antitumor%2520activity%2520in%2520preclinical%2520assays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D6658%26epage%3D6661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yaczko, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tischler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arndt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etienne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grod, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span> </span><span class="NLM_article-title">Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">3965</span><span class="NLM_x">–</span> <span class="NLM_lpage">3977</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0102250" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsFyhsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=3965-3977&author=D.+H.+Boschelliauthor=F.+Yeauthor=Y.+D.+Wangauthor=M.+Dutiaauthor=S.+L.+Johnsonauthor=B.+Wuauthor=K.+Millerauthor=D.+W.+Powellauthor=D.+Yaczkoauthor=M.+Youngauthor=M.+Tischlerauthor=K.+Arndtauthor=C.+Discafaniauthor=C.+Etienneauthor=J.+Gibbonsauthor=J.+Grodauthor=J.+Lucasauthor=J.+M.+Weberauthor=F.+Boschelli&title=Optimization+of+4-phenylamino-3-quinolinecarbonitriles+as+potent+inhibitors+of+Src+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of 4-Phenylamino-3-quinolinecarbonitriles as Potent Inhibitors of Src Kinase Activity</span></div><div class="casAuthors">Boschelli, Diane H.; Ye, Fei; Wang, Yanong D.; Dutia, Minu; Johnson, Steve L.; Wu, Biqi; Miller, Karen; Powell, Dennis W.; Yaczko, Deanna; Young, Mairead; Tischler, Mark; Arndt, Kim; Discafani, Carolyn; Etienne, Carlo; Gibbons, Jay; Grod, Janet; Lucas, Judy; Weber, Jennifer M.; Boschelli, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3965-3977</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Subsequent to the discovery of 4-[(2,4-dichlorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile as an inhibitor of Src kinase activity (IC50 = 30 nM), several addnl. analogs were prepd.  Optimization of the C-4 anilino group led to I [R = Me].  Replacement of the methoxy group at C-7 with a 3-(morpholin-4-yl)propoxy group provided I [R = morpholinopropyl], resulting in increased inhibition of both Src kinase activity and Src-mediated cell proliferation.  Analogs of I [R = morpholinopropyl] with other trisubstituted anilines at C-4 were also potent Src inhibitors, and the propoxy group was preferred over ethoxy, butoxy, or pentoxy.  Replacement of the morpholine group with a 4-methylpiperazine group provided I [R = 4-methylpiperazinopropyl], which had an IC50 of 1.2 nM in the Src enzymic assay, an IC50 of 100 nM for the inhibition of Src-dependent cell proliferation and was selective for Src over non-Src family kinases.  I [R = 4-methylpiperazinopropyl], which had higher 1 and 4 h plasma levels than I [R = 4-morpholinopropyl], effectively inhibited tumor growth in xenograft models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIfrD66BPWqrVg90H21EOLACvtfcHk0liqvgTkJ7MUmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsFyhsrk%253D&md5=88c2d8aa690b9aedbff034682aa3d73e</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1021%2Fjm0102250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0102250%26sid%3Dliteratum%253Aachs%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%2BD.%26aulast%3DDutia%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DS.%2BL.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DPowell%26aufirst%3DD.%2BW.%26aulast%3DYaczko%26aufirst%3DD.%26aulast%3DYoung%26aufirst%3DM.%26aulast%3DTischler%26aufirst%3DM.%26aulast%3DArndt%26aufirst%3DK.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DEtienne%26aufirst%3DC.%26aulast%3DGibbons%26aufirst%3DJ.%26aulast%3DGrod%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DWeber%26aufirst%3DJ.%2BM.%26aulast%3DBoschelli%26aufirst%3DF.%26atitle%3DOptimization%2520of%25204-phenylamino-3-quinolinecarbonitriles%2520as%2520potent%2520inhibitors%2520of%2520Src%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D3965%26epage%3D3977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hennequin, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curwen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fennell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert-van der Brempt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgentin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otterbein, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ple, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costello, G.</span><span> </span><span class="NLM_article-title"><i>N</i>-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2<i>H</i>-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6465</span><span class="NLM_x">–</span> <span class="NLM_lpage">6488</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060434q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6465-6488&author=L.+F.+Hennequinauthor=J.+Allenauthor=J.+Breedauthor=J.+Curwenauthor=M.+Fennellauthor=T.+P.+Greenauthor=C.+Lambert-van+der+Bremptauthor=R.+Morgentinauthor=R.+A.+Normanauthor=A.+Olivierauthor=L.+Otterbeinauthor=P.+A.+Pleauthor=N.+Warinauthor=G.+Costello&title=N-%285-Chloro-1%2C3-benzodioxol-4-yl%29-7-%5B2-%284-methylpiperazin-1-yl%29ethoxy%5D-5-%28tetrahydro-2H-pyran-4-yloxy%29quinazolin-4-amine%2C+a+novel%2C+highly+selective%2C+orally+available%2C+dual-specific+c-Src%2FAbl+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1021%2Fjm060434q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060434q%26sid%3Dliteratum%253Aachs%26aulast%3DHennequin%26aufirst%3DL.%2BF.%26aulast%3DAllen%26aufirst%3DJ.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DCurwen%26aufirst%3DJ.%26aulast%3DFennell%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DT.%2BP.%26aulast%3DLambert-van%2Bder%2BBrempt%26aufirst%3DC.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DOlivier%26aufirst%3DA.%26aulast%3DOtterbein%26aufirst%3DL.%26aulast%3DPle%26aufirst%3DP.%2BA.%26aulast%3DWarin%26aufirst%3DN.%26aulast%3DCostello%26aufirst%3DG.%26atitle%3DN-%25285-Chloro-1%252C3-benzodioxol-4-yl%2529-7-%255B2-%25284-methylpiperazin-1-yl%2529ethoxy%255D-5-%2528tetrahydro-2H-pyran-4-yloxy%2529quinazolin-4-amine%252C%2520a%2520novel%252C%2520highly%2520selective%252C%2520orally%2520available%252C%2520dual-specific%2520c-Src%252FAbl%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6465%26epage%3D6488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelias, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A small molecule−kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.-M.+Leliasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule%E2%88%92kinase+interaction+map+for+clinical+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DLelias%26aufirst%3DJ.-M.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule%25E2%2588%2592kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">1938</span><span class="NLM_x">–</span> <span class="NLM_lpage">1942</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1126%2Fscience.289.5486.1938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=10988075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2000&pages=1938-1942&author=T.+Schindlerauthor=W.+Bornmannauthor=P.+Pellicenaauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Structural+mechanism+for+STI-571+inhibition+of+Abelson+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase</span></div><div class="casAuthors">Schindler, Thomas; Bornmann, William; Pellicena, Patricia; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">5486</span>),
    <span class="NLM_cas:pages">1938-1942</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The inadvertent activation of the Abelson tyrosine kinase (Abl) causes chronic myelogenous leukemia (CML).  A small-mol. inhibitor of Abl (STI-571) is effective in the treatment of CML.  We report the crystal structure of the catalytic domain of Abl, complexed to a variant of STI-571.  Crit. to the binding of STI-571 is the adoption by the kinase of an inactive conformation, in which a centrally located "activation loop" is not phosphorylated.  The conformation of this loop is distinct from that in active protein kinases, as well as in the inactive form of the closely related Src kinases.  These results suggest that compds. that exploit the distinctive inactivation mechanisms of individual protein kinases can achieve both high affinity and high specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9eAZqIQ1aebVg90H21EOLACvtfcHk0lgRe-Z08wFT7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D&md5=56bb233f010f099d0073020ac6b9db59</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1126%2Fscience.289.5486.1938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.289.5486.1938%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DStructural%2520mechanism%2520for%2520STI-571%2520inhibition%2520of%2520Abelson%2520tyrosine%2520kinase%26jtitle%3DScience%26date%3D2000%26volume%3D289%26spage%3D1938%26epage%3D1942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mol, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hosfield, D. J.</span><span> </span><span class="NLM_article-title">Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">639</span><span class="NLM_x">–</span> <span class="NLM_lpage">648</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=15503866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotl2js7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2004&pages=639-648&author=C.+D.+Molauthor=D.+Fabbroauthor=D.+J.+Hosfield&title=Structural+insights+into+the+conformational+selectivity+of+STI-571+and+related+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors</span></div><div class="casAuthors">Mol, Clifford D.; Fabbro, Doriano; Hosfield, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">639-648</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">1367-6733</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  STI-571 (Gleevec) is a highly successful cancer drug due to its activity as an inhibitor of the Abelson cytoplasmic tyrosine kinase (Abl), which is constitutively active in a majority of patients with chronic myelogenous leukemia.  STI-571 also inhibits two type III receptor tyrosine kinases, c-Kit and platelet-derived growth factor receptor, and functions by targeting inactive conformations of these kinases.  This review focuses on recent developments in x-ray co-crystal structure analyses of STI-571 bound to Abl and the c-Kit receptor tyrosine kinase domain, and also three other relevant kinase inhibitor co-crystal structures.  The similar structural features of these inactive kinases suggest they will be useful for the successful drug discovery and development of specific and targeted gene-based cancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg3Zb9Xj-aMrVg90H21EOLACvtfcHk0lgY5DW8zcrkLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotl2js7k%253D&md5=52fc98230a940cfc2b24695f469fe8ca</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMol%26aufirst%3DC.%2BD.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DHosfield%26aufirst%3DD.%2BJ.%26atitle%3DStructural%2520insights%2520into%2520the%2520conformational%2520selectivity%2520of%2520STI-571%2520and%2520related%2520kinase%2520inhibitors%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2004%26volume%3D7%26spage%3D639%26epage%3D648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitenstein, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brueggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntly, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall-Meyers, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callahan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammed, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1016%2Fj.ccr.2005.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=15710326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=129-141&author=E.+Weisbergauthor=P.+W.+Manleyauthor=W.+Breitensteinauthor=J.+Brueggenauthor=S.+W.+Cowan-Jacobauthor=A.+Rayauthor=B.+Huntlyauthor=D.+Fabbroauthor=G.+Fendrichauthor=E.+Hall-Meyersauthor=A.+L.+Kungauthor=J.+Mestanauthor=G.+Q.+Daleyauthor=L.+Callahanauthor=L.+Catleyauthor=C.+Cavazzaauthor=A.+Mohammedauthor=D.+Neubergauthor=R.+D.+Wrightauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Characterization+of+AMN107%2C+a+selective+inhibitor+of+native+and+mutant+Bcr-Abl"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span></div><div class="casAuthors">Weisberg, Ellen; Manley, Paul W.; Breitenstein, Werner; Brueggen, Josef; Cowan-Jacob, Sandra W.; Ray, Arghya; Huntly, Brian; Fabbro, Doriano; Fendrich, Gabriele; Hall-Meyers, Elizabeth; Kung, Andrew L.; Mestan, Juergen; Daley, George Q.; Callahan, Linda; Catley, Laurie; Cavazza, Cara; Mohammed, Azam; Neuberg, Donna; Wright, Renee D.; Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-141</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-pos. (Ph+) acute lymphoblastic leukemia (ALL).  We describe a novel selective inhibitor of Bcr-Abl, AMN107 (IC50 < 30 nM), which is significantly more potent than imatinib, and active against a no. of imatinib-resistant Bcr-Abl mutants.  Crystallog. anal. of Abl-AMN107 complexes provides a structural explanation for the differential activity of AMN107 and imatinib against imatinib-resistant Bcr-Abl.  Consistent with its in vitro and pharmacokinetic profile, AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolonged survival in imatinib-resistant CML mouse models.  AMN107 is a promising new inhibitor for the therapy of CML and Ph+ ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow6QF3qX2uO7Vg90H21EOLACvtfcHk0lgY5DW8zcrkLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D&md5=d28e1a54b982951f8d3e6ef1d2d3b2eb</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DBreitenstein%26aufirst%3DW.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DHuntly%26aufirst%3DB.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DHall-Meyers%26aufirst%3DE.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DCallahan%26aufirst%3DL.%26aulast%3DCatley%26aufirst%3DL.%26aulast%3DCavazza%26aufirst%3DC.%26aulast%3DMohammed%26aufirst%3DA.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DWright%26aufirst%3DR.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DCharacterization%2520of%2520AMN107%252C%2520a%2520selective%2520inhibitor%2520of%2520native%2520and%2520mutant%2520Bcr-Abl%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D129%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Golemovic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verstovsek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manshouri, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alland, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arlinghaus, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beran, M.</span><span> </span><span class="NLM_article-title">AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">4941</span><span class="NLM_x">–</span> <span class="NLM_lpage">4947</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1158%2F1078-0432.CCR-04-2601" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2006&pages=4941-4947&author=M.+Golemovicauthor=S.+Verstovsekauthor=F.+Gilesauthor=J.+Cortesauthor=T.+Manshouriauthor=P.+W.+Manleyauthor=J.+Mestanauthor=M.+Duganauthor=L.+Allandauthor=J.+D.+Griffinauthor=R.+B.+Arlinghausauthor=T.+Sunauthor=H.+Kantarjianauthor=M.+Beran&title=AMN107%2C+a+novel+aminopyrimidine+inhibitor+of+Bcr-Abl%2C+has+in+vitro+activity+against+imatinib-resistant+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-2601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-2601%26sid%3Dliteratum%253Aachs%26aulast%3DGolemovic%26aufirst%3DM.%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DManshouri%26aufirst%3DT.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DDugan%26aufirst%3DM.%26aulast%3DAlland%26aufirst%3DL.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DArlinghaus%26aufirst%3DR.%2BB.%26aulast%3DSun%26aufirst%3DT.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DBeran%26aufirst%3DM.%26atitle%3DAMN107%252C%2520a%2520novel%2520aminopyrimidine%2520inhibitor%2520of%2520Bcr-Abl%252C%2520has%2520in%2520vitro%2520activity%2520against%2520imatinib-resistant%2520chronic%2520myeloid%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D11%26spage%3D4941%26epage%3D4947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span> </span><span class="NLM_article-title">Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Proteins Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1754</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1016%2Fj.bbapap.2005.07.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=16172030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlags7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1754&publication_year=2005&pages=3-13&author=P.+W.+Manleyauthor=S.+W.+Cowan-Jacobauthor=J.+Mestan&title=Advances+in+the+structural+biology%2C+design+and+clinical+development+of+Bcr-Abl+kinase+inhibitors+for+the+treatment+of+chronic+myeloid+leukaemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16cR"><div class="casContent"><span class="casTitleNuber">16c</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia</span></div><div class="casAuthors">Manley, Paul William; Cowan-Jacob, Sandra W.; Mestan, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1754</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">3-13</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The constitutively activated Abl tyrosine kinase domain of the chimeric Bcr-Abl oncoprotein is responsible for the transformation of hematopoietic stem cells and the symptoms of chronic myeloid leukemia (CML).  Imatinib targets the tyrosine kinase activity of Bcr-Abl and is a first-line therapy for this malignancy.  Although highly effective in chronic phase CML, patients who have progressed to the advanced phase of the disease frequently fail to respond to imatinib or develop resistance to therapy and relapse.  This is often due to the emergence of clones expressing mutant forms of Bcr-Abl, which exhibit a decreased sensitivity towards inhibition by imatinib.  Considerable progress has recently been made in understanding the structural biol. of Abl and the mol. basis for resistance, facilitating the discovery and development of second generation drugs designed to combat mutant forms of Bcr-Abl.  The first of these compds. to enter clin. development were BMS-354825 (BristolMyersSquibb) and AMN107 (Novartis Pharma) and, from Phase I results, both of these promise a breakthrough in the treatment of imatinib-resistant CML.  Recent advances with these and other promising classes of new CML drugs are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0fkeC4vxU_bVg90H21EOLACvtfcHk0lhl--kmAYIL4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlags7fI&md5=b9d67d465f61804d2acd78605a4e9a75</span></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2005.07.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2005.07.040%26sid%3Dliteratum%253Aachs%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DMestan%26aufirst%3DJ.%26atitle%3DAdvances%2520in%2520the%2520structural%2520biology%252C%2520design%2520and%2520clinical%2520development%2520of%2520Bcr-Abl%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520chronic%2520myeloid%2520leukaemia%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2005%26volume%3D1754%26spage%3D3%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Horio, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naito, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayase, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niwa, T.</span><span> </span><span class="NLM_article-title">Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2712</span><span class="NLM_x">–</span> <span class="NLM_lpage">2717</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2712-2717&author=T.+Horioauthor=T.+Hamasakiauthor=T.+Inoueauthor=T.+Wakayamaauthor=S.+Itouauthor=H.+Naitoauthor=T.+Asakiauthor=H.+Hayaseauthor=T.+Niwa&title=Structural+factors+contributing+to+the+Abl%2FLyn+dual+inhibitory+activity+of+3-substituted+benzamide+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHorio%26aufirst%3DT.%26aulast%3DHamasaki%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DWakayama%26aufirst%3DT.%26aulast%3DItou%26aufirst%3DS.%26aulast%3DNaito%26aufirst%3DH.%26aulast%3DAsaki%26aufirst%3DT.%26aulast%3DHayase%26aufirst%3DH.%26aulast%3DNiwa%26aufirst%3DT.%26atitle%3DStructural%2520factors%2520contributing%2520to%2520the%2520Abl%252FLyn%2520dual%2520inhibitory%2520activity%2520of%25203-substituted%2520benzamide%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D2712%26epage%3D2717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Asaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higashioka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umehara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naito, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niwa, T.</span><span> </span><span class="NLM_article-title">Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1421</span><span class="NLM_x">–</span> <span class="NLM_lpage">1425</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=1421-1425&author=T.+Asakiauthor=Y.+Sugiyamaauthor=T.+Hamamotoauthor=M.+Higashiokaauthor=M.+Umeharaauthor=H.+Naitoauthor=T.+Niwa&title=Design+and+synthesis+of+3-substituted+benzamide+derivatives+as+Bcr-Abl+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAsaki%26aufirst%3DT.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DHamamoto%26aufirst%3DT.%26aulast%3DHigashioka%26aufirst%3DM.%26aulast%3DUmehara%26aufirst%3DM.%26aulast%3DNaito%26aufirst%3DH.%26aulast%3DNiwa%26aufirst%3DT.%26atitle%3DDesign%2520and%2520synthesis%2520of%25203-substituted%2520benzamide%2520derivatives%2520as%2520Bcr-Abl%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D1421%26epage%3D1425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kimura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naito, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuroda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuasa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokota, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamitsuji, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawata, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakaya, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naruoka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niwa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirabayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maekawa, T.</span><span> </span><span class="NLM_article-title">NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">3948</span><span class="NLM_x">–</span> <span class="NLM_lpage">3954</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=3948-3954&author=S.+Kimuraauthor=H.+Naitoauthor=H.+Segawaauthor=J.+Kurodaauthor=T.+Yuasaauthor=K.+Satoauthor=A.+Yokotaauthor=Y.+Kamitsujiauthor=E.+Kawataauthor=E.+Ashiharaauthor=Y.+Nakayaauthor=H.+Naruokaauthor=T.+Wakayamaauthor=K.+Nasuauthor=T.+Asakiauthor=T.+Niwaauthor=K.+Hirabayashiauthor=T.+Maekawa&title=NS-187%2C+a+potent+and+selective+dual+Bcr-Abl%2FLyn+tyrosine+kinase+inhibitor%2C+is+a+novel+agent+for+imatinib-resistant+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKimura%26aufirst%3DS.%26aulast%3DNaito%26aufirst%3DH.%26aulast%3DSegawa%26aufirst%3DH.%26aulast%3DKuroda%26aufirst%3DJ.%26aulast%3DYuasa%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DYokota%26aufirst%3DA.%26aulast%3DKamitsuji%26aufirst%3DY.%26aulast%3DKawata%26aufirst%3DE.%26aulast%3DAshihara%26aufirst%3DE.%26aulast%3DNakaya%26aufirst%3DY.%26aulast%3DNaruoka%26aufirst%3DH.%26aulast%3DWakayama%26aufirst%3DT.%26aulast%3DNasu%26aufirst%3DK.%26aulast%3DAsaki%26aufirst%3DT.%26aulast%3DNiwa%26aufirst%3DT.%26aulast%3DHirabayashi%26aufirst%3DK.%26aulast%3DMaekawa%26aufirst%3DT.%26atitle%3DNS-187%252C%2520a%2520potent%2520and%2520selective%2520dual%2520Bcr-Abl%252FLyn%2520tyrosine%2520kinase%2520inhibitor%252C%2520is%2520a%2520novel%2520agent%2520for%2520imatinib-resistant%2520leukemia%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D3948%26epage%3D3954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lowinger, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. A.</span><span> </span><span class="NLM_article-title">Design and discovery of small molecules targeting Raf-1 kinase</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2269</span><span class="NLM_x">–</span> <span class="NLM_lpage">2278</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.2174%2F1381612023393125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=12369855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD38XnvVGntrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=2269-2278&author=T.+B.+Lowingerauthor=B.+Riedlauthor=J.+Dumasauthor=R.+A.+Smith&title=Design+and+discovery+of+small+molecules+targeting+Raf-1+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">Design and discovery of small molecules targeting raf-1 kinase</span></div><div class="casAuthors">Lowinger, Timothy B.; Riedl, Bernd; Dumas, Jacques; Smith, Roger A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2269-2278</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review.  Raf kinase, an enzyme which acts downstream in the Ras signaling pathway, is involved in cancerous cell proliferation.  Thus, small mol. inhibitors of Raf kinase activity may be important agents for the treatment of cancer.  A novel class of Raf-1 inhibitors was discovered, using a combination of medicinal and combinatorial chem. approaches.  This effort culminated in the identification of the clin. candidate BAY 43-9006, currently undergoing Phase I clin. trials.  The present review summarizes the medicinal chem. development of ureas as highly potent inhibitors of Raf-1 kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqviNIBK_IYW7Vg90H21EOLACvtfcHk0lhl--kmAYIL4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnvVGntrk%253D&md5=a62445c3fb50083175ee4863ae84f6ce</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.2174%2F1381612023393125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612023393125%26sid%3Dliteratum%253Aachs%26aulast%3DLowinger%26aufirst%3DT.%2BB.%26aulast%3DRiedl%26aufirst%3DB.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26atitle%3DDesign%2520and%2520discovery%2520of%2520small%2520molecules%2520targeting%2520Raf-1%2520kinase%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2002%26volume%3D8%26spage%3D2269%26epage%3D2278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wan, P. T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barford, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">Mechanism of activation of the Raf-Erk signaling pathway by oncogenic mutations of B-Raf</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">855</span><span class="NLM_x">–</span> <span class="NLM_lpage">867</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1016%2FS0092-8674%2804%2900215-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=15035987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=855-867&author=P.+T.+C.+Wanauthor=M.+J.+Garnettauthor=S.+M.+Roeauthor=S.+Leeauthor=D.+Niculescu-Duvazauthor=V.+M.+Goodauthor=C.+M.+Jonesauthor=C.+J.+Marshallauthor=C.+J.+Springerauthor=D.+Barfordauthor=R.+Marais&title=Mechanism+of+activation+of+the+Raf-Erk+signaling+pathway+by+oncogenic+mutations+of+B-Raf"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span></div><div class="casAuthors">Wan, Paul T. C.; Garnett, Mathew J.; Roe, S. Mark; Lee, Sharlene; Niculescu-Duvaz, Dan; Good, Valerie M.; Project, Cancer Genome; Jones, C. Michael; Marshall, Christopher J.; Springer, Caroline J.; Barford, David; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">855-867</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Over 30 mutations of the B-RAF gene assocd. with human cancers have been identified, the majority of which are located within the kinase domain.  Here the authors show that of 22 B-RAF mutants analyzed, 18 have elevated kinase activity and signal to ERK in vivo.  Surprisingly, three mutants have reduced kinase activity towards MEK in vitro but, by activating C-RAF in vivo, signal to ERK in cells.  The structures of wild type and oncogenic V599EB-RAF kinase domains in complex with the RAF inhibitor BAY43-9006 show that the activation segment is held in an inactive conformation by assocn. with the P loop.  The clustering of most mutations to these two regions suggests that disruption of this interaction converts B-RAF into its active conformation.  The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYiQicwc1xVLVg90H21EOLACvtfcHk0ljJOHfHFaeCeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D&md5=4cc020056c64e514286c000666da1972</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900215-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900215-6%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DP.%2BT.%2BC.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DGood%26aufirst%3DV.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BM.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DMechanism%2520of%2520activation%2520of%2520the%2520Raf-Erk%2520signaling%2520pathway%2520by%2520oncogenic%2520mutations%2520of%2520B-Raf%26jtitle%3DCell%26date%3D2004%26volume%3D116%26spage%3D855%26epage%3D867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Pargellis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Churchill, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirillo, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmore, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grob, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pav, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regan, J.</span><span> </span><span class="NLM_article-title">Inhibition of p38 Map kinase by utilizing a novel allosteric binding site</span> <span class="citation_source-journal">Nat. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">268</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1038%2Fnsb770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=11896401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=268-272&author=C.+Pargellisauthor=L.+Tongauthor=L.+Churchillauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=A.+G.+Grahamauthor=P.+M.+Grobauthor=E.+R.+Hickeyauthor=N.+Mossauthor=S.+Pavauthor=J.+Regan&title=Inhibition+of+p38+Map+kinase+by+utilizing+a+novel+allosteric+binding+site"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span></div><div class="casAuthors">Pargellis, Christopher; Tong, Liang; Churchill, Laurie; Cirillo, Pier F.; Gilmore, Thomas; Graham, Anne G.; Grob, Peter M.; Hickey, Eugene R.; Moss, Neil; Pav, Susan; Regan, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">268-272</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">The p38 MAP kinase plays a crucial role in regulating the prodn. of proinflammatory cytokines, such as tumor necrosis factor and interleukin-1.  Blocking this kinase may offer an effective therapy for treating many inflammatory diseases.  Here we report a new allosteric binding site for a diaryl urea class of highly potent and selective inhibitors against human p38 MAP kinase.  The formation of this binding site requires a large conformational change not obsd. previously for any of the protein Ser/Thr kinases.  This change is in the highly conserved Asp-Phe-Gly motif within the active site of the kinase.  Soln. studies demonstrate that this class of compds. has slow binding kinetics, consistent with the requirement for conformational change.  Improving interactions in this allosteric pocket, as well as establishing binding interactions in the ATP pocket, enhanced the affinity of the inhibitors by 12,000-fold.  One of the most potent compds. in this series, BIRB 796, has picomolar affinity for the kinase and low nanomolar inhibitory activity in cell culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT8_QT7_pbYrVg90H21EOLACvtfcHk0ljJOHfHFaeCeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D&md5=68850ecdbe08df4285ba38cfa2c93ea4</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnsb770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb770%26sid%3Dliteratum%253Aachs%26aulast%3DPargellis%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DChurchill%26aufirst%3DL.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DGrob%26aufirst%3DP.%2BM.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DMoss%26aufirst%3DN.%26aulast%3DPav%26aufirst%3DS.%26aulast%3DRegan%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520p38%2520Map%2520kinase%2520by%2520utilizing%2520a%2520novel%2520allosteric%2520binding%2520site%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2002%26volume%3D9%26spage%3D268%26epage%3D272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Dai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartandi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albert, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bousquet, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunha, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaser, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcotte, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moskey, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoll, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tapang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelides, M. R.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-(4-(3-amino-1<i>H</i>-indazol-4-yl)phenyl)-<i>N</i>'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1584</span><span class="NLM_x">–</span> <span class="NLM_lpage">1597</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm061280h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1584-1597&author=Y.+Daiauthor=K.+Hartandiauthor=Z.+Jiauthor=A.+A.+Ahmedauthor=D.+H.+Albertauthor=J.+L.+Bauchauthor=J.+J.+Bouskaauthor=P.+F.+Bousquetauthor=G.+A.+Cunhaauthor=K.+B.+Glaserauthor=C.+M.+Harrisauthor=D.+Hickmanauthor=J.+Guoauthor=J.+Liauthor=P.+A.+Marcotteauthor=K.+C.+Marshauthor=M.+D.+Moskeyauthor=R.+L.+Martinauthor=A.+M.+Olsonauthor=D.+J.+Osterlingauthor=L.+J.+Peaseauthor=N.+B.+Soniauthor=K.+D.+Stewartauthor=V.+S.+Stollauthor=P.+Tapangauthor=D.+R.+Reuterauthor=S.+K.+Davidsenauthor=M.+R.+Michaelides&title=Discovery+of+N-%284-%283-amino-1H-indazol-4-yl%29phenyl%29-N%27-%282-fluoro-5-methylphenyl%29urea+%28ABT-869%29%2C+a+3-aminoindazole-based+orally+active+multitargeted+receptor+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm061280h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061280h%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DY.%26aulast%3DHartandi%26aufirst%3DK.%26aulast%3DJi%26aufirst%3DZ.%26aulast%3DAhmed%26aufirst%3DA.%2BA.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DBauch%26aufirst%3DJ.%2BL.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DBousquet%26aufirst%3DP.%2BF.%26aulast%3DCunha%26aufirst%3DG.%2BA.%26aulast%3DGlaser%26aufirst%3DK.%2BB.%26aulast%3DHarris%26aufirst%3DC.%2BM.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMarcotte%26aufirst%3DP.%2BA.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DMoskey%26aufirst%3DM.%2BD.%26aulast%3DMartin%26aufirst%3DR.%2BL.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DPease%26aufirst%3DL.%2BJ.%26aulast%3DSoni%26aufirst%3DN.%2BB.%26aulast%3DStewart%26aufirst%3DK.%2BD.%26aulast%3DStoll%26aufirst%3DV.%2BS.%26aulast%3DTapang%26aufirst%3DP.%26aulast%3DReuter%26aufirst%3DD.%2BR.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26atitle%3DDiscovery%2520of%2520N-%25284-%25283-amino-1H-indazol-4-yl%2529phenyl%2529-N%2527-%25282-fluoro-5-methylphenyl%2529urea%2520%2528ABT-869%2529%252C%2520a%25203-aminoindazole-based%2520orally%2520active%2520multitargeted%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1584%26epage%3D1597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffregen, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdullah, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moseson, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohacek, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">2532</span><span class="NLM_x">–</span> <span class="NLM_lpage">2539</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2004&pages=2532-2539&author=T.+O%E2%80%99Hareauthor=R.+Pollockauthor=E.+P.+Stoffregenauthor=J.+A.+Keatsauthor=O.+M.+Abdullahauthor=E.+M.+Mosesonauthor=V.+M.+Riveraauthor=H.+Tangauthor=C.+A.+Metcalfauthor=R.+S.+Bohacekauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=W.+C.+Shakespeareauthor=D.+Dalgarnoauthor=T.+Clacksonauthor=T.+K.+Sawyerauthor=M.+W.+Deiningerauthor=B.+J.+Druker&title=Inhibition+of+wild-type+and+mutant+Bcr-Abl+by+AP23464%2C+a+potent+ATP-based+oncogenic+protein+kinase+inhibitor%3A+implications+for+CML"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DPollock%26aufirst%3DR.%26aulast%3DStoffregen%26aufirst%3DE.%2BP.%26aulast%3DKeats%26aufirst%3DJ.%2BA.%26aulast%3DAbdullah%26aufirst%3DO.%2BM.%26aulast%3DMoseson%26aufirst%3DE.%2BM.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DBohacek%26aufirst%3DR.%2BS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DInhibition%2520of%2520wild-type%2520and%2520mutant%2520Bcr-Abl%2520by%2520AP23464%252C%2520a%2520potent%2520ATP-based%2520oncogenic%2520protein%2520kinase%2520inhibitor%253A%2520implications%2520for%2520CML%26jtitle%3DBlood%26date%3D2004%26volume%3D104%26spage%3D2532%26epage%3D2539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohacek, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span> </span><span class="NLM_article-title">Activity of dual Src-Abl inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">9244</span><span class="NLM_x">–</span> <span class="NLM_lpage">9249</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=9244-9249&author=M.+Azamauthor=V.+Nardiauthor=W.+C.+Shakespeareauthor=C.+A.+Metcalfauthor=R.+S.+Bohacekauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=P.+Slizauthor=D.+R.+Veachauthor=W.+G.+Bornmannauthor=B.+Clarksonauthor=D.+C.+Dalgarnoauthor=T.+K.+Sawyerauthor=G.+Q.+Daley&title=Activity+of+dual+Src-Abl+inhibitors+highlights+the+role+of+BCR%2FABL+kinase+dynamics+in+drug+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DNardi%26aufirst%3DV.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DBohacek%26aufirst%3DR.%2BS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DSliz%26aufirst%3DP.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26atitle%3DActivity%2520of%2520dual%2520Src-Abl%2520inhibitors%2520highlights%2520the%2520role%2520of%2520BCR%252FABL%2520kinase%2520dynamics%2520in%2520drug%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D9244%26epage%3D9249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lentini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broudy, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russian, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span> </span><span class="NLM_article-title">Novel <i>N</i><sup>9</sup>-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4907</span><span class="NLM_x">–</span> <span class="NLM_lpage">4912</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4907-4912&author=Y.+Wangauthor=W.+C.+Shakespeareauthor=W.-S.+Huangauthor=R.+Sundaramoorthiauthor=S.+Lentiniauthor=S.+Dasauthor=S.+Liuauthor=G.+Bandaauthor=D.+Wenauthor=X.+Zhuauthor=Q.+Xuauthor=J.+Keatsauthor=F.+Wangauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+T.+Snodgrassauthor=M.+I.+Broudyauthor=K.+Russianauthor=D.+Dalgarnoauthor=T.+Clacksonauthor=T.+K.+Sawyer&title=Novel+N9-arenethenyl+purines+as+potent+dual+Src%2FAbl+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DLentini%26aufirst%3DS.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DBanda%26aufirst%3DG.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSnodgrass%26aufirst%3DJ.%2BT.%26aulast%3DBroudy%26aufirst%3DM.%2BI.%26aulast%3DRussian%26aufirst%3DK.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26atitle%3DNovel%2520N9-arenethenyl%2520purines%2520as%2520potent%2520dual%2520Src%252FAbl%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4907%26epage%3D4912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Rational design of inhibitors that bind to inactive kinase conformations</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1038%2Fnchembio799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=16783341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=358-364&author=Y.+Liuauthor=N.+S.+Gray&title=Rational+design+of+inhibitors+that+bind+to+inactive+kinase+conformations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23aR"><div class="casContent"><span class="casTitleNuber">23a</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of inhibitors that bind to inactive kinase conformations</span></div><div class="casAuthors">Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">358-364</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The majority of kinase inhibitors, known as type I inhibitors that have been developed so far target the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated.  Recently, crystal structures of inhibitors such as imatinib, BIRB796, and sorafenib (BAY43-9006), known as type II inhibitors, have revealed a new binding mode that exploits an addnl. binding site immediately adjacent to the region occupied by ATP.  This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation.  The examn. of binding features of known type II inhibitors is discussed and a pharmacophore model currently used in the design of a new generation of structurally diverse type II inhibitors is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxahsMPlhgDbVg90H21EOLACvtfcHk0lgFcAfUuJoplg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D&md5=4a9347a44a2cf4a412c9741fdcc5696b</span></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=10.1038%2Fnchembio799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio799%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DRational%2520design%2520of%2520inhibitors%2520that%2520bind%2520to%2520inactive%2520kinase%2520conformations%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26spage%3D358%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Okram, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagle, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spraggon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">A general strategy for creating “inactive-conformation” Abl inhibitors</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">779</span><span class="NLM_x">–</span> <span class="NLM_lpage">786</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1016%2Fj.chembiol.2006.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=16873026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD28XntlGisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=779-786&author=B.+Okramauthor=A.+Nagleauthor=F.+J.+Adrianauthor=C.+Leeauthor=P.+Renauthor=X.+Wangauthor=T.+Simauthor=Y.+Xieauthor=X.+Wangauthor=G.+Xiaauthor=G.+Spraggonauthor=M.+Warmuthauthor=Y.+Liuauthor=N.+S.+Gray&title=A+general+strategy+for+creating+%E2%80%9Cinactive-conformation%E2%80%9D+Abl+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23bR"><div class="casContent"><span class="casTitleNuber">23b</span><div class="casTitle"><span class="NLM_cas:atitle">A General Strategy for Creating "Inactive-Conformation" Abl Inhibitors</span></div><div class="casAuthors">Okram, Barun; Nagle, Advait; Adrian, Francisco J.; Lee, Christian; Ren, Pingda; Wang, Xia; Sim, Taebo; Xie, Yongping; Wang, Xing; Xia, Gang; Spraggon, Glen; Warmuth, Markus; Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">779-786</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Kinase inhibitors that bind to the ATP cleft can be broadly classified into two groups: Those that bind exclusively to the ATP site with the kinase assuming a conformation otherwise conducive to phosphotransfer (type I), and those that exploit a hydrophobic site immediately adjacent to the ATP pocket made accessible by a conformational rearrangement of the activation loop (type II).  To date, all type II inhibitors were discovered by using structure-activity-guided optimization strategies.  Here, we describe a general pharmacophore model of type II inhibition that enables a rational "hybrid-design" approach whereby a 3-trifluoromethylbenzamide functionality is appended to four distinct type I scaffolds in order to convert them into their corresponding type II counterparts.  We demonstrate that the designed compds. function as type II inhibitors by using biochem. and cellular kinase assays and by cocrystallog. with Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEmN-Rh-LxOLVg90H21EOLACvtfcHk0lgFcAfUuJoplg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntlGisL0%253D&md5=84514353c00e20f85225f62d00dc2529</span></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2006.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2006.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DOkram%26aufirst%3DB.%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DAdrian%26aufirst%3DF.%2BJ.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DSpraggon%26aufirst%3DG.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DA%2520general%2520strategy%2520for%2520creating%2520%25E2%2580%259Cinactive-conformation%25E2%2580%259D%2520Abl%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2006%26volume%3D13%26spage%3D779%26epage%3D786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Sherman, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friesner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farid, R.</span><span> </span><span class="NLM_article-title">Novel procedure for modeling ligand/receptor induced fit effects</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">534</span><span class="NLM_x">–</span> <span class="NLM_lpage">553</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050540c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlCgsr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=534-553&author=W.+Shermanauthor=T.+Dayauthor=M.+P.+Jacobsonauthor=R.+A.+Friesnerauthor=R.+Farid&title=Novel+procedure+for+modeling+ligand%2Freceptor+induced+fit+effects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Procedure for Modeling Ligand/Receptor Induced Fit Effects</span></div><div class="casAuthors">Sherman, Woody; Day, Tyler; Jacobson, Matthew P.; Friesner, Richard A.; Farid, Ramy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">534-553</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present a novel protein-ligand docking method that accurately accounts for both ligand and receptor flexibility by iteratively combining rigid receptor docking (Glide) with protein structure prediction (Prime) techniques.  While traditional rigid-receptor docking methods are useful when the receptor structure does not change substantially upon ligand binding, success is limited when the protein must be "induced" into the correct binding conformation for a given ligand.  We provide an in-depth description of our novel methodol. and present results for 21 pharmaceutically relevant examples.  Traditional rigid-receptor docking for these 21 cases yields an av. RMSD of 5.5 Å.  The av. ligand RMSD for docking to a flexible receptor for the 21 pairs is 1.4 Å; the RMSD is ≤1.8 Å for 18 of the cases.  For the three cases with RMSDs greater than 1.8 Å, the core of the ligand is properly docked and all key protein/ligand interactions are captured.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm3E6ctnPGSrVg90H21EOLACvtfcHk0liW-hjGnk2XjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlCgsr7I&md5=388811ead5cee1fd460951263de486cb</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm050540c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050540c%26sid%3Dliteratum%253Aachs%26aulast%3DSherman%26aufirst%3DW.%26aulast%3DDay%26aufirst%3DT.%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DFarid%26aufirst%3DR.%26atitle%3DNovel%2520procedure%2520for%2520modeling%2520ligand%252Freceptor%2520induced%2520fit%2520effects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D534%26epage%3D553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stehle, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schelling, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Schravendijk, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrade, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grossman, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacNeil, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keenan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohacek, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weigele, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T.</span><span> </span><span class="NLM_article-title">Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">46</span><span class="NLM_x">–</span> <span class="NLM_lpage">57</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1111%2Fj.1747-0285.2005.00316.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=16492148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsVSjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2006&pages=46-57&author=D.+Dalgarnoauthor=T.+Stehleauthor=S.+Narulaauthor=P.+Schellingauthor=M.+R.+van+Schravendijkauthor=S.+Adamsauthor=L.+Andradeauthor=J.+Keatsauthor=M.+Ramauthor=L.+Jinauthor=T.+Grossmanauthor=I.+MacNeilauthor=C.+Metcalfauthor=W.+Shakespeareauthor=Y.+Wangauthor=T.+Keenanauthor=R.+Sundaramoorthiauthor=R.+Bohacekauthor=M.+Weigeleauthor=T.+Sawyer&title=Structural+basis+of+Src+tyrosine+kinase+inhibition+with+a+new+class+of+potent+and+selective+trisubstituted+purine-based+compounds"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds</span></div><div class="casAuthors">Dalgarno, David; Stehle, Thilo; Narula, Surinder; Schelling, Pierre; van Schravendijk, Marie Rose; Adams, Susan; Andrade, Lawrence; Keats, Jeff; Ram, Mary; Jin, Lei; Grossman, Trudy; MacNeil, Ian; Metcalf, Chester, III; Shakespeare, William; Wang, Yihan; Keenan, Terry; Sundaramoorthi, Raji; Bohacek, Regine; Weigele, Manfred; Sawyer, Tomi</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-57</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The tyrosine kinase pp60src (Src) is the prototypical member of a family of proteins that participate in a broad array of cellular signal transduction processes, including cell growth, differentiation, survival, adhesion, and migration.  Abnormal Src family kinase (SFK) signaling has been linked to several disease states, including osteoporosis and cancer metastases.  Src has thus emerged as a mol. target for the discovery of small-mol. inhibitors that regulate Src kinase activity by binding to the ATP pocket within the catalytic domain.  Here, we present crystal structures of the kinase domain of Src in complex with two purine-based inhibitors: AP23451, a small-mol. inhibitor designed to inhibit Src-dependent bone resorption, and AP23464, a small-mol. inhibitor designed to inhibit the Src-dependent metastatic spread of cancer.  In each case, a trisubstituted purine template core was elaborated using structure-based drug design to yield a potent Src kinase inhibitor.  These structures represent early examples of high affinity purine-based Src family kinase-inhibitor complexes, and they provide a detailed view of the specific protein-ligand interactions that lead to potent inhibition of Src.  In particular, the 3-hydroxyphenethyl N9 substituent of AP23464 forms unique interactions with the protein that are crit. to the picomolar affinity of this compd. for Src.  The comparison of these new structures with two relevant kinase-inhibitor complexes provides a structural basis for the obsd. kinase inhibitory selectivity.  Further comparisons reveal a concerted induced-fit movement between the N- and C-terminal lobes of the kinase that correlates with the affinity of the ligand.  Binding of the most potent inhibitor, AP23464, results in the largest induced-fit movement, which can be directly linked to interactions of the hydrophenethyl N9 substituent with a region at the interface between the two lobes.  A less pronounced induced-fit movement is also obsd. in the Src-AP23451 complex.  These new structures illustrate how the combination of structural, computational, and medicinal chem. can be used to rationalize the process of developing high affinity, selective tyrosine kinase inhibitors as potential therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqAcWZyLy8JrVg90H21EOLACvtfcHk0liW-hjGnk2XjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsVSjt7Y%253D&md5=5a89de976e29e65aec0553c84e2e0b92</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2005.00316.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2005.00316.x%26sid%3Dliteratum%253Aachs%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DStehle%26aufirst%3DT.%26aulast%3DNarula%26aufirst%3DS.%26aulast%3DSchelling%26aufirst%3DP.%26aulast%3Dvan%2BSchravendijk%26aufirst%3DM.%2BR.%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DAndrade%26aufirst%3DL.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DRam%26aufirst%3DM.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DGrossman%26aufirst%3DT.%26aulast%3DMacNeil%26aufirst%3DI.%26aulast%3DMetcalf%26aufirst%3DC.%26aulast%3DShakespeare%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKeenan%26aufirst%3DT.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DBohacek%26aufirst%3DR.%26aulast%3DWeigele%26aufirst%3DM.%26aulast%3DSawyer%26aufirst%3DT.%26atitle%3DStructural%2520basis%2520of%2520Src%2520tyrosine%2520kinase%2520inhibition%2520with%2520a%2520new%2520class%2520of%2520potent%2520and%2520selective%2520trisubstituted%2520purine-based%2520compounds%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2006%26volume%3D67%26spage%3D46%26epage%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Boesen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madsen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henriksen, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahl, O.</span><span> </span><span class="NLM_article-title">Preparation of <i>N</i>-(alk-1-enyl) nucleobase compounds by Horner and Horner−Wadsworth−Emmons reactions</span> <span class="citation_source-journal">J. Chem. Soc., Perkin Trans. 1</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_fpage">2015</span><span class="NLM_x">–</span> <span class="NLM_lpage">2021</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&pages=2015-2021&author=T.+Boesenauthor=C.+Madsenauthor=U.+Henriksenauthor=O.+Dahl&title=Preparation+of+N-%28alk-1-enyl%29+nucleobase+compounds+by+Horner+and+Horner%E2%88%92Wadsworth%E2%88%92Emmons+reactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoesen%26aufirst%3DT.%26aulast%3DMadsen%26aufirst%3DC.%26aulast%3DHenriksen%26aufirst%3DU.%26aulast%3DDahl%26aufirst%3DO.%26atitle%3DPreparation%2520of%2520N-%2528alk-1-enyl%2529%2520nucleobase%2520compounds%2520by%2520Horner%2520and%2520Horner%25E2%2588%2592Wadsworth%25E2%2588%2592Emmons%2520reactions%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%26date%3D2000%26spage%3D2015%26epage%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Huang, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lentini, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span> </span><span class="NLM_article-title">Facile synthesis of 9-(arenethenyl)purines via Heck reaction of 9-vinylpurines and aryl halides</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">7388</span><span class="NLM_x">–</span> <span class="NLM_lpage">7391</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=7388-7391&author=W.-S.+Huangauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=R.+M.+Thomasauthor=D.+Wenauthor=S.+Liuauthor=S.+P.+Lentiniauthor=S.+Dasauthor=G.+Bandaauthor=T.+K.+Sawyerauthor=W.+C.+Shakespeare&title=Facile+synthesis+of+9-%28arenethenyl%29purines+via+Heck+reaction+of+9-vinylpurines+and+aryl+halides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DR.%2BM.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLentini%26aufirst%3DS.%2BP.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DBanda%26aufirst%3DG.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DFacile%2520synthesis%2520of%25209-%2528arenethenyl%2529purines%2520via%2520Heck%2520reaction%2520of%25209-vinylpurines%2520and%2520aryl%2520halides%26jtitle%3DTetrahedron%2520Lett.%26date%3D2007%26volume%3D48%26spage%3D7388%26epage%3D7391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Pitha, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ts’o, P. O. P.</span><span> </span><span class="NLM_article-title"><i>N</i>-Vinyl derivatives of substituted pyrimidines and purines</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1968</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1341</span><span class="NLM_x">–</span> <span class="NLM_lpage">1344</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo01268a006" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1968&pages=1341-1344&author=J.+Pithaauthor=P.+O.+P.+Ts%E2%80%99o&title=N-Vinyl+derivatives+of+substituted+pyrimidines+and+purines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjo01268a006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo01268a006%26sid%3Dliteratum%253Aachs%26aulast%3DPitha%26aufirst%3DJ.%26aulast%3DTs%25E2%2580%2599o%26aufirst%3DP.%2BO.%2BP.%26atitle%3DN-Vinyl%2520derivatives%2520of%2520substituted%2520pyrimidines%2520and%2520purines%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1968%26volume%3D33%26spage%3D1341%26epage%3D1344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Huang, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span> </span><span class="NLM_article-title">An efficient synthesis of nilotinib (AMN107)</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_fpage">2121</span><span class="NLM_x">–</span> <span class="NLM_lpage">2124</span><div class="note"><p class="first last"> and references cited therein</p></div></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1055%2Fs-2007-983754" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpslCjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&pages=2121-2124&author=W.-S.+Huangauthor=W.+C.+Shakespeare&title=An+efficient+synthesis+of+nilotinib+%28AMN107%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">An efficient synthesis of nilotinib (AMN107)</span></div><div class="casAuthors">Huang, Wei-Sheng; Shakespeare, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2121-2124</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">A concise synthesis of AMN107, a compd. currently undergoing several phase II/III clin. trials for chronic myelogenous leukemia, is described.  The new procedure reduces the no. of synthetic steps from eight to four, with an overall yield of 65%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVk1pQeYvBWbVg90H21EOLACvtfcHk0lhnkhm3f2ZLVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpslCjtbY%253D&md5=4ca31907c33acd3510b7dcfa4e70374c</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1055%2Fs-2007-983754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2007-983754%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DAn%2520efficient%2520synthesis%2520of%2520nilotinib%2520%2528AMN107%2529%26jtitle%3DSynthesis%26date%3D2007%26spage%3D2121%26epage%3D2124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Pierce, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ter Haar, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binch, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, P.</span><span> </span><span class="NLM_article-title">CH···O and CH···N hydrogen bonds in ligand design: A novel quinazolin-4-ylthiazol-2-ylamine protein kinase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1278</span><span class="NLM_x">–</span> <span class="NLM_lpage">1281</span><div class="note"><p class="first last">and references cited therein</p></div></span><div class="citationLinks">[<a href="/doi/10.1021/jm0492249" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1278-1281&author=A.+C.+Pierceauthor=E.+ter+Haarauthor=H.+M.+Binchauthor=D.+P.+Kayauthor=S.+R.+Patelauthor=P.+Li&title=CH%C2%B7%C2%B7%C2%B7O+and+CH%C2%B7%C2%B7%C2%B7N+hydrogen+bonds+in+ligand+design%3A+A+novel+quinazolin-4-ylthiazol-2-ylamine+protein+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm0492249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0492249%26sid%3Dliteratum%253Aachs%26aulast%3DPierce%26aufirst%3DA.%2BC.%26aulast%3Dter%2BHaar%26aufirst%3DE.%26aulast%3DBinch%26aufirst%3DH.%2BM.%26aulast%3DKay%26aufirst%3DD.%2BP.%26aulast%3DPatel%26aufirst%3DS.%2BR.%26aulast%3DLi%26aufirst%3DP.%26atitle%3DCH%25C2%25B7%25C2%25B7%25C2%25B7O%2520and%2520CH%25C2%25B7%25C2%25B7%25C2%25B7N%2520hydrogen%2520bonds%2520in%2520ligand%2520design%253A%2520A%2520novel%2520quinazolin-4-ylthiazol-2-ylamine%2520protein%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1278%26epage%3D1281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Daylight Chemical Information System, Inc.</span><a href="http://www.daylight.com" class="extLink">http://www.daylight.com</a>, accessed March 2005.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Daylight+Chemical+Information+System%2C+Inc.http%3A%2F%2Fwww.daylight.com%2C+accessed+March+2005."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Seeliger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">299</span><span class="NLM_x">–</span> <span class="NLM_lpage">311</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1016%2Fj.str.2007.01.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=17355866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisleisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=299-311&author=M.+A.+Seeligerauthor=B.+Nagarauthor=F.+Frankauthor=X.+Caoauthor=M.+N.+Hendersonauthor=J.+Kuriyan&title=c-Src+binds+to+the+cancer+drug+imatinib+with+an+inactive+Abl%2Fc-Kit+conformation+and+a+distributed+thermodynamic+penalty"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32aR"><div class="casContent"><span class="casTitleNuber">32a</span><div class="casTitle"><span class="NLM_cas:atitle">c-Src Binds to the Cancer Drug Imatinib with an Inactive Abl/c-Kit Conformation and a Distributed Thermodynamic Penalty</span></div><div class="casAuthors">Seeliger, Markus A.; Nagar, Bhushan; Frank, Filipp; Cao, Xiaoxian; Henderson, M. Nidanie; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">299-311</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The cancer drug imatinib inhibits the tyrosine kinases c-Abl, c-Kit, and the PDGF receptor.  Imatinib is less effective against c-Src, which is difficult to understand because residues interacting with imatinib in crystal structures of Abl and c-Kit are conserved in c-Src.  The crystal structure of the c-Src kinase domain in complex with imatinib closely resembles that of Abl•imatinib and c-Kit•imatinib, and differs significantly from the inactive "Src/CDK" conformation of the Src family kinases.  Attempts to increase the affinity of c-Src for imatinib by swapping residues with the corresponding residues in Abl have not been successful, suggesting that the thermodn. penalty for adoption of the imatinib-binding conformation by c-Src is distributed over a broad region of the structure.  Two mutations that are expected to destabilize the inactive Src/CDK conformation increase drug sensitivity 15-fold, suggesting that the free-energy balance between different inactive states is a key to imatinib binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2SQGjjXdg1LVg90H21EOLACvtfcHk0lhnkhm3f2ZLVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisleisbY%253D&md5=ddfbcf06d91b408ca5fb25af9774c334</span></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2007.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2007.01.015%26sid%3Dliteratum%253Aachs%26aulast%3DSeeliger%26aufirst%3DM.%2BA.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DFrank%26aufirst%3DF.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DHenderson%26aufirst%3DM.%2BN.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3Dc-Src%2520binds%2520to%2520the%2520cancer%2520drug%2520imatinib%2520with%2520an%2520inactive%2520Abl%252Fc-Kit%2520conformation%2520and%2520a%2520distributed%2520thermodynamic%2520penalty%26jtitle%3DStructure%26date%3D2007%26volume%3D15%26spage%3D299%26epage%3D311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Levinson, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuchment, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koldobskiy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karplus, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J. A</span><span> </span><span class="NLM_article-title">Src-like inactive conformation in the Abl tyrosine kinase domain</span> <span class="citation_source-journal">PLoS Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">753</span><span class="NLM_x">–</span> <span class="NLM_lpage">767</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2006&pages=753-767&author=N.+M.+Levinsonauthor=O.+Kuchmentauthor=K.+Shenauthor=M.+A.+Youngauthor=M.+Koldobskiyauthor=M.+Karplusauthor=P.+A.+Coleauthor=J.+A+Kuriyan&title=Src-like+inactive+conformation+in+the+Abl+tyrosine+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLevinson%26aufirst%3DN.%2BM.%26aulast%3DKuchment%26aufirst%3DO.%26aulast%3DShen%26aufirst%3DK.%26aulast%3DYoung%26aufirst%3DM.%2BA.%26aulast%3DKoldobskiy%26aufirst%3DM.%26aulast%3DKarplus%26aufirst%3DM.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DKuriyan%26aufirst%3DJ.%2BA%26atitle%3DSrc-like%2520inactive%2520conformation%2520in%2520the%2520Abl%2520tyrosine%2520kinase%2520domain%26jtitle%3DPLoS%2520Biol.%26date%3D2006%26volume%3D4%26spage%3D753%26epage%3D767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">4236</span><span class="NLM_x">–</span> <span class="NLM_lpage">4243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=12154025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4236-4243&author=B.+Nagarauthor=W.+G.+Bornmannauthor=P.+Pellicenaauthor=T.+Schindlerauthor=D.+R.+Veachauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Crystal+structures+of+the+kinase+domain+of+c-Abl+in+complex+with+the+small+molecule+inhibitors+PD173955+and+imatinib+%28STI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32cR"><div class="casContent"><span class="casTitleNuber">32c</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span></div><div class="casAuthors">Nagar, Bhushan; Bornmann, William G.; Pellicena, Patricia; Schindler, Thomas; Veach, Darren R.; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4236-4243</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia.  Small mol. inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia.  We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).  Both compds. bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways.  As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate.  In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase.  The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex.  In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571.  The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5qYZHMOZCrVg90H21EOLACvtfcHk0ljoZDvfd1Ic0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D&md5=843213cd6038ed82a0e43dce56e81a91</span></div><a href="/servlet/linkout?suffix=cit32c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structures%2520of%2520the%2520kinase%2520domain%2520of%2520c-Abl%2520in%2520complex%2520with%2520the%2520small%2520molecule%2520inhibitors%2520PD173955%2520and%2520imatinib%2520%2528STI-571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D4236%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jahnke, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liebetanz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span> </span><span class="NLM_article-title">The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">861</span><span class="NLM_x">–</span> <span class="NLM_lpage">871</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32d&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1016%2Fj.str.2005.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32d&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=15939018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32d&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltFCksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=861-871&author=S.+W.+Cowan-Jacobauthor=G.+Fendrichauthor=P.+W.+Manleyauthor=W.+Jahnkeauthor=D.+Fabbroauthor=J.+Liebetanzauthor=T.+Meyer&title=The+crystal+structure+of+a+c-Src+complex+in+an+active+conformation+suggests+possible+steps+in+c-Src+activation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32dR"><div class="casContent"><span class="casTitleNuber">32d</span><div class="casTitle"><span class="NLM_cas:atitle">The Crystal Structure of a c-Src Complex in an Active Conformation Suggests Possible Steps in c-Src Activation</span></div><div class="casAuthors">Cowan-Jacob, Sandra W.; Fendrich, Gabriele; Manley, Paul W.; Jahnke, Wolfgang; Fabbro, Doriano; Liebetanz, Janis; Meyer, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">861-871</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The regulation of the activity of Abl and Src family tyrosine kinases is mediated by intramol. interactions between the SH3, SH2, and kinase (SH1) domains.  We have detd. the crystal structure of an unphosphorylated form of c-Src in which the SH2 domain is not bound to the C-terminal tail.  This results in an open structure where the kinase domain adopts an active conformation and the C terminus binds within a hydrophobic pocket in the C-terminal lobe.  NMR binding studies support the hypothesis that an N-terminal myristate could bind in this pocket, as obsd. for Abl, suggesting that c-Src may also be regulated by myristate binding.  In addn., the structure contains a des-Me analog of the antileukemia drug imatinib (STI571; Gleevec).  This structure reveals why the drug shows a low affinity for active kinase conformations, contributing to its excellent kinase selectivity profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpipzhBFIZrQ7Vg90H21EOLACvtfcHk0ljoZDvfd1Ic0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltFCksLk%253D&md5=f0de83e5bca45fe96795e5327e6d1369</span></div><a href="/servlet/linkout?suffix=cit32d&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2005.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2005.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DLiebetanz%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DT.%26atitle%3DThe%2520crystal%2520structure%2520of%2520a%2520c-Src%2520complex%2520in%2520an%2520active%2520conformation%2520suggests%2520possible%2520steps%2520in%2520c-Src%2520activation%26jtitle%3DStructure%26date%3D2005%26volume%3D13%26spage%3D861%26epage%3D871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Dar, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Small molecule recognition of c-Src via the Imatinib-binding conformation</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1015</span><span class="NLM_x">–</span> <span class="NLM_lpage">1022</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1016%2Fj.chembiol.2008.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=18940662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1KmsrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=1015-1022&author=A.+C.+Darauthor=M.+S.+Lopezauthor=K.+M.+Shokat&title=Small+molecule+recognition+of+c-Src+via+the+Imatinib-binding+conformation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Recognition of c-Src via the Imatinib-Binding Conformation</span></div><div class="casAuthors">Dar, Arvin C.; Lopez, Michael S.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1015-1022</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The cancer drug, Imatinib, is a selective Abl kinase inhibitor that does not inhibit the closely related kinase c-Src.  This one drug and its ability to selectively inhibit Abl over c-Src has been a guiding principle in virtually all kinase drug discovery efforts in the last 15 years.  A prominent hypothesis explaining the selectivity of Imatinib is that Abl has an intrinsic ability to adopt an inactive conformation (termed DFG-out), whereas c-Src appears to pay a high intrinsic energetic penalty for adopting this conformation, effectively excluding Imatinib from its ATP pocket.  This explanation of the difference in binding affinity of Imatinib for Abl vs. c-Src makes the striking prediction that it would not be possible to design an inhibitor that binds to the DFG-out conformation of c-Src with high affinity.  The authors report the discovery of a series of such inhibitors.  The authors use structure-activity relationships and x-ray crystallog. to confirm the authors' findings.  These studies suggest that small mols. are capable of inducing the generally unfavorable DFG-out conformation in c-Src.  Structural comparison between c-Src in complex with these inhibitors allows the authors to speculate on the differential selectivity of Imatinib for c-Src and Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgbxnfmxtR-LVg90H21EOLACvtfcHk0ljoZDvfd1Ic0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1KmsrfP&md5=f1047f4a56359511939164a3c2604cb6</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2008.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2008.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DDar%26aufirst%3DA.%2BC.%26aulast%3DLopez%26aufirst%3DM.%2BS.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DSmall%2520molecule%2520recognition%2520of%2520c-Src%2520via%2520the%2520Imatinib-binding%2520conformation%26jtitle%3DChem.%2520Biol.%26date%3D2008%26volume%3D15%26spage%3D1015%26epage%3D1022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">DiMauro, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newcomb, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nunes, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bemis, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boucher, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchanan, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckner, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cee, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deak, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epstein, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faust, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geuns-Meyer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henkle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodous, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masse, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGowan, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgenstern, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliveira, dos Santos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powers, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlinson, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tudor, Y.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turci, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welcher, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span> </span><span class="NLM_article-title">Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: Synthesis, SAR, and in vivo anti-inflammatory activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">5671</span><span class="NLM_x">–</span> <span class="NLM_lpage">5686</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0605482" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD28XosVChsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5671-5686&author=E.+F.+DiMauroauthor=J.+Newcombauthor=J.+J.+Nunesauthor=J.+E.+Bemisauthor=C.+Boucherauthor=J.+L.+Buchananauthor=W.+H.+Bucknerauthor=V.+J.+Ceeauthor=L.+Chaiauthor=H.+L.+Deakauthor=L.+Epsteinauthor=T.+Faustauthor=P.+Gallantauthor=S.+D.+Geuns-Meyerauthor=A.+Goreauthor=Y.+Guauthor=B.+Henkleauthor=B.+L.+Hodousauthor=F.+Hsiehauthor=X.+Huangauthor=J.+L.+Kimauthor=J.+Leeauthor=M.+W.+Martinauthor=C.+E.+Masseauthor=D.+C.+McGowanauthor=D.+Metzauthor=D.+Mohnauthor=K.+A.+Morgensternauthor=A.+Oliveira%2C+dos+Santosauthor=V.+F.+Patelauthor=D.+Powersauthor=P.+E.+Roseauthor=S.+Schneiderauthor=S.+A.+Tomlinsonauthor=Y.-Y.+Tudorauthor=S.+M.+Turciauthor=A.+A.+Welcherauthor=R.+D.+Whiteauthor=H.+Zhaoauthor=L.+Zhuauthor=X.+Zhu&title=Discovery+of+aminoquinazolines+as+potent%2C+orally+bioavailable+inhibitors+of+Lck%3A+Synthesis%2C+SAR%2C+and+in+vivo+anti-inflammatory+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Aminoquinazolines as Potent, Orally Bioavailable Inhibitors of Lck: Synthesis, SAR, and in Vivo Anti-Inflammatory Activity</span></div><div class="casAuthors">DiMauro, Erin F.; Newcomb, John; Nunes, Joseph J.; Bemis, Jean E.; Boucher, Christina; Buchanan, John L.; Buckner, William H.; Cee, Victor J.; Chai, Lilly; Deak, Holly L.; Epstein, Linda F.; Faust, Ted; Gallant, Paul; Geuns-Meyer, Stephanie D.; Gore, Anu; Gu, Yan; Henkle, Brad; Hodous, Brian L.; Hsieh, Faye; Huang, Xin; Kim, Joseph L.; Lee, Josie H.; Martin, Matthew W.; Masse, Craig E.; McGowan, David C.; Metz, Daniela; Mohn, Deanna; Morgenstern, Kurt A.; Oliveira-dos-Santos, Antonio; Patel, Vinod F.; Powers, David; Rose, Paul E.; Schneider, Stephen; Tomlinson, Susan A.; Tudor, Yan-Yan; Turci, Susan M.; Welcher, Andrew A.; White, Ryan D.; Zhao, Huilin; Zhu, Li; Zhu, Xiaotian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5671-5686</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The lymphocyte-specific kinase (Lck) is a cytoplasmic tyrosine kinase of the Src family expressed in T cells and natural killer (NK) cells.  Genetic evidence in both mice and humans demonstrates that Lck kinase activity is crit. for signaling mediated by the T cell receptor (TCR), which leads to normal T cell development and activation.  Selective inhibition of Lck is expected to offer a new therapy for the treatment of T-cell-mediated autoimmune and inflammatory disease.  Screening of our kinase-preferred collection identified aminoquinazoline I as a potent, nonselective inhibitor of Lck and T cell proliferation.  In this report, we describe the synthesis and structure-activity relationships of a series of novel aminoquinazolines possessing in vitro mechanism-based potency.  Two optimized, orally bioavailable compds. exhibit antiinflammatory activity (ED50 of 22 and 11 mg/kg, resp.) in the anti-CD3-induced prodn. of interleukin-2 (IL-2) in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm7qaZo8QJ6bVg90H21EOLACvtfcHk0liAfiS-JiX_rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XosVChsLk%253D&md5=3ed1152bf34749755fdd9c2f8f25950c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm0605482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0605482%26sid%3Dliteratum%253Aachs%26aulast%3DDiMauro%26aufirst%3DE.%2BF.%26aulast%3DNewcomb%26aufirst%3DJ.%26aulast%3DNunes%26aufirst%3DJ.%2BJ.%26aulast%3DBemis%26aufirst%3DJ.%2BE.%26aulast%3DBoucher%26aufirst%3DC.%26aulast%3DBuchanan%26aufirst%3DJ.%2BL.%26aulast%3DBuckner%26aufirst%3DW.%2BH.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DChai%26aufirst%3DL.%26aulast%3DDeak%26aufirst%3DH.%2BL.%26aulast%3DEpstein%26aufirst%3DL.%26aulast%3DFaust%26aufirst%3DT.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DGeuns-Meyer%26aufirst%3DS.%2BD.%26aulast%3DGore%26aufirst%3DA.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DHenkle%26aufirst%3DB.%26aulast%3DHodous%26aufirst%3DB.%2BL.%26aulast%3DHsieh%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DM.%2BW.%26aulast%3DMasse%26aufirst%3DC.%2BE.%26aulast%3DMcGowan%26aufirst%3DD.%2BC.%26aulast%3DMetz%26aufirst%3DD.%26aulast%3DMohn%26aufirst%3DD.%26aulast%3DMorgenstern%26aufirst%3DK.%2BA.%26aulast%3DOliveira%252C%2Bdos%2BSantos%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DPowers%26aufirst%3DD.%26aulast%3DRose%26aufirst%3DP.%2BE.%26aulast%3DSchneider%26aufirst%3DS.%26aulast%3DTomlinson%26aufirst%3DS.%2BA.%26aulast%3DTudor%26aufirst%3DY.-Y.%26aulast%3DTurci%26aufirst%3DS.%2BM.%26aulast%3DWelcher%26aufirst%3DA.%2BA.%26aulast%3DWhite%26aufirst%3DR.%2BD.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520aminoquinazolines%2520as%2520potent%252C%2520orally%2520bioavailable%2520inhibitors%2520of%2520Lck%253A%2520Synthesis%252C%2520SAR%252C%2520and%2520in%2520vivo%2520anti-inflammatory%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5671%26epage%3D5686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_etal"></span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Azam%2C+M.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DAzam%26aufirst%3DM." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Wang, Y.; Huang, W.-S.; Sundaramoorthi, R.; Zhu, X.; Thomas, R. M.; Shakespeare, W. C.; Dalgarno, D. C.; Sawyer, T. K.</span><span> </span><span class="NLM_article-title">Preparation of purine heterocyclic derivatives as kinase inhibitors for therapeutic use as anticancer agents</span>. PCT Int. Appl. WO 2007021937,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=Y.+Wang&author=W.-S.+Huang&author=R.+Sundaramoorthi&author=X.+Zhu&author=R.+M.+Thomas&author=W.+C.+Shakespeare&author=D.+C.+Dalgarno&author=T.+K.+Sawyer&title=Preparation+of+purine+heterocyclic+derivatives+as+kinase+inhibitors+for+therapeutic+use+as+anticancer+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26atitle%3DPreparation%2520of%2520purine%2520heterocyclic%2520derivatives%2520as%2520kinase%2520inhibitors%2520for%2520therapeutic%2520use%2520as%2520anticancer%2520agents%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2a','cit2b'],'ref3':['cit3a','cit3b'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6a','cit6b','cit6c','cit6d','cit6e','cit6f','cit6g','cit6h'],'ref7':['cit7a','cit7b','cit7c','cit7d'],'ref8':['cit8'],'ref9':['cit9a','cit9b'],'ref10':['cit10'],'ref11':['cit11a','cit11b','cit11c','cit11d','cit11e','cit11f','cit11g'],'ref12':['cit12'],'ref13':['cit13a','cit13b'],'ref14':['cit14'],'ref15':['cit15a','cit15b'],'ref16':['cit16a','cit16b','cit16c'],'ref17':['cit17a','cit17b','cit17c'],'ref18':['cit18a','cit18b'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21a','cit21b'],'ref22':['cit22'],'ref23':['cit23a','cit23b'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32a','cit32b','cit32c','cit32d'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 35 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Guangyan Du, Suman Rao, Deepak Gurbani, Nathaniel J. Henning, Jie Jiang, Jianwei Che, Annan Yang, Scott B. Ficarro, Jarrod A. Marto, Andrew J. Aguirre, Peter K. Sorger, Kenneth D. Westover, Tinghu Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Nathanael S. Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (4)
                                     , 1624-1641. <a href="https://doi.org/10.1021/acs.jmedchem.9b01502" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01502</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01502%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Based%252BDesign%252Bof%252Ba%252BPotent%252Band%252BSelective%252BCovalent%252BInhibitor%252Bfor%252BSRC%252BKinase%252BThat%252BTargets%252Ba%252BP-Loop%252BCysteine%26aulast%3DDu%26aufirst%3DGuangyan%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D09092019%26date%3D30012020%26date%3D14012020%26volume%3D63%26issue%3D4%26spage%3D1624%26epage%3D1641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mingwei Zhou, Xuefei Tan, Yimin Hu, Hong C. Shen, <span class="NLM_string-name hlFld-ContribAuthor">Xuhong Qian</span>. </span><span class="cited-content_cbyCitation_article-title">Highly Chemo- and Regioselective Vinylation of N-Heteroarenes with Vinylsulfonium Salts. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (15)
                                     , 8627-8635. <a href="https://doi.org/10.1021/acs.joc.8b00682" title="DOI URL">https://doi.org/10.1021/acs.joc.8b00682</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b00682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b00682%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DHighly%252BChemo-%252Band%252BRegioselective%252BVinylation%252Bof%252BN-Heteroarenes%252Bwith%252BVinylsulfonium%252BSalts%26aulast%3DZhou%26aufirst%3DMingwei%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D16032018%26date%3D08062018%26date%3D25052018%26volume%3D83%26issue%3D15%26spage%3D8627%26epage%3D8635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Zhou</span>, <span class="hlFld-ContribAuthor ">Jiang  Wang</span>, <span class="hlFld-ContribAuthor ">Zhanni  Gu</span>, <span class="hlFld-ContribAuthor ">Shuni  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Zhu</span>, <span class="hlFld-ContribAuthor ">José Luis  Aceña</span>, <span class="hlFld-ContribAuthor ">Vadim A.  Soloshonok</span>, <span class="hlFld-ContribAuthor ">Kunisuke  Izawa</span>, and <span class="hlFld-ContribAuthor ">Hong  Liu</span>  . </span><span class="cited-content_cbyCitation_article-title">Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2016,</strong> <em>116 </em>
                                    (2)
                                     , 422-518. <a href="https://doi.org/10.1021/acs.chemrev.5b00392" title="DOI URL">https://doi.org/10.1021/acs.chemrev.5b00392</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.5b00392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.5b00392%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DNext%252BGeneration%252Bof%252BFluorine-Containing%252BPharmaceuticals%25252C%252BCompounds%252BCurrently%252Bin%252BPhase%252BII%2525E2%252580%252593III%252BClinical%252BTrials%252Bof%252BMajor%252BPharmaceutical%252BCompanies%25253A%252BNew%252BStructural%252BTrends%252Band%252BTherapeutic%252BAreas%26aulast%3DZhou%26aufirst%3DYu%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D06072015%26date%3D12012016%26date%3D27012016%26volume%3D116%26issue%3D2%26spage%3D422%26epage%3D518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Savade  Solanki</span>, <span class="hlFld-ContribAuthor ">Paolo  Innocenti</span>, <span class="hlFld-ContribAuthor ">Corine  Mas-Droux</span>, <span class="hlFld-ContribAuthor ">Kathy  Boxall</span>, <span class="hlFld-ContribAuthor ">Caterina  Barillari</span>, <span class="hlFld-ContribAuthor ">Rob L. M.  van Montfort</span>, <span class="hlFld-ContribAuthor ">G. Wynne  Aherne</span>, <span class="hlFld-ContribAuthor ">Richard  Bayliss</span>, and <span class="hlFld-ContribAuthor ">Swen  Hoelder</span>  . </span><span class="cited-content_cbyCitation_article-title">Benzimidazole Inhibitors Induce a DFG-Out Conformation of Never in Mitosis Gene A-Related Kinase 2 (Nek2) without Binding to the Back Pocket and Reveal a Nonlinear Structure−Activity Relationship. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2011,</strong> <em>54 </em>
                                    (6)
                                     , 1626-1639. <a href="https://doi.org/10.1021/jm1011726" title="DOI URL">https://doi.org/10.1021/jm1011726</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm1011726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm1011726%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBenzimidazole%252BInhibitors%252BInduce%252Ba%252BDFG-Out%252BConformation%252Bof%252BNever%252Bin%252BMitosis%252BGene%252BA-Related%252BKinase%252B2%252B%252528Nek2%252529%252Bwithout%252BBinding%252Bto%252Bthe%252BBack%252BPocket%252Band%252BReveal%252Ba%252BNonlinear%252BStructure%2525E2%252588%252592Activity%252BRelationship%26aulast%3DSolanki%26aufirst%3DSavade%26date%3D2011%26date%3D2011%26date%3D2010%26date%3D09092010%26date%3D02032011%26date%3D24032011%26volume%3D54%26issue%3D6%26spage%3D1626%26epage%3D1639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hwan Geun  Choi</span>, <span class="hlFld-ContribAuthor ">Pingda  Ren</span>, <span class="hlFld-ContribAuthor ">Francisco  Adrian</span>, <span class="hlFld-ContribAuthor ">Fangxian  Sun</span>, <span class="hlFld-ContribAuthor ">Hyun Soo  Lee</span>, <span class="hlFld-ContribAuthor ">Xia  Wang</span>, <span class="hlFld-ContribAuthor ">Qiang  Ding</span>, <span class="hlFld-ContribAuthor ">Guobao  Zhang</span>, <span class="hlFld-ContribAuthor ">Yongping  Xie</span>, <span class="hlFld-ContribAuthor ">Jianming  Zhang</span>, <span class="hlFld-ContribAuthor ">Yi  Liu</span>, <span class="hlFld-ContribAuthor ">Tove  Tuntland</span>, <span class="hlFld-ContribAuthor ">Markus  Warmuth</span>, <span class="hlFld-ContribAuthor ">Paul W.  Manley</span>, <span class="hlFld-ContribAuthor ">Jürgen  Mestan</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span> and <span class="hlFld-ContribAuthor ">Taebo  Sim</span>  . </span><span class="cited-content_cbyCitation_article-title">A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of Bcr-Abl. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2010,</strong> <em>53 </em>
                                    (15)
                                     , 5439-5448. <a href="https://doi.org/10.1021/jm901808w" title="DOI URL">https://doi.org/10.1021/jm901808w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm901808w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm901808w%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BType-II%252BKinase%252BInhibitor%252BCapable%252Bof%252BInhibiting%252Bthe%252BT315I%252B%2525E2%252580%25259CGatekeeper%2525E2%252580%25259D%252BMutant%252Bof%252BBcr-Abl%26aulast%3DChoi%26aufirst%3DHwan%2BGeun%26date%3D2010%26date%3D2010%26date%3D2009%26date%3D08122009%26date%3D06072010%26date%3D12082010%26volume%3D53%26issue%3D15%26spage%3D5439%26epage%3D5448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei-Sheng  Huang</span>, <span class="hlFld-ContribAuthor ">Chester A.  Metcalf</span>, <span class="hlFld-ContribAuthor ">Raji  Sundaramoorthi</span>, <span class="hlFld-ContribAuthor ">Yihan  Wang</span>, <span class="hlFld-ContribAuthor ">Dong  Zou</span>, <span class="hlFld-ContribAuthor ">R. Mathew  Thomas</span>, <span class="hlFld-ContribAuthor ">Xiaotian  Zhu</span>, <span class="hlFld-ContribAuthor ">Lisi  Cai</span>, <span class="hlFld-ContribAuthor ">David  Wen</span>, <span class="hlFld-ContribAuthor ">Shuangying  Liu</span>, <span class="hlFld-ContribAuthor ">Jan  Romero</span>, <span class="hlFld-ContribAuthor ">Jiwei  Qi</span>, <span class="hlFld-ContribAuthor ">Ingrid  Chen</span>, <span class="hlFld-ContribAuthor ">Geetha  Banda</span>, <span class="hlFld-ContribAuthor ">Scott P.  Lentini</span>, <span class="hlFld-ContribAuthor ">Sasmita  Das</span>, <span class="hlFld-ContribAuthor ">Qihong  Xu</span>, <span class="hlFld-ContribAuthor ">Jeff  Keats</span>, <span class="hlFld-ContribAuthor ">Frank  Wang</span>, <span class="hlFld-ContribAuthor ">Scott  Wardwell</span>, <span class="hlFld-ContribAuthor ">Yaoyu  Ning</span>, <span class="hlFld-ContribAuthor ">Joseph T.  Snodgrass</span>, <span class="hlFld-ContribAuthor ">Marc I.  Broudy</span>, <span class="hlFld-ContribAuthor ">Karin  Russian</span>, <span class="hlFld-ContribAuthor ">Tianjun  Zhou</span>, <span class="hlFld-ContribAuthor ">Lois  Commodore</span>, <span class="hlFld-ContribAuthor ">Narayana I.  Narasimhan</span>, <span class="hlFld-ContribAuthor ">Qurish K.  Mohemmad</span>, <span class="hlFld-ContribAuthor ">John  Iuliucci</span>, <span class="hlFld-ContribAuthor ">Victor M.  Rivera</span>, <span class="hlFld-ContribAuthor ">David C.  Dalgarno</span>, <span class="hlFld-ContribAuthor ">Tomi K.  Sawyer</span>, <span class="hlFld-ContribAuthor ">Tim  Clackson</span> and <span class="hlFld-ContribAuthor ">William C.  Shakespeare</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2010,</strong> <em>53 </em>
                                    (12)
                                     , 4701-4719. <a href="https://doi.org/10.1021/jm100395q" title="DOI URL">https://doi.org/10.1021/jm100395q</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm100395q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm100395q%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B3-%25255B2-%252528Imidazo%25255B1%25252C2-b%25255Dpyridazin-3-yl%252529ethynyl%25255D-4-methyl-N-%25257B4-%25255B%2525284-methylpiperazin-1-yl%252529methyl%25255D-3-%252528trifluoromethyl%252529phenyl%25257Dbenzamide%252B%252528AP24534%252529%25252C%252Ba%252BPotent%25252C%252BOrally%252BActive%252BPan-Inhibitor%252Bof%252BBreakpoint%252BCluster%252BRegion-Abelson%252B%252528BCR-ABL%252529%252BKinase%252BIncluding%252Bthe%252BT315I%252BGatekeeper%252BMutant%26aulast%3DHuang%26aufirst%3DWei-Sheng%26date%3D2010%26date%3D2010%26date%3D2010%26date%3D29032010%26date%3D01062010%26date%3D24062010%26volume%3D53%26issue%3D12%26spage%3D4701%26epage%3D4719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard  Morphy</span>. </span><span class="cited-content_cbyCitation_article-title">Selectively Nonselective Kinase Inhibition: Striking the Right Balance. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2010,</strong> <em>53 </em>
                                    (4)
                                     , 1413-1437. <a href="https://doi.org/10.1021/jm901132v" title="DOI URL">https://doi.org/10.1021/jm901132v</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm901132v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm901132v%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSelectively%252BNonselective%252BKinase%252BInhibition%25253A%252BStriking%252Bthe%252BRight%252BBalance%26aulast%3DMorphy%26aufirst%3DRichard%26date%3D2010%26date%3D2009%26date%3D2009%26date%3D30072009%26date%3D27102009%26date%3D25022010%26volume%3D53%26issue%3D4%26spage%3D1413%26epage%3D1437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cheolhee  Kim</span>, <span class="hlFld-ContribAuthor ">Eunae  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Rational Drug Design Approach of Receptor Tyrosine Kinase Type III Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2020,</strong> <em>26 </em>
                                    (42)
                                     , 7623-7640. <a href="https://doi.org/10.2174/0929867325666180622143548" title="DOI URL">https://doi.org/10.2174/0929867325666180622143548</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867325666180622143548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867325666180622143548%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DRational%252BDrug%252BDesign%252BApproach%252Bof%252BReceptor%252BTyrosine%252BKinase%252BType%252BIII%252BInhibitors%26aulast%3DKim%26aufirst%3DCheolhee%26date%3D2020%26volume%3D26%26issue%3D42%26spage%3D7623%26epage%3D7640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefano  Agnello</span>, <span class="hlFld-ContribAuthor ">Michael  Brand</span>, <span class="hlFld-ContribAuthor ">Mathieu F.  Chellat</span>, <span class="hlFld-ContribAuthor ">Silvia  Gazzola</span>, <span class="hlFld-ContribAuthor ">Rainer  Riedl</span>. </span><span class="cited-content_cbyCitation_article-title">Eine strukturelle Evaluierung medizinalchemischer Strategien gegen Wirkstoffresistenzen. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2019,</strong> <em>131 </em>
                                    (11)
                                     , 3336-3383. <a href="https://doi.org/10.1002/ange.201802416" title="DOI URL">https://doi.org/10.1002/ange.201802416</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201802416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201802416%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DEine%252Bstrukturelle%252BEvaluierung%252Bmedizinalchemischer%252BStrategien%252Bgegen%252BWirkstoffresistenzen%26aulast%3DAgnello%26aufirst%3DStefano%26date%3D2019%26date%3D2019%26volume%3D131%26issue%3D11%26spage%3D3336%26epage%3D3383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefano  Agnello</span>, <span class="hlFld-ContribAuthor ">Michael  Brand</span>, <span class="hlFld-ContribAuthor ">Mathieu F.  Chellat</span>, <span class="hlFld-ContribAuthor ">Silvia  Gazzola</span>, <span class="hlFld-ContribAuthor ">Rainer  Riedl</span>. </span><span class="cited-content_cbyCitation_article-title">A Structural View on Medicinal Chemistry Strategies against Drug Resistance. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2019,</strong> <em>58 </em>
                                    (11)
                                     , 3300-3345. <a href="https://doi.org/10.1002/anie.201802416" title="DOI URL">https://doi.org/10.1002/anie.201802416</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201802416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201802416%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DA%252BStructural%252BView%252Bon%252BMedicinal%252BChemistry%252BStrategies%252Bagainst%252BDrug%252BResistance%26aulast%3DAgnello%26aufirst%3DStefano%26date%3D2019%26date%3D2019%26volume%3D58%26issue%3D11%26spage%3D3300%26epage%3D3345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alejandra M.  Petrilli</span>, <span class="hlFld-ContribAuthor ">Jeanine  Garcia</span>, <span class="hlFld-ContribAuthor ">Marga  Bott</span>, <span class="hlFld-ContribAuthor ">Stephani Klingeman  Plati</span>, <span class="hlFld-ContribAuthor ">Christine T.  Dinh</span>, <span class="hlFld-ContribAuthor ">Olena R.  Bracho</span>, <span class="hlFld-ContribAuthor ">Denise  Yan</span>, <span class="hlFld-ContribAuthor ">Bing  Zou</span>, <span class="hlFld-ContribAuthor ">Rahul  Mittal</span>, <span class="hlFld-ContribAuthor ">Fred F.  Telischi</span>, <span class="hlFld-ContribAuthor ">Xue-Zhong  Liu</span>, <span class="hlFld-ContribAuthor ">Long-Sheng  Chang</span>, <span class="hlFld-ContribAuthor ">D. Bradley  Welling</span>, <span class="hlFld-ContribAuthor ">Alicja J.  Copik</span>, <span class="hlFld-ContribAuthor ">Cristina  Fernández-Valle</span>. </span><span class="cited-content_cbyCitation_article-title">Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2017,</strong> <em>8 </em>
                                    (19)
                                     , 31666-31681. <a href="https://doi.org/10.18632/oncotarget.15912" title="DOI URL">https://doi.org/10.18632/oncotarget.15912</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.15912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.15912%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DPonatinib%252Bpromotes%252Ba%252BG1%252Bcell-cycle%252Barrest%252Bof%252Bmerlin%25252FNF2-deficient%252Bhuman%252Bschwann%252Bcells%26aulast%3DPetrilli%26aufirst%3DAlejandra%2BM.%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D19%26spage%3D31666%26epage%3D31681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul W.  Manley</span>, <span class="hlFld-ContribAuthor ">Nikolaus J.  Stiefl</span>. </span><span class="cited-content_cbyCitation_article-title">Progress in the Discovery of BCR-ABL Kinase Inhibitors for the Treatment of Leukemia. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 1-37. <a href="https://doi.org/10.1007/7355_2017_5" title="DOI URL">https://doi.org/10.1007/7355_2017_5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2017_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2017_5%26sid%3Dliteratum%253Aachs%26atitle%3DProgress%252Bin%252Bthe%252BDiscovery%252Bof%252BBCR-ABL%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BLeukemia%26aulast%3DManley%26aufirst%3DPaul%2BW.%26date%3D2017%26spage%3D1%26epage%3D37%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DCancer%252BII%26aulast%3DWaring%26aufirst%3DMichael%2BJ.%26date%3D2018%26volume%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giuseppe  Tridente</span>. </span><span class="cited-content_cbyCitation_article-title">Ponatinib. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 481-504. <a href="https://doi.org/10.1016/B978-0-12-809400-6.00022-6" title="DOI URL">https://doi.org/10.1016/B978-0-12-809400-6.00022-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-809400-6.00022-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-809400-6.00022-6%26sid%3Dliteratum%253Aachs%26atitle%3DPonatinib%26aulast%3DTridente%26aufirst%3DGiuseppe%26date%3D2017%26spage%3D481%26epage%3D504%26pub%3DElsevier%26atitle%3DAdverse%252BEvents%252Band%252BOncotargeted%252BKinase%252BInhibitors%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sahil  Sharma</span>, <span class="hlFld-ContribAuthor ">Jagjeet  Singh</span>, <span class="hlFld-ContribAuthor ">Ritu  Ojha</span>, <span class="hlFld-ContribAuthor ">Harbinder  Singh</span>, <span class="hlFld-ContribAuthor ">Manpreet  Kaur</span>, <span class="hlFld-ContribAuthor ">P.M.S.  Bedi</span>, <span class="hlFld-ContribAuthor ">Kunal  Nepali</span>. </span><span class="cited-content_cbyCitation_article-title">Design strategies, structure activity relationship and mechanistic insights for purines as kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>112 </em>, 298-346. <a href="https://doi.org/10.1016/j.ejmech.2016.02.018" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.02.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.02.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.02.018%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Bstrategies%25252C%252Bstructure%252Bactivity%252Brelationship%252Band%252Bmechanistic%252Binsights%252Bfor%252Bpurines%252Bas%252Bkinase%252Binhibitors%26aulast%3DSharma%26aufirst%3DSahil%26date%3D2016%26volume%3D112%26spage%3D298%26epage%3D346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel J.  Burdick</span>, <span class="hlFld-ContribAuthor ">Shumei  Wang</span>, <span class="hlFld-ContribAuthor ">Christopher  Heise</span>, <span class="hlFld-ContribAuthor ">Borlan  Pan</span>, <span class="hlFld-ContribAuthor ">Jake  Drummond</span>, <span class="hlFld-ContribAuthor ">JianPing  Yin</span>, <span class="hlFld-ContribAuthor ">Lauren  Goeser</span>, <span class="hlFld-ContribAuthor ">Steven  Magnuson</span>, <span class="hlFld-ContribAuthor ">Jeff  Blaney</span>, <span class="hlFld-ContribAuthor ">John  Moffat</span>, <span class="hlFld-ContribAuthor ">Weiru  Wang</span>, <span class="hlFld-ContribAuthor ">Huifen  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Fragment-based discovery of potent ERK2 pyrrolopyrazine inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (21)
                                     , 4728-4732. <a href="https://doi.org/10.1016/j.bmcl.2015.08.048" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.08.048</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.08.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.08.048%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DFragment-based%252Bdiscovery%252Bof%252Bpotent%252BERK2%252Bpyrrolopyrazine%252Binhibitors%26aulast%3DBurdick%26aufirst%3DDaniel%2BJ.%26date%3D2015%26volume%3D25%26issue%3D21%26spage%3D4728%26epage%3D4732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nasim  Shams</span>, <span class="hlFld-ContribAuthor ">Mohammad Hossein  Mosslemin</span>, <span class="hlFld-ContribAuthor ">Hossein  Anaraki-Ardakani</span>. </span><span class="cited-content_cbyCitation_article-title">An Efficient Synthesis of Bis-Purine Derivatives by a PPh
              3
              -catalysed Double Addition of Dialkylated Xanthine Derivatives to Alkyl Propiolates. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Research</span><span> <strong>2015,</strong> <em>39 </em>
                                    (9)
                                     , 499-501. <a href="https://doi.org/10.3184/174751915X14396278385301" title="DOI URL">https://doi.org/10.3184/174751915X14396278385301</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3184/174751915X14396278385301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3184%2F174751915X14396278385301%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Research%26atitle%3DAn%252BEfficient%252BSynthesis%252Bof%252BBis-Purine%252BDerivatives%252Bby%252Ba%252BPPh%252B3%252B-catalysed%252BDouble%252BAddition%252Bof%252BDialkylated%252BXanthine%252BDerivatives%252Bto%252BAlkyl%252BPropiolates%26aulast%3DShams%26aufirst%3DNasim%26date%3D2015%26date%3D2015%26volume%3D39%26issue%3D9%26spage%3D499%26epage%3D501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shaojie  Ma</span>, <span class="hlFld-ContribAuthor ">Guohua  Zeng</span>, <span class="hlFld-ContribAuthor ">Danqing  Fang</span>, <span class="hlFld-ContribAuthor ">Juping  Wang</span>, <span class="hlFld-ContribAuthor ">Wenjuan  Wu</span>, <span class="hlFld-ContribAuthor ">Wenguo  Xie</span>, <span class="hlFld-ContribAuthor ">Shepei  Tan</span>, <span class="hlFld-ContribAuthor ">Kangcheng  Zheng</span>. </span><span class="cited-content_cbyCitation_article-title">Studies of N
              9
              -arenthenyl purines as novel DFG-in and DFG-out dual Src/Abl inhibitors using 3D-QSAR, docking and molecular dynamics simulations. </span><span class="cited-content_cbyCitation_journal-name">Molecular BioSystems</span><span> <strong>2015,</strong> <em>11 </em>
                                    (2)
                                     , 394-406. <a href="https://doi.org/10.1039/C4MB00350K" title="DOI URL">https://doi.org/10.1039/C4MB00350K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C4MB00350K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC4MB00350K%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520BioSystems%26atitle%3DStudies%252Bof%252BN%252B9%252B-arenthenyl%252Bpurines%252Bas%252Bnovel%252BDFG-in%252Band%252BDFG-out%252Bdual%252BSrc%25252FAbl%252Binhibitors%252Busing%252B3D-QSAR%25252C%252Bdocking%252Band%252Bmolecular%252Bdynamics%252Bsimulations%26aulast%3DMa%26aufirst%3DShaojie%26date%3D2015%26date%3D2015%26volume%3D11%26issue%3D2%26spage%3D394%26epage%3D406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard B.  Silverman</span>, <span class="hlFld-ContribAuthor ">Mark W.  Holladay</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Resistance and Drug Synergism. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 333-356. <a href="https://doi.org/10.1016/B978-0-12-382030-3.00007-6" title="DOI URL">https://doi.org/10.1016/B978-0-12-382030-3.00007-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-382030-3.00007-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-382030-3.00007-6%26sid%3Dliteratum%253Aachs%26atitle%3DDrug%252BResistance%252Band%252BDrug%252BSynergism%26aulast%3DSilverman%26aufirst%3DRichard%2BB.%26date%3D2014%26spage%3D333%26epage%3D356%26pub%3DElsevier%26atitle%3DThe%252BOrganic%252BChemistry%252Bof%252BDrug%252BDesign%252Band%252BDrug%252BAction%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Atul  Manvar</span>, <span class="hlFld-ContribAuthor ">Anamik  Shah</span>. </span><span class="cited-content_cbyCitation_article-title">Microwave-assisted chemistry of purines and xanthines. An overview. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2013,</strong> <em>69 </em>
                                    (38)
                                     , 8105-8127. <a href="https://doi.org/10.1016/j.tet.2013.06.034" title="DOI URL">https://doi.org/10.1016/j.tet.2013.06.034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2013.06.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2013.06.034%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DMicrowave-assisted%252Bchemistry%252Bof%252Bpurines%252Band%252Bxanthines.%252BAn%2525C2%2525A0overview%26aulast%3DManvar%26aufirst%3DAtul%26date%3D2013%26volume%3D69%26issue%3D38%26spage%3D8105%26epage%3D8127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jindrich  Kania</span>, <span class="hlFld-ContribAuthor ">Lise-Lotte  Gundersen</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of
              N
              -Alkenylpurines by Rearrangements of the Corresponding
              N
              -Allyl Isomers: Scopes and Limitations. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2013,</strong> <em>2013 </em>
                                    (10)
                                     , 2008-2019. <a href="https://doi.org/10.1002/ejoc.201201455" title="DOI URL">https://doi.org/10.1002/ejoc.201201455</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201201455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201201455%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252BN%252B-Alkenylpurines%252Bby%252BRearrangements%252Bof%252Bthe%252BCorresponding%252BN%252B-Allyl%252BIsomers%25253A%252BScopes%252Band%252BLimitations%26aulast%3DKania%26aufirst%3DJindrich%26date%3D2013%26date%3D2013%26volume%3D2013%26issue%3D10%26spage%3D2008%26epage%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongtao  Zhao</span>, <span class="hlFld-ContribAuthor ">Danzhi  Huang</span>, <span class="hlFld-ContribAuthor ">Amedeo  Caflisch</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Tyrosine Kinase Inhibitors by Docking into an Inactive Kinase Conformation Generated by Molecular Dynamics. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2012,</strong> <em>7 </em>
                                    (11)
                                     , 1983-1990. <a href="https://doi.org/10.1002/cmdc.201200331" title="DOI URL">https://doi.org/10.1002/cmdc.201200331</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201200331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201200331%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DDiscovery%252Bof%252BTyrosine%252BKinase%252BInhibitors%252Bby%252BDocking%252Binto%252Ban%252BInactive%252BKinase%252BConformation%252BGenerated%252Bby%252BMolecular%252BDynamics%26aulast%3DZhao%26aufirst%3DHongtao%26date%3D2012%26date%3D2012%26volume%3D7%26issue%3D11%26spage%3D1983%26epage%3D1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Frank  Lovering</span>, <span class="hlFld-ContribAuthor ">Joseph  McDonald</span>, <span class="hlFld-ContribAuthor ">Gavin A.  Whitlock</span>, <span class="hlFld-ContribAuthor ">Paul A.  Glossop</span>, <span class="hlFld-ContribAuthor ">Chris  Phillips</span>, <span class="hlFld-ContribAuthor ">Andrew  Bent</span>, <span class="hlFld-ContribAuthor ">Yogesh  Sabnis</span>, <span class="hlFld-ContribAuthor ">Mark  Ryan</span>, <span class="hlFld-ContribAuthor ">Lori  Fitz</span>, <span class="hlFld-ContribAuthor ">Julie  Lee</span>, <span class="hlFld-ContribAuthor ">Jeanne S.  Chang</span>, <span class="hlFld-ContribAuthor ">Seungil  Han</span>, <span class="hlFld-ContribAuthor ">Ravi  Kurumbail</span>, <span class="hlFld-ContribAuthor ">Atli  Thorarensen</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Type-II Inhibitors Using Kinase Structures. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2012,</strong> <em>80 </em>
                                    (5)
                                     , 657-664. <a href="https://doi.org/10.1111/j.1747-0285.2012.01443.x" title="DOI URL">https://doi.org/10.1111/j.1747-0285.2012.01443.x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/j.1747-0285.2012.01443.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fj.1747-0285.2012.01443.x%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DIdentification%252Bof%252BType-II%252BInhibitors%252BUsing%252BKinase%252BStructures%26aulast%3DLovering%26aufirst%3DFrank%26date%3D2012%26date%3D2012%26volume%3D80%26issue%3D5%26spage%3D657%26epage%3D664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francesca  Musumeci</span>, <span class="hlFld-ContribAuthor ">Silvia  Schenone</span>, <span class="hlFld-ContribAuthor ">Chiara  Brullo</span>, <span class="hlFld-ContribAuthor ">Maurizio  Botta</span>. </span><span class="cited-content_cbyCitation_article-title">An update on dual Src/Abl inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2012,</strong> <em>4 </em>
                                    (6)
                                     , 799-822. <a href="https://doi.org/10.4155/fmc.12.29" title="DOI URL">https://doi.org/10.4155/fmc.12.29</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc.12.29&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc.12.29%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DAn%252Bupdate%252Bon%252Bdual%252BSrc%25252FAbl%252Binhibitors%26aulast%3DMusumeci%26aufirst%3DFrancesca%26date%3D2012%26volume%3D4%26issue%3D6%26spage%3D799%26epage%3D822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuang  Lü</span>, <span class="hlFld-ContribAuthor ">Qun  Luo</span>, <span class="hlFld-ContribAuthor ">Xiang  Hao</span>, <span class="hlFld-ContribAuthor ">Xianchan  Li</span>, <span class="hlFld-ContribAuthor ">Liyun  Ji</span>, <span class="hlFld-ContribAuthor ">Wei  Zheng</span>, <span class="hlFld-ContribAuthor ">Fuyi  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and docking study of 2-phenylaminopyrimidine Abl tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2011,</strong> <em>21 </em>
                                    (23)
                                     , 6964-6968. <a href="https://doi.org/10.1016/j.bmcl.2011.09.127" title="DOI URL">https://doi.org/10.1016/j.bmcl.2011.09.127</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2011.09.127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2011.09.127%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bdocking%252Bstudy%252Bof%252B2-phenylaminopyrimidine%252BAbl%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DL%25C3%25BC%26aufirst%3DShuang%26date%3D2011%26volume%3D21%26issue%3D23%26spage%3D6964%26epage%3D6968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mathew  Thomas</span>, <span class="hlFld-ContribAuthor ">Wei-Sheng  Huang</span>, <span class="hlFld-ContribAuthor ">David  Wen</span>, <span class="hlFld-ContribAuthor ">Xiaotian  Zhu</span>, <span class="hlFld-ContribAuthor ">Yihan  Wang</span>, <span class="hlFld-ContribAuthor ">Chester A.  Metcalf</span>, <span class="hlFld-ContribAuthor ">Shuangying  Liu</span>, <span class="hlFld-ContribAuthor ">Ingrid  Chen</span>, <span class="hlFld-ContribAuthor ">Jan  Romero</span>, <span class="hlFld-ContribAuthor ">Dong  Zou</span>, <span class="hlFld-ContribAuthor ">Raji  Sundaramoorthi</span>, <span class="hlFld-ContribAuthor ">Feng  Li</span>, <span class="hlFld-ContribAuthor ">Jiwei  Qi</span>, <span class="hlFld-ContribAuthor ">Lisi  Cai</span>, <span class="hlFld-ContribAuthor ">Tianjun  Zhou</span>, <span class="hlFld-ContribAuthor ">Lois  Commodore</span>, <span class="hlFld-ContribAuthor ">Qihong  Xu</span>, <span class="hlFld-ContribAuthor ">Jeff  Keats</span>, <span class="hlFld-ContribAuthor ">Frank  Wang</span>, <span class="hlFld-ContribAuthor ">Scott  Wardwell</span>, <span class="hlFld-ContribAuthor ">Yaoyu  Ning</span>, <span class="hlFld-ContribAuthor ">Joseph T.  Snodgrass</span>, <span class="hlFld-ContribAuthor ">Marc I.  Broudy</span>, <span class="hlFld-ContribAuthor ">Karin  Russian</span>, <span class="hlFld-ContribAuthor ">John  Iuliucci</span>, <span class="hlFld-ContribAuthor ">Victor M.  Rivera</span>, <span class="hlFld-ContribAuthor ">Tomi K.  Sawyer</span>, <span class="hlFld-ContribAuthor ">David C.  Dalgarno</span>, <span class="hlFld-ContribAuthor ">Tim  Clackson</span>, <span class="hlFld-ContribAuthor ">William C.  Shakespeare</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR–ABL including the T315I gatekeeper mutant. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2011,</strong> <em>21 </em>
                                    (12)
                                     , 3743-3748. <a href="https://doi.org/10.1016/j.bmcl.2011.04.060" title="DOI URL">https://doi.org/10.1016/j.bmcl.2011.04.060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2011.04.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2011.04.060%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252B5-%252528arenethynyl%252529%252Bhetero-monocyclic%252Bderivatives%252Bas%252Bpotent%252Binhibitors%252Bof%252BBCR%2525E2%252580%252593ABL%252Bincluding%252Bthe%252BT315I%252Bgatekeeper%252Bmutant%26aulast%3DThomas%26aufirst%3DMathew%26date%3D2011%26volume%3D21%26issue%3D12%26spage%3D3743%26epage%3D3748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roxana E.  Iacob</span>, <span class="hlFld-ContribAuthor ">Jianming  Zhang</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>, <span class="hlFld-ContribAuthor ">John R.  Engen</span>, . </span><span class="cited-content_cbyCitation_article-title">Allosteric Interactions between the Myristate- and ATP-Site of the Abl Kinase. </span><span class="cited-content_cbyCitation_journal-name">PLoS ONE</span><span> <strong>2011,</strong> <em>6 </em>
                                    (1)
                                     , e15929. <a href="https://doi.org/10.1371/journal.pone.0015929" title="DOI URL">https://doi.org/10.1371/journal.pone.0015929</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0015929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0015929%26sid%3Dliteratum%253Aachs%26jtitle%3DPLoS%2520ONE%26atitle%3DAllosteric%252BInteractions%252Bbetween%252Bthe%252BMyristate-%252Band%252BATP-Site%252Bof%252Bthe%252BAbl%252BKinase%26aulast%3DIacob%26aufirst%3DRoxana%2BE.%26date%3D2011%26date%3D2011%26volume%3D6%26issue%3D1%26spage%3De15929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alfonso  Quintás-Cardama</span>, <span class="hlFld-ContribAuthor ">Hagop  Kantarjian</span>, <span class="hlFld-ContribAuthor ">Jorge  Cortes</span>. </span><span class="cited-content_cbyCitation_article-title">Third-Generation Tyrosine Kinase Inhibitors and Beyond. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Hematology</span><span> <strong>2010,</strong> <em>47 </em>
                                    (4)
                                     , 371-380. <a href="https://doi.org/10.1053/j.seminhematol.2010.06.004" title="DOI URL">https://doi.org/10.1053/j.seminhematol.2010.06.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1053/j.seminhematol.2010.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1053%2Fj.seminhematol.2010.06.004%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Hematology%26atitle%3DThird-Generation%252BTyrosine%252BKinase%252BInhibitors%252Band%252BBeyond%26aulast%3DQuint%25C3%25A1s-Cardama%26aufirst%3DAlfonso%26date%3D2010%26volume%3D47%26issue%3D4%26spage%3D371%26epage%3D380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silvia  Schenone</span>, <span class="hlFld-ContribAuthor ">Chiara  Brullo</span>, <span class="hlFld-ContribAuthor ">Francesca  Musumeci</span>, <span class="hlFld-ContribAuthor ">Maurizio  Botta</span>. </span><span class="cited-content_cbyCitation_article-title">Novel dual Src/Abl inhibitors for hematologic and solid malignancies. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2010,</strong> <em>19 </em>
                                    (8)
                                     , 931-945. <a href="https://doi.org/10.1517/13543784.2010.499898" title="DOI URL">https://doi.org/10.1517/13543784.2010.499898</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543784.2010.499898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543784.2010.499898%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DNovel%252Bdual%252BSrc%25252FAbl%252Binhibitors%252Bfor%252Bhematologic%252Band%252Bsolid%252Bmalignancies%26aulast%3DSchenone%26aufirst%3DSilvia%26date%3D2010%26date%3D2010%26volume%3D19%26issue%3D8%26spage%3D931%26epage%3D945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">He  Huang</span>, <span class="hlFld-ContribAuthor ">Jingui  Ma</span>, <span class="hlFld-ContribAuthor ">Jianmei  Shi</span>, <span class="hlFld-ContribAuthor ">Linghua  Meng</span>, <span class="hlFld-ContribAuthor ">Hualiang  Jiang</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2010,</strong> <em>18 </em>
                                    (13)
                                     , 4615-4624. <a href="https://doi.org/10.1016/j.bmc.2010.05.032" title="DOI URL">https://doi.org/10.1016/j.bmc.2010.05.032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2010.05.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2010.05.032%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bpurine%252Bderivatives%252Bwith%252Bpotent%252Band%252Bselective%252Binhibitory%252Bactivity%252Bagainst%252Bc-Src%252Btyrosine%252Bkinase%26aulast%3DHuang%26aufirst%3DHe%26date%3D2010%26volume%3D18%26issue%3D13%26spage%3D4615%26epage%3D4624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xianming  Deng</span>, <span class="hlFld-ContribAuthor ">Sang Min  Lim</span>, <span class="hlFld-ContribAuthor ">Jianming  Zhang</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Broad spectrum alkynyl inhibitors of T315I Bcr-Abl. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2010,</strong> <em>20 </em>
                                    (14)
                                     , 4196-4200. <a href="https://doi.org/10.1016/j.bmcl.2010.05.043" title="DOI URL">https://doi.org/10.1016/j.bmcl.2010.05.043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2010.05.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2010.05.043%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DBroad%252Bspectrum%252Balkynyl%252Binhibitors%252Bof%252BT315I%252BBcr-Abl%26aulast%3DDeng%26aufirst%3DXianming%26date%3D2010%26volume%3D20%26issue%3D14%26spage%3D4196%26epage%3D4200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ellen  Weisberg</span>, <span class="hlFld-ContribAuthor ">Hwan Geun  Choi</span>, <span class="hlFld-ContribAuthor ">Arghya  Ray</span>, <span class="hlFld-ContribAuthor ">Rosemary  Barrett</span>, <span class="hlFld-ContribAuthor ">Jianming  Zhang</span>, <span class="hlFld-ContribAuthor ">Taebo  Sim</span>, <span class="hlFld-ContribAuthor ">Wenjun  Zhou</span>, <span class="hlFld-ContribAuthor ">Markus  Seeliger</span>, <span class="hlFld-ContribAuthor ">Michael  Cameron</span>, <span class="hlFld-ContribAuthor ">Mohammed  Azam</span>, <span class="hlFld-ContribAuthor ">Jonathan A.  Fletcher</span>, <span class="hlFld-ContribAuthor ">Maria  Debiec-Rychter</span>, <span class="hlFld-ContribAuthor ">Mark  Mayeda</span>, <span class="hlFld-ContribAuthor ">Daisy  Moreno</span>, <span class="hlFld-ContribAuthor ">Andrew L.  Kung</span>, <span class="hlFld-ContribAuthor ">Pasi Antero  Janne</span>, <span class="hlFld-ContribAuthor ">Roya  Khosravi-Far</span>, <span class="hlFld-ContribAuthor ">Junia V.  Melo</span>, <span class="hlFld-ContribAuthor ">Paul W.  Manley</span>, <span class="hlFld-ContribAuthor ">Sophia  Adamia</span>, <span class="hlFld-ContribAuthor ">Catherine  Wu</span>, <span class="hlFld-ContribAuthor ">Nathanael  Gray</span>, <span class="hlFld-ContribAuthor ">James D.  Griffin</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. </span><span class="cited-content_cbyCitation_journal-name">Blood</span><span> <strong>2010,</strong> <em>115 </em>
                                    (21)
                                     , 4206-4216. <a href="https://doi.org/10.1182/blood-2009-11-251751" title="DOI URL">https://doi.org/10.1182/blood-2009-11-251751</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1182/blood-2009-11-251751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1182%2Fblood-2009-11-251751%26sid%3Dliteratum%253Aachs%26jtitle%3DBlood%26atitle%3DDiscovery%252Bof%252Ba%252Bsmall-molecule%252Btype%252BII%252Binhibitor%252Bof%252Bwild-type%252Band%252Bgatekeeper%252Bmutants%252Bof%252BBCR-ABL%25252C%252BPDGFR%2525CE%2525B1%25252C%252BKit%25252C%252Band%252BSrc%252Bkinases%25253A%252Bnovel%252Btype%252BII%252Binhibitor%252Bof%252Bgatekeeper%252Bmutants%26aulast%3DWeisberg%26aufirst%3DEllen%26date%3D2010%26volume%3D115%26issue%3D21%26spage%3D4206%26epage%3D4216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pratistha  Ranjitkar</span>, <span class="hlFld-ContribAuthor ">Amanda M.  Brock</span>, <span class="hlFld-ContribAuthor ">Dustin J.  Maly</span>. </span><span class="cited-content_cbyCitation_article-title">Affinity Reagents that Target a Specific Inactive Form of Protein Kinases. </span><span class="cited-content_cbyCitation_journal-name">Chemistry & Biology</span><span> <strong>2010,</strong> <em>17 </em>
                                    (2)
                                     , 195-206. <a href="https://doi.org/10.1016/j.chembiol.2010.01.008" title="DOI URL">https://doi.org/10.1016/j.chembiol.2010.01.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2010.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2010.01.008%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%2526%2520Biology%26atitle%3DAffinity%252BReagents%252Bthat%252BTarget%252Ba%252BSpecific%252BInactive%252BForm%252Bof%252BProtein%252BKinases%26aulast%3DRanjitkar%26aufirst%3DPratistha%26date%3D2010%26volume%3D17%26issue%3D2%26spage%3D195%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohammad  Azam</span>, <span class="hlFld-ContribAuthor ">John T.  Powers</span>, <span class="hlFld-ContribAuthor ">William  Einhorn</span>, <span class="hlFld-ContribAuthor ">Wei-Sheng  Huang</span>, <span class="hlFld-ContribAuthor ">William C.  Shakespeare</span>, <span class="hlFld-ContribAuthor ">Xiaotian  Zhu</span>, <span class="hlFld-ContribAuthor ">David  Dalgarno</span>, <span class="hlFld-ContribAuthor ">Tim  Clackson</span>, <span class="hlFld-ContribAuthor ">Tomi K.  Sawyer</span>, <span class="hlFld-ContribAuthor ">George Q.  Daley</span>. </span><span class="cited-content_cbyCitation_article-title">AP24163 Inhibits the Gatekeeper Mutant of BCR-ABL and Suppresses
              In vitro
              Resistance. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2010,</strong> <em>75 </em>
                                    (2)
                                     , 223-227. <a href="https://doi.org/10.1111/j.1747-0285.2009.00911.x" title="DOI URL">https://doi.org/10.1111/j.1747-0285.2009.00911.x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/j.1747-0285.2009.00911.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fj.1747-0285.2009.00911.x%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DAP24163%252BInhibits%252Bthe%252BGatekeeper%252BMutant%252Bof%252BBCR-ABL%252Band%252BSuppresses%252BIn%252Bvitro%252BResistance%26aulast%3DAzam%26aufirst%3DMohammad%26date%3D2010%26volume%3D75%26issue%3D2%26spage%3D223%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tianjun  Zhou</span>, <span class="hlFld-ContribAuthor ">Lois  Commodore</span>, <span class="hlFld-ContribAuthor ">Wei-Sheng  Huang</span>, <span class="hlFld-ContribAuthor ">Yihan  Wang</span>, <span class="hlFld-ContribAuthor ">Tomi K.  Sawyer</span>, <span class="hlFld-ContribAuthor ">William C.  Shakespeare</span>, <span class="hlFld-ContribAuthor ">Tim  Clackson</span>, <span class="hlFld-ContribAuthor ">Xiaotian  Zhu</span>, <span class="hlFld-ContribAuthor ">David C.  Dalgarno</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Analysis of DFG-in and DFG-out Dual Src-Abl Inhibitors Sharing a Common Vinyl Purine Template. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2010,</strong> <em>75 </em>
                                    (1)
                                     , 18-28. <a href="https://doi.org/10.1111/j.1747-0285.2009.00905.x" title="DOI URL">https://doi.org/10.1111/j.1747-0285.2009.00905.x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/j.1747-0285.2009.00905.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fj.1747-0285.2009.00905.x%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DStructural%252BAnalysis%252Bof%252BDFG-in%252Band%252BDFG-out%252BDual%252BSrc-Abl%252BInhibitors%252BSharing%252Ba%252BCommon%252BVinyl%252BPurine%252BTemplate%26aulast%3DZhou%26aufirst%3DTianjun%26date%3D2010%26volume%3D75%26issue%3D1%26spage%3D18%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas  O'Hare</span>, <span class="hlFld-ContribAuthor ">William C.  Shakespeare</span>, <span class="hlFld-ContribAuthor ">Xiaotian  Zhu</span>, <span class="hlFld-ContribAuthor ">Christopher A.  Eide</span>, <span class="hlFld-ContribAuthor ">Victor M.  Rivera</span>, <span class="hlFld-ContribAuthor ">Frank  Wang</span>, <span class="hlFld-ContribAuthor ">Lauren T.  Adrian</span>, <span class="hlFld-ContribAuthor ">Tianjun  Zhou</span>, <span class="hlFld-ContribAuthor ">Wei-Sheng  Huang</span>, <span class="hlFld-ContribAuthor ">Qihong  Xu</span>, <span class="hlFld-ContribAuthor ">Chester A.  Metcalf</span>, <span class="hlFld-ContribAuthor ">Jeffrey W.  Tyner</span>, <span class="hlFld-ContribAuthor ">Marc M.  Loriaux</span>, <span class="hlFld-ContribAuthor ">Amie S.  Corbin</span>, <span class="hlFld-ContribAuthor ">Scott  Wardwell</span>, <span class="hlFld-ContribAuthor ">Yaoyu  Ning</span>, <span class="hlFld-ContribAuthor ">Jeffrey A.  Keats</span>, <span class="hlFld-ContribAuthor ">Yihan  Wang</span>, <span class="hlFld-ContribAuthor ">Raji  Sundaramoorthi</span>, <span class="hlFld-ContribAuthor ">Mathew  Thomas</span>, <span class="hlFld-ContribAuthor ">Dong  Zhou</span>, <span class="hlFld-ContribAuthor ">Joseph  Snodgrass</span>, <span class="hlFld-ContribAuthor ">Lois  Commodore</span>, <span class="hlFld-ContribAuthor ">Tomi K.  Sawyer</span>, <span class="hlFld-ContribAuthor ">David C.  Dalgarno</span>, <span class="hlFld-ContribAuthor ">Michael W.N.  Deininger</span>, <span class="hlFld-ContribAuthor ">Brian J.  Druker</span>, <span class="hlFld-ContribAuthor ">Tim  Clackson</span>. </span><span class="cited-content_cbyCitation_article-title">AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance. </span><span class="cited-content_cbyCitation_journal-name">Cancer Cell</span><span> <strong>2009,</strong> <em>16 </em>
                                    (5)
                                     , 401-412. <a href="https://doi.org/10.1016/j.ccr.2009.09.028" title="DOI URL">https://doi.org/10.1016/j.ccr.2009.09.028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ccr.2009.09.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ccr.2009.09.028%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Cell%26atitle%3DAP24534%25252C%252Ba%252BPan-BCR-ABL%252BInhibitor%252Bfor%252BChronic%252BMyeloid%252BLeukemia%25252C%252BPotently%252BInhibits%252Bthe%252BT315I%252BMutant%252Band%252BOvercomes%252BMutation-Based%252BResistance%26aulast%3DO%2527Hare%26aufirst%3DThomas%26date%3D2009%26volume%3D16%26issue%3D5%26spage%3D401%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900166t&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative kinase inhibitors targeting the DFG-out conformation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900166t&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of DFG-out dual Src/Abl inhibitors based on <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900166t&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Model of designed inhibitor <b>3a</b> bound to Abl kinase</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900166t&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of 3-(Trifluoromethyl)benzamides <b>3</b><sup>a</sup></div><p class="last"></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900166t&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) RNH<sub>2</sub>, THF, rt, 5 h; (b) 2.5 mol % Pd(OAc)<sub>2</sub>, 5 mol % P(<i>o</i>-tol)<sub>3</sub>, 120 mol % (<i>i</i>-Pr)<sub>2</sub>NEt, DMF, 100 °C, 15 h; (c) 3-CF<sub>3</sub>C<sub>6</sub>H<sub>4</sub>CO<sub>2</sub>H, EDCI, HOBt, THF, rt, overnight; (d) 2 equiv ArNH<sub>2</sub>, 10 mol % Pd<sub>2</sub>(dba)<sub>3</sub>, 15 mol % PhP(c-hexyl)<sub>2</sub>, 1.5 equiv K<sub>3</sub>PO<sub>4</sub>, μW, 150 °C, 5 or 10 min.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Reverse Amides <b>9</b> and Urea <b>11</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900166t&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) SOCl<sub>2</sub>, reflux, 1 h, (ii) ArNH<sub>2</sub>, (<i>i</i>-Pr)<sub>2</sub>NEt, cat. DMAP, THF, rt, 2 h; (b) 2.5 mol % Pd(OAc)<sub>2</sub>, 5 mol % P(<i>o</i>-tol)<sub>3</sub>, 120 mol % (<i>i</i>-Pr)<sub>2</sub>NEt, DMF, 100 °C, 15 h; (c) 3-CF<sub>3</sub>C<sub>6</sub>H<sub>4</sub>NCO, CH<sub>2</sub>Cl<sub>2</sub>, rt, 4 h.</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Analogues <b>14</b> and <b>17</b> Bearing Additional B Ring Substitutions<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900166t&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) imidazole or 4-methylimidazole, 15 mol % 8-hydroxyquinoline, 15 mol % CuI, 110 mol % K<sub>2</sub>CO<sub>3</sub>, DMSO, 120 °C, 15 h; (b) 3-iodo-4-methylbenzoyl chloride, (<i>i</i>-Pr)<sub>2</sub>NEt, THF, rt, 2 h; (c) 2.5 mol % Pd(OAc)<sub>2</sub>, 5 mol % P(<i>o</i>-tol)<sub>3</sub>, 120 mol % (<i>i</i>-Pr)<sub>2</sub>NEt, DMF, 100 °C, 15 h; (d) 4 equiv morpholine or 4-methylpiperazine, 2 equiv CsOH·H<sub>2</sub>O, DMSO, 120 °C, 4 h.</p></p></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Orally bioavailable “DFG-in” <i>N</i><sup>9</sup>-(arenethenyl)purine.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900166t&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Representative dual Src/Abl kinase inhibitors targeting the “DFG-in” conformations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900166t&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Model of compound <b>9i</b> bound to Abl (left) and Src (right).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900166t&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. In vivo efficacy of <b>9i</b> in a Ba/F3 WT Bcr-Abl survival model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900166t&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. In vivo efficacy of <b>9i</b> in a Src Y527F mouse tumor model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900166t&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/medium/jm-2009-00166t_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Model of compound <b>14a</b> bound to Abl T315I.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-15/jm900166t/production/images/large/jm-2009-00166t_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900166t&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i70">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66884" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66884" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 36 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Nowell, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hungerford, D. A.</span><span> </span><span class="NLM_article-title">A minute chromosome in chronic granulocytic leukemia</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1960</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">1497</span><span class="NLM_x">–</span> <span class="NLM_lpage">1501</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=1960&pages=1497-1501&author=P.+C.+Nowellauthor=D.+A.+Hungerford&title=A+minute+chromosome+in+chronic+granulocytic+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNowell%26aufirst%3DP.%2BC.%26aulast%3DHungerford%26aufirst%3DD.%2BA.%26atitle%3DA%2520minute%2520chromosome%2520in%2520chronic%2520granulocytic%2520leukemia%26jtitle%3DScience%26date%3D1960%26volume%3D132%26spage%3D1497%26epage%3D1501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rowley, J. D.</span><span> </span><span class="NLM_article-title">A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">243</span><span class="NLM_x">, </span> <span class="NLM_fpage">290</span><span class="NLM_x">–</span> <span class="NLM_lpage">293</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=243&publication_year=1973&pages=290-293&author=J.+D.+Rowley&title=A+new+consistent+chromosomal+abnormality+in+chronic+myelogenous+leukemia+identified+by+quinacrine+fluorescence+and+Giemsa+staining"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRowley%26aufirst%3DJ.%2BD.%26atitle%3DA%2520new%2520consistent%2520chromosomal%2520abnormality%2520in%2520chronic%2520myelogenous%2520leukemia%2520identified%2520by%2520quinacrine%2520fluorescence%2520and%2520Giemsa%2520staining%26jtitle%3DNature%26date%3D1973%26volume%3D243%26spage%3D290%26epage%3D293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Groffen, J</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephenson, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heisterkamp, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Klein, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartram, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosveld, G.</span><span> </span><span class="NLM_article-title">Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">93</span><span class="NLM_x">–</span> <span class="NLM_lpage">99</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1984&pages=93-99&author=J+Groffenauthor=J.+R.+Stephensonauthor=N.+Heisterkampauthor=A.+de+Kleinauthor=C.+R.+Bartramauthor=G.+Grosveld&title=Philadelphia+chromosomal+breakpoints+are+clustered+within+a+limited+region%2C+bcr%2C+on+chromosome+22"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGroffen%26aufirst%3DJ%26aulast%3DStephenson%26aufirst%3DJ.%2BR.%26aulast%3DHeisterkamp%26aufirst%3DN.%26aulast%3Dde%2BKlein%26aufirst%3DA.%26aulast%3DBartram%26aufirst%3DC.%2BR.%26aulast%3DGrosveld%26aufirst%3DG.%26atitle%3DPhiladelphia%2520chromosomal%2520breakpoints%2520are%2520clustered%2520within%2520a%2520limited%2520region%252C%2520bcr%252C%2520on%2520chromosome%252022%26jtitle%3DCell%26date%3D1984%26volume%3D36%26spage%3D93%26epage%3D99" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lugo, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pendergast, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, O. N.</span><span> </span><span class="NLM_article-title">Tyrosine kinase activity and transformation potency of Bcr-Abl oncogene products</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">247</span><span class="NLM_x">, </span> <span class="NLM_fpage">1079</span><span class="NLM_x">–</span> <span class="NLM_lpage">1082</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=247&publication_year=1990&pages=1079-1082&author=T.+G.+Lugoauthor=A.+M.+Pendergastauthor=A.+J.+Mullerauthor=O.+N.+Witte&title=Tyrosine+kinase+activity+and+transformation+potency+of+Bcr-Abl+oncogene+products"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLugo%26aufirst%3DT.%2BG.%26aulast%3DPendergast%26aufirst%3DA.%2BM.%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DTyrosine%2520kinase%2520activity%2520and%2520transformation%2520potency%2520of%2520Bcr-Abl%2520oncogene%2520products%26jtitle%3DScience%26date%3D1990%26volume%3D247%26spage%3D1079%26epage%3D1082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Chronic myeloid leukemia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">340</span><span class="NLM_x">, </span> <span class="NLM_fpage">1330</span><span class="NLM_x">–</span> <span class="NLM_lpage">1340</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1056%2FNEJM199904293401706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=10219069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A280%3ADyaK1M3hvFOlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=1999&pages=1330-1340&author=C.+L.+Sawyers&title=Chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic myeloid leukemia</span></div><div class="casAuthors">Sawyers C L</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1330-40</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR38AD8e0PJ50HdcurJClFcfW6udTcc2ebW-_Oap3He5rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M3hvFOlug%253D%253D&md5=45ce459ec092eda659cb1e20cb5c8604</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1056%2FNEJM199904293401706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199904293401706%26sid%3Dliteratum%253Aachs%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DChronic%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1999%26volume%3D340%26spage%3D1330%26epage%3D1340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matter, A.</span><span> </span><span class="NLM_article-title">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1038%2Fnrd839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=12120256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=493-502&author=R.+Capdevilleauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=A.+Matter&title=Glivec+%28STI571%2C+imatinib%29%2C+a+rationally+developed%2C+targeted+anticancer+drug"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span></div><div class="casAuthors">Capdeville, Renaud; Buchdunger, Elisabeth; Zimmermann, Juerg; Matter, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">493-502</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research.  Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery program was initiated with the aim of rationally developing targeted anticancer therapies.  Here, we describe how this program led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeI0HV4de6ObVg90H21EOLACvtfcHk0li6tu3yACq_Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D&md5=c8f6b7a66f74b64f0dedb5e641097acc</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrd839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd839%26sid%3Dliteratum%253Aachs%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26atitle%3DGlivec%2520%2528STI571%252C%2520imatinib%2529%252C%2520a%2520rationally%2520developed%252C%2520targeted%2520anticancer%2520drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D493%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochhaus, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukemia</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">356</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1038%2Fnrc2126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=17457302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksFSiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=345-356&author=E.+Weisbergauthor=P.+W.+Manleyauthor=S.+W.+Cowan-Jacobauthor=A.+Hochhausauthor=J.+D.+Griffin&title=Second+generation+inhibitors+of+BCR-ABL+for+the+treatment+of+imatinib-resistant+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukemia</span></div><div class="casAuthors">Weisberg, Ellen; Manley, Paul W.; Cowan-Jacob, Sandra W.; Hochhaus, Andreas; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">345-356</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Imatinib, a small-mol. ABL kinase inhibitor, is a highly effective therapy for early-phase chronic myeloid leukemia (CML), which has constitutively active ABL kinase activity owing to the expression of the BCR-ABL fusion protein.  However, there is a high relapse rate among advanced- and blast-crisis-phase patients owing to the development of mutations in the ABL kinase domain that cause drug resistance.  Several second-generation ABL kinase inhibitors have been or are being developed for the treatment of imatinib-resistant CML.  Here, we describe the mechanism of action of imatinib in CML, the structural basis of imatinib resistance, and the potential of second-generation BCR-ABL inhibitors to circumvent resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxlco2ZKndcbVg90H21EOLACvtfcHk0li6tu3yACq_Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksFSiu7o%253D&md5=36735dff94df075862a60b26d3f358e5</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc2126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2126%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DSecond%2520generation%2520inhibitors%2520of%2520BCR-ABL%2520for%2520the%2520treatment%2520of%2520imatinib-resistant%2520chronic%2520myeloid%2520leukemia%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D345%26epage%3D356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Overriding imatinib resistance with a novel Abl kinase inhibitor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">305</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">402</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1126%2Fscience.1099480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=15256671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1egtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2004&pages=399-402&author=N.+P.+Shahauthor=C.+Tranauthor=F.+Y.+Leeauthor=P.+Chenauthor=D.+Norrisauthor=C.+L.+Sawyers&title=Overriding+imatinib+resistance+with+a+novel+Abl+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor</span></div><div class="casAuthors">Shah, Neil P.; Tran, Chris; Lee, Francis Y.; Chen, Ping; Norris, Derek; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">305</span>
        (<span class="NLM_cas:issue">5682</span>),
    <span class="NLM_cas:pages">399-402</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Resistance to the ABL kinase inhibitor imatinib (STI571 or Gleevec) in chronic myeloid leukemia (CML) occurs through selection for tumor cells harboring BCR-ABL kinase domain point mutations that interfere with drug binding.  Crystallog. studies predict that most imatinib-resistant mutants should remain sensitive to inhibitors that bind ABL with less stringent conformational requirements.  BMS-354825 is an orally bioavailable ABL kinase inhibitor with two-log increased potency relative to imatinib that retains activity against 14 of 15 imatinib-resistant BCR-ABL mutants.  BMS-354825 prolongs survival of mice with BCR-ABL-driven disease and inhibits proliferation of BCR-ABL-pos. bone marrow progenitor cells from patients with imatinib-sensitive and imatinib-resistant CML.  These data illustrate how mol. insight into kinase inhibitor resistance can guide the design of second-generation targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0O0Lhe8nKCrVg90H21EOLACvtfcHk0liqq9H8ehmKWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1egtrY%253D&md5=b3827c3419b4c6b57893b11fd68f1f96</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099480%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DTran%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DOverriding%2520imatinib%2520resistance%2520with%2520a%2520novel%2520Abl%2520kinase%2520inhibitor%26jtitle%3DScience%26date%3D2004%26volume%3D305%26spage%3D399%26epage%3D402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">O'Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffregen, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">4500</span><span class="NLM_x">–</span> <span class="NLM_lpage">4505</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=4500-4505&author=T.+O%27Hareauthor=D.+K.+Waltersauthor=E.+P.+Stoffregenauthor=T.+Jiaauthor=P.+W.+Manleyauthor=J.+Mestanauthor=S.+W.+Cowan-Jacobauthor=F.+Y.+Leeauthor=M.+C.+Heinrichauthor=M.+W.+N.+Deiningerauthor=B.+J.+Druker&title=In+vitro+activity+of+Bcr-Abl+inhibitors+AMN107+and+BMS-354825+against+clinically+relevant+imatinib-resistant+Abl+kinase+domain+mutants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%2527Hare%26aufirst%3DT.%26aulast%3DWalters%26aufirst%3DD.%2BK.%26aulast%3DStoffregen%26aufirst%3DE.%2BP.%26aulast%3DJia%26aufirst%3DT.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%2BN.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DIn%2520vitro%2520activity%2520of%2520Bcr-Abl%2520inhibitors%2520AMN107%2520and%2520BMS-354825%2520against%2520clinically%2520relevant%2520imatinib-resistant%2520Abl%2520kinase%2520domain%2520mutants%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D4500%26epage%3D4505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">O'Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W. N.</span><span> </span><span class="NLM_article-title">Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">2242</span><span class="NLM_x">–</span> <span class="NLM_lpage">2249</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=2242-2249&author=T.+O%27Hareauthor=C.+A.+Eideauthor=M.+W.+N.+Deininger&title=Bcr-Abl+kinase+domain+mutations%2C+drug+resistance%2C+and+the+road+to+a+cure+for+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%2527Hare%26aufirst%3DT.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%2BN.%26atitle%3DBcr-Abl%2520kinase%2520domain%2520mutations%252C%2520drug%2520resistance%252C%2520and%2520the%2520road%2520to%2520a%2520cure%2520for%2520chronic%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D2242%26epage%3D2249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">O'Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span> </span><span class="NLM_article-title">New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check</span> <span class="citation_source-journal">Exp. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">865</span><span class="NLM_x">–</span> <span class="NLM_lpage">878</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2008&pages=865-878&author=T.+O%27Hareauthor=C.+A.+Eideauthor=M.+W.+Deininger&title=New+Bcr-Abl+inhibitors+in+chronic+myeloid+leukemia%3A+keeping+resistance+in+check"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%2527Hare%26aufirst%3DT.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DNew%2520Bcr-Abl%2520inhibitors%2520in%2520chronic%2520myeloid%2520leukemia%253A%2520keeping%2520resistance%2520in%2520check%26jtitle%3DExp.%2520Opin.%2520Invest.%2520Drugs%26date%3D2008%26volume%3D17%26spage%3D865%26epage%3D878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Lee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voi, M.</span><span> </span><span class="NLM_article-title">Overcoming kinase resistance in chronic myeloid leukemia</span> <span class="citation_source-journal">Int. J. Biochem. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">334</span><span class="NLM_x">–</span> <span class="NLM_lpage">343</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1016%2Fj.biocel.2007.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=18401881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitVentrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2008&pages=334-343&author=F.+Leeauthor=A.+Fandiauthor=M.+Voi&title=Overcoming+kinase+resistance+in+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6eR"><div class="casContent"><span class="casTitleNuber">6e</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming kinase resistance in chronic myeloid leukemia</span></div><div class="casAuthors">Lee, Francis; Fandi, Abderrahim; Voi, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">334-343</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Imatinib is a small-mol. inhibitor of BCR-ABL tyrosine kinase activity, with proven efficacy and tolerability.  Despite imatinib's activity, the development of resistance, whether BCR-ABL dependent or independent, is a concern.  BCR-ABL-dependent resistance is commonly a result of mutations in the BCR-ABL gene, which can induce a structural predisposition towards the active conformation of the protein, resulting in a shift in the equil. of BCR-ABL from inactive, which imatinib binds, to active, which imatinib is unable to bind.  BCR-ABL gene amplification may play a role in the development of imatinib resistance in patients with CML.  There are a no. of BCR-ABL-independent mechanisms of imatinib resistance, including the efflux protein multidrug resistance protein-1, of which imatinib is a substrate.  Another mechanism may be the development of alternative pathways of disease progression, leading to less reliance on BCR-ABL; indeed, the SRC family tyrosine kinases LYN and HCK have been frequently implicated in treatment resistance and progression of CML.  Clearly, imatinib resistance requires the development of other treatment options.  Dasatinib, with increased binding potency (325-fold greater potency than imatinib for wild-type BCR-ABL), inhibition of both the active and inactive formation of BCR-ABL, and targeting of SRC family kinases, is the only agent approved for the treatment of patients with imatinib-resistant or -intolerant CML and Ph+ ALL.  Dasatinib is highly active in all phases of these diseases, and is active in the majority of imatinib-resistant mutations, with the exception of T315I.  The development of agents that effectively inhibit T315I mutations suggests that future treatment options will include combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJsI4yyauR8bVg90H21EOLACvtfcHk0lg9Uu4J70vVKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitVentrw%253D&md5=7662265f4fb1e2f7bac9bf14bd1e6ab1</span></div><a href="/servlet/linkout?suffix=cit6e&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2007.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2007.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DF.%26aulast%3DFandi%26aufirst%3DA.%26aulast%3DVoi%26aufirst%3DM.%26atitle%3DOvercoming%2520kinase%2520resistance%2520in%2520chronic%2520myeloid%2520leukemia%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2008%26volume%3D40%26spage%3D334%26epage%3D343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Tanaka, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, S.</span><span> </span><span class="NLM_article-title">Abl tyrosine kinase inhibitors for overriding Bcr-Abl/ T315I: from the second to third generation</span> <span class="citation_source-journal">Exp. Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1387</span><span class="NLM_x">–</span> <span class="NLM_lpage">1398</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1586%2F14737140.8.9.1387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=18759691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOhsrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1387-1398&author=R.+Tanakaauthor=S.+Kimura&title=Abl+tyrosine+kinase+inhibitors+for+overriding+Bcr-Abl%2F+T315I%3A+from+the+second+to+third+generation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6fR"><div class="casContent"><span class="casTitleNuber">6f</span><div class="casTitle"><span class="NLM_cas:atitle">Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation</span></div><div class="casAuthors">Tanaka, Ruriko; Kimura, Shinya</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1387-1398</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Treatment of chronic myeloid leukemia (CML) has changed drastically with the emergence of the Abl tyrosine kinase inhibitor (TKI), imatinib mesylate.  However, primary and secondary resistance have frequently been reported, particularly in patients with advanced-stage disease.  Point mutations within the Abl kinase domain that interfere with imatinib binding are the most crit. cause of imatinib resistance.  In order to override this resistance, several second generation ATP-competitive Abl TKIs including dasatinib, nilotinib, bosutinib and INNO-406 have been developed.  Despite promising clin. results from these novel Abl TKIs for most mutations, the frequently obsd. mutant T315I is not effectively targeted by any of these agents.  Thus, identification of novel agents and the development of new strategies for the effective treatment of CML patients with the T315I mutation are important and challenging tasks.  In this review, the current status of novel agents for CML treatment is overviewed as follows: pathogenesis and features of CML; imatinib and second-generation Abl TKIs; why Abl TKIs are not effective against T315I; and novel agents that may override the T315I mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHnGTn_O-afbVg90H21EOLACvtfcHk0lg9Uu4J70vVKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOhsrrO&md5=afe3c45934c38478967b259deddd2cb9</span></div><a href="/servlet/linkout?suffix=cit6f&amp;dbid=16384&amp;doi=10.1586%2F14737140.8.9.1387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.8.9.1387%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DR.%26aulast%3DKimura%26aufirst%3DS.%26atitle%3DAbl%2520tyrosine%2520kinase%2520inhibitors%2520for%2520overriding%2520Bcr-Abl%252F%2520T315I%253A%2520from%2520the%2520second%2520to%2520third%2520generation%26jtitle%3DExp.%2520Rev.%2520Anticancer%2520Ther.%26date%3D2008%26volume%3D8%26spage%3D1387%26epage%3D1398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Noronha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dneprovskaia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebansky, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohse, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPherson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palanki, M. S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pathak, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soll, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, B.</span><span> </span><span class="NLM_article-title">Inhibitors of ABL and the ABL- T315I mutation</span> <span class="citation_source-journal">Curr. Top. Med. Chem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">905</span><span class="NLM_x">–</span> <span class="NLM_lpage">921</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.2174%2F156802608784911635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=18673174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVantL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=905-921&author=G.+Noronhaauthor=J.+Caoauthor=C.+P.+Chowauthor=E.+Dneprovskaiaauthor=R.+M.+Fineauthor=J.+Hoodauthor=X.+Kangauthor=B.+Klebanskyauthor=D.+Lohseauthor=C.+C.+Makauthor=A.+McPhersonauthor=M.+S.+S.+Palankiauthor=V.+P.+Pathakauthor=J.+Renickauthor=R.+Sollauthor=B.+Zeng&title=Inhibitors+of+ABL+and+the+ABL-+T315I+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6gR"><div class="casContent"><span class="casTitleNuber">6g</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of ABL and the ABL-T315I mutation</span></div><div class="casAuthors">Noronha, Glenn; Cao, Jianguo; Chow, Chun P.; Dneprovskaia, Elena; Fine, Richard M.; Hood, John; Kang, Xinshan; Klebansky, Boris; Lohse, Dan; Mak, Chi Ching; McPherson, Andrew; Palanki, Moorthy S. S.; Pathak, Ved P.; Renick, Joel; Soll, Richard; Zeng, Binqi</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">905-921</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Chronic myelogenous leukemia (CML) is a hematol. stem cell disorder caused by increased and unregulated growth of myeloid cells in the bone marrow, and the accumulation of excessive white blood cells.  Abelson tyrosine kinase (ABL) is a non-receptor tyrosine kinase involved in cell growth and proliferation and is usually under tight control.  However, 95% of CML patients have the ABL gene from chromosome 9 fused with the breakpoint cluster (BCR) gene from chromosome 22, resulting in a short chromosome known as the Philadelphia chromosome.  This Philadelphia chromosome is responsible for the prodn. of BCR-ABL, a constitutively active tyrosine kinase that causes uncontrolled cellular proliferation.  An ABL inhibitor, imatinib, was approved by the FDA for the treatment of CML, and is currently used as first line therapy.  However, a high percentage of clin. relapse has been obsd. due to long term treatment with imatinib.  A majority of these relapsed patients have several point mutations at and around the ATP binding pocket of the ABL kinase domain in BCR-ABL.  To address the resistance of mutated BCR-ABL to imatinib, 2nd generation inhibitors such as dasatinib, and nilotinib were developed.  These compds. were approved for the treatment of CML patients who are resistant to imatinib.  All of the BCR-ABL mutants are inhibited by the 2nd generation inhibitors with the exception of the T3151 mutant.  Several 3rd generation inhibitors such as AP24534, VX-680 (MK-0457), PHA-739358, PPY-A, XL-228, SGX-70393, FTY720 and TG101113 are being developed to target the T3151 mutation.  The early results from these compds. are encouraging and it is anticipated that physicians will have addnl. drugs at their disposal for the treatment of patients with the mutated BCR-ABL-T315I.  The success of these inhibitors has greater implication not only in CML, but also in other diseases driven by kinases where the mutated gatekeeper residue plays a major role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCjbrW8rt8HbVg90H21EOLACvtfcHk0lg9Uu4J70vVKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVantL8%253D&md5=c61dc3941c9fd71ddd4ed02732e80998</span></div><a href="/servlet/linkout?suffix=cit6g&amp;dbid=16384&amp;doi=10.2174%2F156802608784911635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608784911635%26sid%3Dliteratum%253Aachs%26aulast%3DNoronha%26aufirst%3DG.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DChow%26aufirst%3DC.%2BP.%26aulast%3DDneprovskaia%26aufirst%3DE.%26aulast%3DFine%26aufirst%3DR.%2BM.%26aulast%3DHood%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DX.%26aulast%3DKlebansky%26aufirst%3DB.%26aulast%3DLohse%26aufirst%3DD.%26aulast%3DMak%26aufirst%3DC.%2BC.%26aulast%3DMcPherson%26aufirst%3DA.%26aulast%3DPalanki%26aufirst%3DM.%2BS.%2BS.%26aulast%3DPathak%26aufirst%3DV.%2BP.%26aulast%3DRenick%26aufirst%3DJ.%26aulast%3DSoll%26aufirst%3DR.%26aulast%3DZeng%26aufirst%3DB.%26atitle%3DInhibitors%2520of%2520ABL%2520and%2520the%2520ABL-%2520T315I%2520mutation%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem%26date%3D2008%26volume%3D8%26spage%3D905%26epage%3D921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Therapeutic options against BCR-ABL1 T315I -positive chronic myelogenous leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">4392</span><span class="NLM_x">–</span> <span class="NLM_lpage">4399</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6h&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1158%2F1078-0432.CCR-08-0117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6h&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=18628453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6h&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosFGit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=4392-4399&author=A.+Quintas-Cardamaauthor=J.+Cortes&title=Therapeutic+options+against+BCR-ABL1+T315I+-positive+chronic+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6hR"><div class="casContent"><span class="casTitleNuber">6h</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Cortes, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4392-4399</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Despite the efficacy of imatinib therapy in chronic myelogenous leukemia, the development of resistance continues to challenge the treatment of this disease.  Mutations within the kinase domain of BCR-ABL1 constitute the most frequent mechanism of resistance in patients with chronic myelogenous leukemia treated with imatinib or the second generation tyrosine kinase inhibitors nilotinib and dasatinib.  Of particular concern is the substitution of the threonine residue at the highly conserved gatekeeper residue 315 with a bulkier hydrophobic isoleucine amino acid.  This mutation causes steric hindrance precluding the access ATP-competitive inhibitors to the ATP-binding pocket.  To expedite the identification of strategies to override the resistance imposed by the T315I mutation, several strategies have been pursued, including the exploitation of BCR-ABL1 kinase sites distant from the ATP-binding pocket to cripple the kinase activity of the enzyme and inhibiting signaling pathways downstream from BCR-ABL1.  Recent insights gained regarding the structural biol. of T315I have led to the development of a variety of compds. against this mutant.  We herein summarize the most clin. promising anti-T315I therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplJ8bpmJXGkrVg90H21EOLACvtfcHk0lh1TNy_8OzDUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosFGit74%253D&md5=01688b0795daf1ca29c7ad4a98e3977b</span></div><a href="/servlet/linkout?suffix=cit6h&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0117%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DTherapeutic%2520options%2520against%2520BCR-ABL1%2520T315I%2520-positive%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D4392%26epage%3D4399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mahon, F.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayette, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagarde, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belloc, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turcq, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belanger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leroy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etienne, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roche, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquet, J.-M.</span><span> </span><span class="NLM_article-title">Evidence that resistance to nilotinib may be due to Bcr-Abl, Pgp, or Src kinase overexpression</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">9809</span><span class="NLM_x">–</span> <span class="NLM_lpage">9816</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1158%2F0008-5472.CAN-08-1008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=19047160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVegtbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9809-9816&author=F.-X.+Mahonauthor=S.+Hayetteauthor=V.+Lagardeauthor=F.+Bellocauthor=B.+Turcqauthor=F.+Nicoliniauthor=C.+Belangerauthor=P.+W.+Manleyauthor=C.+Leroyauthor=G.+Etienneauthor=S.+Rocheauthor=J.-M.+Pasquet&title=Evidence+that+resistance+to+nilotinib+may+be+due+to+Bcr-Abl%2C+Pgp%2C+or+Src+kinase+overexpression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression</span></div><div class="casAuthors">Mahon, Francois-Xavier; Hayette, Sandrine; Lagarde, Valerie; Belloc, Francis; Turcq, Beatrice; Nicolini, Franck; Belanger, Coralie; Manley, Paul W.; Leroy, Cedric; Etienne, Gabriel; Roche, Serge; Pasquet, Jean-Max</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9809-9816</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeting the tyrosine kinase activity of Bcr-Abl is an attractive therapeutic strategy in chronic myeloid leukemia (CML) and in Bcr-Abl-pos. acute lymphoblastic leukemia.  Whereas imatinib, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for CML, second-generation inhibitors of Bcr-Abl tyrosine kinase such as nilotinib or dasatinib have been developed for the treatment of imatinib-resistant or imatinib-intolerant disease.  In the current study, we generated nilotinib-resistant cell lines and investigated their mechanism of resistance.  Overexpression of BCR-ABL and multidrug resistance gene (MDR-1) were found among the investigated mechanisms.  We showed that nilotinib is a substrate of the multidrug resistance gene product, P-glycoprotein, using verapamil or PSC833 to block binding.  Up-regulated expression of p53/56 Lyn kinase, both at the mRNA and protein level, was found in one of the resistant cell lines and Lyn silencing by small interfering RNA restored sensitivity to nilotinib.  Moreover, failure of nilotinib treatment was accompanied by an increase of Lyn mRNA expression in patients with resistant CML.  Two Src kinase inhibitors (PP1 and PP2) partially removed resistance but did not significantly inhibit Bcr-Abl tyrosine kinase activity.  In contrast, dasatinib, a dual Bcr-Abl and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn.  Such mechanisms of resistance are close to those obsd. in imatinib-resistant cell lines and emphasize the crit. role of Lyn in nilotinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjFLZ5Im5NArVg90H21EOLACvtfcHk0lh1TNy_8OzDUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVegtbjK&md5=3a129d5e8e4fe09a82b9b10ab9995906</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1008%26sid%3Dliteratum%253Aachs%26aulast%3DMahon%26aufirst%3DF.-X.%26aulast%3DHayette%26aufirst%3DS.%26aulast%3DLagarde%26aufirst%3DV.%26aulast%3DBelloc%26aufirst%3DF.%26aulast%3DTurcq%26aufirst%3DB.%26aulast%3DNicolini%26aufirst%3DF.%26aulast%3DBelanger%26aufirst%3DC.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DLeroy%26aufirst%3DC.%26aulast%3DEtienne%26aufirst%3DG.%26aulast%3DRoche%26aufirst%3DS.%26aulast%3DPasquet%26aufirst%3DJ.-M.%26atitle%3DEvidence%2520that%2520resistance%2520to%2520nilotinib%2520may%2520be%2520due%2520to%2520Bcr-Abl%252C%2520Pgp%252C%2520or%2520Src%2520kinase%2520overexpression%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D9809%26epage%3D9816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schenone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manetti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botta, M.</span><span> </span><span class="NLM_article-title">Last findings on dual inhibitors of Abl and Src tyrosine-kinases</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">201</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=191-201&author=S.+Schenoneauthor=F.+Manettiauthor=M.+Botta&title=Last+findings+on+dual+inhibitors+of+Abl+and+Src+tyrosine-kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchenone%26aufirst%3DS.%26aulast%3DManetti%26aufirst%3DF.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DLast%2520findings%2520on%2520dual%2520inhibitors%2520of%2520Abl%2520and%2520Src%2520tyrosine-kinases%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D191%26epage%3D201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kantarjian, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Important therapeutic targets in chronic myelogenous leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1089</span><span class="NLM_x">–</span> <span class="NLM_lpage">1097</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1158%2F1078-0432.CCR-06-2147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=17317816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvF2hsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1089-1097&author=H.+M.+Kantarjianauthor=F.+Gilesauthor=A.+Quintas-Cardamaauthor=J.+Cortes&title=Important+therapeutic+targets+in+chronic+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">Important Therapeutic Targets in Chronic Myelogenous Leukemia</span></div><div class="casAuthors">Kantarjian, Hagop M.; Giles, Francis; Quintas-Cardama, Alfonso; Cortes, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1089-1097</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Review the state-of-art knowledge of the biol. and therapy of chronic myelogenous leukemia (CML).  Exptl. Design: A review of the literature was undertaken to summarize current information on the pathophysiol. of CML and to update data of imatinib mesylate therapy, mechanisms of resistance, and in vitro and clin. data with the new tyrosine kinase inhibitors.  Results: Imatinib, which targets the ABL kinase activity of BCR-ABL, has prolonged survival in CML.  Despite the efficacy of imatinib, some patients in chronic phase and more in advanced phases of CML develop resistance, frequently as a result of BCR-ABL tyrosine kinase domain mutants that impair imatinib binding but retain enzymic activity.  New tyrosine kinase inhibitors inhibit BCR-ABL more potently than imatinib and maintain activity against an array of imatinib-resistant BCR-ABL mutants.  The IC50 values of nilotinib and dasatinib are at least 10- to 100-fold lower for BCR-ABL compared with imatinib.  Phase I-II trials of nilotinib and dasatinib showed high activity in imatinib-resistant CML and Philadelphia chromosome-pos. ALL.  Dasatinib also inhibits members of the Src family of kinases (SFKs); nilotinib does not.  Whether SFKs have a crit. role in imatinib resistance or BCR-ABL-mediated oncogenesis is unresolved.  Agents that target signals downstream of BCR-ABL (e.g. Ras/Raf and phosphatidylinositol 3-kinase) are under investigation.  Conclusions: Understanding the pathophysiol. of CML and mechanisms of resistance has produced effective targeted strategies for imatinib-resistant CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6TUXDbtEOxrVg90H21EOLACvtfcHk0lh1TNy_8OzDUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvF2hsL4%253D&md5=a750a241b963ee917314b672103ca154</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-2147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-2147%26sid%3Dliteratum%253Aachs%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DImportant%2520therapeutic%2520targets%2520in%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D1089%26epage%3D1097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Martinelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soverini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccarani, M.</span><span> </span><span class="NLM_article-title">Dual tyrosine kinase inhibitors in chronic myeloid leukemia</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1872</span><span class="NLM_x">–</span> <span class="NLM_lpage">1879</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=1872-1879&author=G.+Martinelliauthor=S.+Soveriniauthor=G.+Rostiauthor=M.+Baccarani&title=Dual+tyrosine+kinase+inhibitors+in+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DSoverini%26aufirst%3DS.%26aulast%3DRosti%26aufirst%3DG.%26aulast%3DBaccarani%26aufirst%3DM.%26atitle%3DDual%2520tyrosine%2520kinase%2520inhibitors%2520in%2520chronic%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2005%26volume%3D19%26spage%3D1872%26epage%3D1879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelletier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Etten, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span> </span><span class="NLM_article-title">Requirement of Src kinases Lyn, Hck and Fgr for <i>BCR-ABL1</i>-induced B-lymphoblastic leukemia but not chronic myeloid leukemia</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">453</span><span class="NLM_x">–</span> <span class="NLM_lpage">461</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1038%2Fng1343" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=15098032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFSnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2004&pages=453-461&author=Y.+Huauthor=Y.+Liuauthor=S.+Pelletierauthor=E.+Buchdungerauthor=M.+Warmuthauthor=D.+Fabbroauthor=M.+Hallekauthor=R.+A.+Van+Ettenauthor=S.+Li&title=Requirement+of+Src+kinases+Lyn%2C+Hck+and+Fgr+for+BCR-ABL1-induced+B-lymphoblastic+leukemia+but+not+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia</span></div><div class="casAuthors">Hu, Yiguo; Liu, Yuhua; Pelletier, Shawn; Buchdunger, Elisabeth; Warmuth, Markus; Fabbro, Doriano; Hallek, Michael; Van Etten, Richard A.; Li, Shaoguang</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">453-461</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Abl kinase inhibitor imatinib mesylate is the preferred treatment for Philadelphia chromosome-pos. (Ph+) chronic myeloid leukemia (CML) in chronic phase but is much less effective in CML blast crisis or Ph+ B-cell acute lymphoblastic leukemia (B-ALL).  Here, we show that Bcr-Abl activated the Src kinases Lyn, Hck and Fgr in B-lymphoid cells.  BCR-ABL1 retrovirus-transduced marrow from mice lacking all three Src kinases efficiently induced CML but not B-ALL in recipients.  The kinase inhibitor CGP76030 impaired the proliferation of B-lymphoid cells expressing Bcr-Abl in vitro and prolonged survival of mice with B-ALL but not CML.  The combination of CGP76030 and imatinib was superior to imatinib alone in this regard.  The biochem. target of CGP76030 in leukemia cells was Src kinases, not Bcr-Abl.  These results implicate Src family kinases as therapeutic targets in Ph+ B-ALL and suggest that simultaneous inhibition of Src and Bcr-Abl kinases may benefit individuals with Ph+ acute leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsI4S1CAKINbVg90H21EOLACvtfcHk0lhCK5pZbGw2Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFSnt74%253D&md5=9783ffa92e8aee107ee09d05e0d2fa76</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fng1343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng1343%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DPelletier%26aufirst%3DS.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DHallek%26aufirst%3DM.%26aulast%3DVan%2BEtten%26aufirst%3DR.%2BA.%26aulast%3DLi%26aufirst%3DS.%26atitle%3DRequirement%2520of%2520Src%2520kinases%2520Lyn%252C%2520Hck%2520and%2520Fgr%2520for%2520BCR-ABL1-induced%2520B-lymphoblastic%2520leukemia%2520but%2520not%2520chronic%2520myeloid%2520leukemia%26jtitle%3DNat.%2520Genet.%26date%3D2004%26volume%3D36%26spage%3D453%26epage%3D461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Srinivasan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plattner, R.</span><span> </span><span class="NLM_article-title">Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">5648</span><span class="NLM_x">–</span> <span class="NLM_lpage">5655</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=5648-5655&author=D.+Srinivasanauthor=R.+Plattner&title=Activation+of+Abl+tyrosine+kinases+promotes+invasion+of+aggressive+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSrinivasan%26aufirst%3DD.%26aulast%3DPlattner%26aufirst%3DR.%26atitle%3DActivation%2520of%2520Abl%2520tyrosine%2520kinases%2520promotes%2520invasion%2520of%2520aggressive%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D5648%26epage%3D5655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Srinivasan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plattner, R.</span><span> </span><span class="NLM_article-title">Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1095</span><span class="NLM_x">–</span> <span class="NLM_lpage">1105</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=1095-1105&author=D.+Srinivasanauthor=J.+T.+Simsauthor=R.+Plattner&title=Aggressive+breast+cancer+cells+are+dependent+on+activated+Abl+kinases+for+proliferation%2C+anchorage-independent+growth+and+survival"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSrinivasan%26aufirst%3DD.%26aulast%3DSims%26aufirst%3DJ.%2BT.%26aulast%3DPlattner%26aufirst%3DR.%26atitle%3DAggressive%2520breast%2520cancer%2520cells%2520are%2520dependent%2520on%2520activated%2520Abl%2520kinases%2520for%2520proliferation%252C%2520anchorage-independent%2520growth%2520and%2520survival%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D1095%26epage%3D1105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arlinghaus, R.</span><span> </span><span class="NLM_article-title">Activated c-Abl tyrosine kinase in malignant solid tumors</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4385</span><span class="NLM_x">–</span> <span class="NLM_lpage">4391</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=4385-4391&author=J.+Linauthor=R.+Arlinghaus&title=Activated+c-Abl+tyrosine+kinase+in+malignant+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DArlinghaus%26aufirst%3DR.%26atitle%3DActivated%2520c-Abl%2520tyrosine%2520kinase%2520in%2520malignant%2520solid%2520tumors%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D4385%26epage%3D4391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Park, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallick, G. E.</span><span> </span><span class="NLM_article-title">Regulation of angiogenesis and vascular permeability by Src family kinases: opportunities for therapeutic treatment of solid tumors</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1207</span><span class="NLM_x">–</span> <span class="NLM_lpage">1217</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1517%2F14728222.11.9.1207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=17845146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVWmsL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=1207-1217&author=S.+I.+Parkauthor=A.+N.+Shahauthor=J.+Zhangauthor=G.+E.+Gallick&title=Regulation+of+angiogenesis+and+vascular+permeability+by+Src+family+kinases%3A+opportunities+for+therapeutic+treatment+of+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of angiogenesis and vascular permeability by Src family kinases: opportunities for therapeutic treatment of solid tumors</span></div><div class="casAuthors">Park, Serk In; Shah, Ami N.; Zhang, Jing; Gallick, Gary E.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1207-1217</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Aberrant expression or activation of protein tyrosine kinases, including Src and related Src family kinases, is a common occurrence in many human cancers, resulting in deregulation of expression of numerous mediators of cellular functions, including pro-angiogenic mols.  In addn., Src activation regulates vascular permeability of endothelial cells.  How these processes contribute to tumor progression and metastasis are the subjects of this review.  As Src-selective inhibitors have entered clin. trials for a no. of solid tumors, further understanding of the roles of Src kinases in mediating tumor angiogenesis as well as modulating tumor/microenvironment interactions will provide insights into the best use of these inhibitors in treating patients afflicted with tumors in which Src is activated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqweA3eJZ8qArVg90H21EOLACvtfcHk0lhCK5pZbGw2Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVWmsL3O&md5=55e9c22d88680d57d0699b628bf38681</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1517%2F14728222.11.9.1207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.11.9.1207%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%2BI.%26aulast%3DShah%26aufirst%3DA.%2BN.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DGallick%26aufirst%3DG.%2BE.%26atitle%3DRegulation%2520of%2520angiogenesis%2520and%2520vascular%2520permeability%2520by%2520Src%2520family%2520kinases%253A%2520opportunities%2520for%2520therapeutic%2520treatment%2520of%2520solid%2520tumors%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2007%26volume%3D11%26spage%3D1207%26epage%3D1217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Summy, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallick, G. E.</span><span> </span><span class="NLM_article-title">Treatment for advanced tumors: Src reclaims center stage</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1398</span><span class="NLM_x">–</span> <span class="NLM_lpage">1401</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1158%2F1078-0432.CCR-05-2692" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=16533761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD28XitVGmsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=1398-1401&author=J.+M.+Summyauthor=G.+E.+Gallick&title=Treatment+for+advanced+tumors%3A+Src+reclaims+center+stage"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment for advanced tumors: Src reclaims center stage</span></div><div class="casAuthors">Summy, Justin M.; Gallick, Gary E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1398-1401</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The recent advances in roles of Src in tumor progression and clin./translational advances are discussed.  Src activation in tumor cells indirectly regulates Src activity in endothelial cells.  Increased Src activity in the tumor cells increases VEGF expression, resulting in increased binding to VEGF expression, resulting in increased binding to VEGF receptors on endothelial cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2D4rtkj8O3LVg90H21EOLACvtfcHk0liJsK8b3F9_mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitVGmsr4%253D&md5=96eb5f53cf01bd47bc52e250b81e5c71</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-2692&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-2692%26sid%3Dliteratum%253Aachs%26aulast%3DSummy%26aufirst%3DJ.%2BM.%26aulast%3DGallick%26aufirst%3DG.%2BE.%26atitle%3DTreatment%2520for%2520advanced%2520tumors%253A%2520Src%2520reclaims%2520center%2520stage%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D1398%26epage%3D1401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Chen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, C. C.</span><span> </span><span class="NLM_article-title">Src tyrosine kinase as a chemotherapeutic target: is there a clinical case?</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">131</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=123-131&author=T.+Chenauthor=J.+A.+Georgeauthor=C.+C.+Taylor&title=Src+tyrosine+kinase+as+a+chemotherapeutic+target%3A+is+there+a+clinical+case%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DT.%26aulast%3DGeorge%26aufirst%3DJ.%2BA.%26aulast%3DTaylor%26aufirst%3DC.%2BC.%26atitle%3DSrc%2520tyrosine%2520kinase%2520as%2520a%2520chemotherapeutic%2520target%253A%2520is%2520there%2520a%2520clinical%2520case%253F%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2006%26volume%3D17%26spage%3D123%26epage%3D131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Alvarez, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J. E.</span><span> </span><span class="NLM_article-title">The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">1918</span><span class="NLM_x">–</span> <span class="NLM_lpage">1929</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2006&pages=1918-1929&author=R.+H.+Alvarezauthor=H.+M.+Kantarjianauthor=J.+E.+Cortes&title=The+role+of+Src+in+solid+and+hematologic+malignancies%3A+development+of+new-generation+Src+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarez%26aufirst%3DR.%2BH.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26atitle%3DThe%2520role%2520of%2520Src%2520in%2520solid%2520and%2520hematologic%2520malignancies%253A%2520development%2520of%2520new-generation%2520Src%2520inhibitors%26jtitle%3DCancer%26date%3D2006%26volume%3D107%26spage%3D1918%26epage%3D1929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Lesslie, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallick, G. E.</span><span> </span><span class="NLM_article-title">Src family kinases as regulators of angiogenesis: therapeutic implications</span> <span class="citation_source-journal">Curr. Cancer Ther. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">45</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11e&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.2174%2F1573394052952500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11e&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2MXislOjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2005&pages=45-50&author=D.+P.+Lesslieauthor=G.+E.+Gallick&title=Src+family+kinases+as+regulators+of+angiogenesis%3A+therapeutic+implications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11eR"><div class="casContent"><span class="casTitleNuber">11e</span><div class="casTitle"><span class="NLM_cas:atitle">Src family kinases as regulators of angiogenesis: Therapeutic implications</span></div><div class="casAuthors">Lesslie, Donald P.; Gallick, Gary E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Therapy Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-50</span>CODEN:
                <span class="NLM_cas:coden">CCTRCG</span>;
        ISSN:<span class="NLM_cas:issn">1573-3947</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Despite its discovery nearly a century ago, the functions of the Src family of protein tyrosine kinases (SFKs) remain incompletely understood.  While much has been learned regarding the functions of Src family kinases in the last few years, new roles for Src, particularly in promoting the progression of cancer towards the metastatic phenotype, continue to emerge.  SFKs, through their functions as kinases and adapter proteins in signaling complexes, regulate such diverse cellular events as proliferation, migration, cell cycle control, and apoptosis.  In tumor cells, the kinase activity of Src is frequently activated, with greater increases during progressive stages.  Likewise, resistance to chemotherapy also corresponds with Src kinase activity.  Thus, Src activation is predictive of poor prognosis in several tumors.  Recently, selective SFK inhibitors are showing promise in clin. trials in imatinib mesylate (Gleevec, Novartis) resistant chronic myelogenous leukemia.  However, in vitro studies have suggested that Src inhibitors may hold promise in the treatment of solid tumors such as colon and pancreatic cancer in which new therapeutic inhibitors are desperately needed.  This review will summarize briefly the structure and function of Src and the evidence for Src in promoting tumor progression and metastasis.  As recent work in this lab. and others has demonstrated that Src is a regulator of expression of diverse pro-angiogenic factors produced by tumor cells, and a regulator of the endothelial cells that respond to these factors, this review will focus on the role of Src in angiogenesis and potential roles of Src inhibitors as antiangiogenic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2ccgdPedHerVg90H21EOLACvtfcHk0liJsK8b3F9_mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXislOjtbY%253D&md5=35eb77f20a7bd572c4c1b584fcb74735</span></div><a href="/servlet/linkout?suffix=cit11e&amp;dbid=16384&amp;doi=10.2174%2F1573394052952500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1573394052952500%26sid%3Dliteratum%253Aachs%26aulast%3DLesslie%26aufirst%3DD.%2BP.%26aulast%3DGallick%26aufirst%3DG.%2BE.%26atitle%3DSrc%2520family%2520kinases%2520as%2520regulators%2520of%2520angiogenesis%253A%2520therapeutic%2520implications%26jtitle%3DCurr.%2520Cancer%2520Ther.%2520Rev.%26date%3D2005%26volume%3D1%26spage%3D45%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Tsygankov, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shore, S. K.</span><span> </span><span class="NLM_article-title">Src: regulation, role in human carcinogenesis and pharmacological inhibitors</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1745</span><span class="NLM_x">–</span> <span class="NLM_lpage">1756</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11f&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.2174%2F1381612043384457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11f&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=15180537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11f&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktV2gsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=1745-1756&author=A.+Y.+Tsygankovauthor=S.+K.+Shore&title=Src%3A+regulation%2C+role+in+human+carcinogenesis+and+pharmacological+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11fR"><div class="casContent"><span class="casTitleNuber">11f</span><div class="casTitle"><span class="NLM_cas:atitle">SRC: Regulation, role in human carcinogenesis and pharmacological inhibitors</span></div><div class="casAuthors">Tsygankov, A. Y.; Shore, S. K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1745-1756</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The cellular signaling machinery is a complex network of cross-talking proteins that enables dynamic communication between upstream causal factors and downstream effectors.  Non-receptor tyrosine kinases, including Src, are the intermediates of signal transfer, controlling pathways as diverse as cell growth, death, differentiation, migration, and genome maintenance.  When expressed as viral genes these proteins are potent carcinogens.  Furthermore, analogous genetic alterations are obsd., albeit not frequently, in human tumors.  In a variety of tumors including those derived from the colon and breast.  Src is either over expressed or constitutively active in a large percentage of patients.  Increased expression or activity of Src correlates with the stage and metastatic potential of some neoplasia.  The detailed knowledge of Src activation facilitates rational design of drugs that potentially interfere with either binding of ATP or substrate peptides.  Several existing inhibitors are available as lead compds. for further development of Src inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5-BohF8ENQbVg90H21EOLACvtfcHk0liJsK8b3F9_mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktV2gsbg%253D&md5=8e69eb379a1d9a73c51eae47a0d3a7d3</span></div><a href="/servlet/linkout?suffix=cit11f&amp;dbid=16384&amp;doi=10.2174%2F1381612043384457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612043384457%26sid%3Dliteratum%253Aachs%26aulast%3DTsygankov%26aufirst%3DA.%2BY.%26aulast%3DShore%26aufirst%3DS.%2BK.%26atitle%3DSrc%253A%2520regulation%252C%2520role%2520in%2520human%2520carcinogenesis%2520and%2520pharmacological%2520inhibitors%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2004%26volume%3D10%26spage%3D1745%26epage%3D1756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Yeatman, T. J.</span><span> </span><span class="NLM_article-title">A renaissance for Src</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">470</span><span class="NLM_x">–</span> <span class="NLM_lpage">480</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11g&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1038%2Fnrc1366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11g&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=15170449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11g&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVaisbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=470-480&author=T.+J.+Yeatman&title=A+renaissance+for+Src"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11gR"><div class="casContent"><span class="casTitleNuber">11g</span><div class="casTitle"><span class="NLM_cas:atitle">A renaissance for SRC</span></div><div class="casAuthors">Yeatman, Timothy J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">470-480</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  The c-SRC non-receptor tyrosine kinase is overexpressed and activated in a large no. of human malignancies and has been linked to the development of cancer and progression to distant metastases.  These observations have led to the recent targeting of c-SRC for the development of anticancer therapeutics, which show promise as a new avenue for cancer treatment.  Despite this, however, the precise functions of c-SRC in cancer remain unclear.  In addn. to increasing cell proliferation, a key role of c-SRC in cancer seems to be to promote invasion and motility, functions that might contribute to tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCGFL31NDP4LVg90H21EOLACvtfcHk0lhrHvxMwB6orQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVaisbo%253D&md5=e14e862826b2881721d0f6bb14356650</span></div><a href="/servlet/linkout?suffix=cit11g&amp;dbid=16384&amp;doi=10.1038%2Fnrc1366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1366%26sid%3Dliteratum%253Aachs%26aulast%3DYeatman%26aufirst%3DT.%2BJ.%26atitle%3DA%2520renaissance%2520for%2520Src%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D470%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaneda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelius, L. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doweyko, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairchild, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inigo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, M.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wityak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">6658</span><span class="NLM_x">–</span> <span class="NLM_lpage">6661</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049486a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=6658-6661&author=L.+J.+Lombardoauthor=F.+Y.+Leeauthor=P.+Chenauthor=D.+Norrisauthor=J.+C.+Barrishauthor=K.+Behniaauthor=S.+Castanedaauthor=L.+A.+M.+Corneliusauthor=J.+Dasauthor=A.+M.+Doweykoauthor=C.+Fairchildauthor=J.+T.+Huntauthor=I.+Inigoauthor=K.+Johnstonauthor=A.+Kamathauthor=D.+Kanauthor=H.+Kleiauthor=P.+Maratheauthor=S.+Pangauthor=R.+Petersonauthor=S.+Pittauthor=G.+L.+Schievenauthor=R.+J.+Schmidtauthor=J.+Tokarskiauthor=M.-L.+Wenauthor=J.+Wityakauthor=R.+M.+Borzilleri&title=Discovery+of+N-%282-chloro-6-methyl-phenyl%29-2-%286-%284-%282-hydroxyethyl%29-piperazin-1-yl%29-2-methylpyrimidin-4-ylamino%29thiazole-5-carboxamide+%28BMS-354825%29%2C+a+dual+Src%2FAbl+kinase+inhibitor+with+potent+antitumor+activity+in+preclinical+assays"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm049486a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049486a%26sid%3Dliteratum%253Aachs%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DBehnia%26aufirst%3DK.%26aulast%3DCastaneda%26aufirst%3DS.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%2BM.%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DFairchild%26aufirst%3DC.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DInigo%26aufirst%3DI.%26aulast%3DJohnston%26aufirst%3DK.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DKan%26aufirst%3DD.%26aulast%3DKlei%26aufirst%3DH.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DPang%26aufirst%3DS.%26aulast%3DPeterson%26aufirst%3DR.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DSchmidt%26aufirst%3DR.%2BJ.%26aulast%3DTokarski%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DM.-L.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%2520N-%25282-chloro-6-methyl-phenyl%2529-2-%25286-%25284-%25282-hydroxyethyl%2529-piperazin-1-yl%2529-2-methylpyrimidin-4-ylamino%2529thiazole-5-carboxamide%2520%2528BMS-354825%2529%252C%2520a%2520dual%2520Src%252FAbl%2520kinase%2520inhibitor%2520with%2520potent%2520antitumor%2520activity%2520in%2520preclinical%2520assays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D6658%26epage%3D6661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yaczko, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tischler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arndt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etienne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grod, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span> </span><span class="NLM_article-title">Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">3965</span><span class="NLM_x">–</span> <span class="NLM_lpage">3977</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0102250" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsFyhsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=3965-3977&author=D.+H.+Boschelliauthor=F.+Yeauthor=Y.+D.+Wangauthor=M.+Dutiaauthor=S.+L.+Johnsonauthor=B.+Wuauthor=K.+Millerauthor=D.+W.+Powellauthor=D.+Yaczkoauthor=M.+Youngauthor=M.+Tischlerauthor=K.+Arndtauthor=C.+Discafaniauthor=C.+Etienneauthor=J.+Gibbonsauthor=J.+Grodauthor=J.+Lucasauthor=J.+M.+Weberauthor=F.+Boschelli&title=Optimization+of+4-phenylamino-3-quinolinecarbonitriles+as+potent+inhibitors+of+Src+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of 4-Phenylamino-3-quinolinecarbonitriles as Potent Inhibitors of Src Kinase Activity</span></div><div class="casAuthors">Boschelli, Diane H.; Ye, Fei; Wang, Yanong D.; Dutia, Minu; Johnson, Steve L.; Wu, Biqi; Miller, Karen; Powell, Dennis W.; Yaczko, Deanna; Young, Mairead; Tischler, Mark; Arndt, Kim; Discafani, Carolyn; Etienne, Carlo; Gibbons, Jay; Grod, Janet; Lucas, Judy; Weber, Jennifer M.; Boschelli, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3965-3977</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Subsequent to the discovery of 4-[(2,4-dichlorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile as an inhibitor of Src kinase activity (IC50 = 30 nM), several addnl. analogs were prepd.  Optimization of the C-4 anilino group led to I [R = Me].  Replacement of the methoxy group at C-7 with a 3-(morpholin-4-yl)propoxy group provided I [R = morpholinopropyl], resulting in increased inhibition of both Src kinase activity and Src-mediated cell proliferation.  Analogs of I [R = morpholinopropyl] with other trisubstituted anilines at C-4 were also potent Src inhibitors, and the propoxy group was preferred over ethoxy, butoxy, or pentoxy.  Replacement of the morpholine group with a 4-methylpiperazine group provided I [R = 4-methylpiperazinopropyl], which had an IC50 of 1.2 nM in the Src enzymic assay, an IC50 of 100 nM for the inhibition of Src-dependent cell proliferation and was selective for Src over non-Src family kinases.  I [R = 4-methylpiperazinopropyl], which had higher 1 and 4 h plasma levels than I [R = 4-morpholinopropyl], effectively inhibited tumor growth in xenograft models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIfrD66BPWqrVg90H21EOLACvtfcHk0lhrHvxMwB6orQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsFyhsrk%253D&md5=88c2d8aa690b9aedbff034682aa3d73e</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1021%2Fjm0102250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0102250%26sid%3Dliteratum%253Aachs%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%2BD.%26aulast%3DDutia%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DS.%2BL.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DPowell%26aufirst%3DD.%2BW.%26aulast%3DYaczko%26aufirst%3DD.%26aulast%3DYoung%26aufirst%3DM.%26aulast%3DTischler%26aufirst%3DM.%26aulast%3DArndt%26aufirst%3DK.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DEtienne%26aufirst%3DC.%26aulast%3DGibbons%26aufirst%3DJ.%26aulast%3DGrod%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DWeber%26aufirst%3DJ.%2BM.%26aulast%3DBoschelli%26aufirst%3DF.%26atitle%3DOptimization%2520of%25204-phenylamino-3-quinolinecarbonitriles%2520as%2520potent%2520inhibitors%2520of%2520Src%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D3965%26epage%3D3977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hennequin, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curwen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fennell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert-van der Brempt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgentin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otterbein, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ple, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costello, G.</span><span> </span><span class="NLM_article-title"><i>N</i>-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2<i>H</i>-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6465</span><span class="NLM_x">–</span> <span class="NLM_lpage">6488</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060434q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6465-6488&author=L.+F.+Hennequinauthor=J.+Allenauthor=J.+Breedauthor=J.+Curwenauthor=M.+Fennellauthor=T.+P.+Greenauthor=C.+Lambert-van+der+Bremptauthor=R.+Morgentinauthor=R.+A.+Normanauthor=A.+Olivierauthor=L.+Otterbeinauthor=P.+A.+Pleauthor=N.+Warinauthor=G.+Costello&title=N-%285-Chloro-1%2C3-benzodioxol-4-yl%29-7-%5B2-%284-methylpiperazin-1-yl%29ethoxy%5D-5-%28tetrahydro-2H-pyran-4-yloxy%29quinazolin-4-amine%2C+a+novel%2C+highly+selective%2C+orally+available%2C+dual-specific+c-Src%2FAbl+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1021%2Fjm060434q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060434q%26sid%3Dliteratum%253Aachs%26aulast%3DHennequin%26aufirst%3DL.%2BF.%26aulast%3DAllen%26aufirst%3DJ.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DCurwen%26aufirst%3DJ.%26aulast%3DFennell%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DT.%2BP.%26aulast%3DLambert-van%2Bder%2BBrempt%26aufirst%3DC.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DOlivier%26aufirst%3DA.%26aulast%3DOtterbein%26aufirst%3DL.%26aulast%3DPle%26aufirst%3DP.%2BA.%26aulast%3DWarin%26aufirst%3DN.%26aulast%3DCostello%26aufirst%3DG.%26atitle%3DN-%25285-Chloro-1%252C3-benzodioxol-4-yl%2529-7-%255B2-%25284-methylpiperazin-1-yl%2529ethoxy%255D-5-%2528tetrahydro-2H-pyran-4-yloxy%2529quinazolin-4-amine%252C%2520a%2520novel%252C%2520highly%2520selective%252C%2520orally%2520available%252C%2520dual-specific%2520c-Src%252FAbl%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6465%26epage%3D6488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelias, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A small molecule−kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.-M.+Leliasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule%E2%88%92kinase+interaction+map+for+clinical+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DLelias%26aufirst%3DJ.-M.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule%25E2%2588%2592kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">1938</span><span class="NLM_x">–</span> <span class="NLM_lpage">1942</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1126%2Fscience.289.5486.1938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=10988075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2000&pages=1938-1942&author=T.+Schindlerauthor=W.+Bornmannauthor=P.+Pellicenaauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Structural+mechanism+for+STI-571+inhibition+of+Abelson+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase</span></div><div class="casAuthors">Schindler, Thomas; Bornmann, William; Pellicena, Patricia; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">5486</span>),
    <span class="NLM_cas:pages">1938-1942</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The inadvertent activation of the Abelson tyrosine kinase (Abl) causes chronic myelogenous leukemia (CML).  A small-mol. inhibitor of Abl (STI-571) is effective in the treatment of CML.  We report the crystal structure of the catalytic domain of Abl, complexed to a variant of STI-571.  Crit. to the binding of STI-571 is the adoption by the kinase of an inactive conformation, in which a centrally located "activation loop" is not phosphorylated.  The conformation of this loop is distinct from that in active protein kinases, as well as in the inactive form of the closely related Src kinases.  These results suggest that compds. that exploit the distinctive inactivation mechanisms of individual protein kinases can achieve both high affinity and high specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9eAZqIQ1aebVg90H21EOLACvtfcHk0lg5DISIB9PRVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D&md5=56bb233f010f099d0073020ac6b9db59</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1126%2Fscience.289.5486.1938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.289.5486.1938%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DStructural%2520mechanism%2520for%2520STI-571%2520inhibition%2520of%2520Abelson%2520tyrosine%2520kinase%26jtitle%3DScience%26date%3D2000%26volume%3D289%26spage%3D1938%26epage%3D1942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mol, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hosfield, D. J.</span><span> </span><span class="NLM_article-title">Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">639</span><span class="NLM_x">–</span> <span class="NLM_lpage">648</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=15503866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotl2js7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2004&pages=639-648&author=C.+D.+Molauthor=D.+Fabbroauthor=D.+J.+Hosfield&title=Structural+insights+into+the+conformational+selectivity+of+STI-571+and+related+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors</span></div><div class="casAuthors">Mol, Clifford D.; Fabbro, Doriano; Hosfield, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">639-648</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">1367-6733</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  STI-571 (Gleevec) is a highly successful cancer drug due to its activity as an inhibitor of the Abelson cytoplasmic tyrosine kinase (Abl), which is constitutively active in a majority of patients with chronic myelogenous leukemia.  STI-571 also inhibits two type III receptor tyrosine kinases, c-Kit and platelet-derived growth factor receptor, and functions by targeting inactive conformations of these kinases.  This review focuses on recent developments in x-ray co-crystal structure analyses of STI-571 bound to Abl and the c-Kit receptor tyrosine kinase domain, and also three other relevant kinase inhibitor co-crystal structures.  The similar structural features of these inactive kinases suggest they will be useful for the successful drug discovery and development of specific and targeted gene-based cancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg3Zb9Xj-aMrVg90H21EOLACvtfcHk0lg5DISIB9PRVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotl2js7k%253D&md5=52fc98230a940cfc2b24695f469fe8ca</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMol%26aufirst%3DC.%2BD.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DHosfield%26aufirst%3DD.%2BJ.%26atitle%3DStructural%2520insights%2520into%2520the%2520conformational%2520selectivity%2520of%2520STI-571%2520and%2520related%2520kinase%2520inhibitors%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2004%26volume%3D7%26spage%3D639%26epage%3D648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitenstein, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brueggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntly, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall-Meyers, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callahan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammed, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1016%2Fj.ccr.2005.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=15710326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=129-141&author=E.+Weisbergauthor=P.+W.+Manleyauthor=W.+Breitensteinauthor=J.+Brueggenauthor=S.+W.+Cowan-Jacobauthor=A.+Rayauthor=B.+Huntlyauthor=D.+Fabbroauthor=G.+Fendrichauthor=E.+Hall-Meyersauthor=A.+L.+Kungauthor=J.+Mestanauthor=G.+Q.+Daleyauthor=L.+Callahanauthor=L.+Catleyauthor=C.+Cavazzaauthor=A.+Mohammedauthor=D.+Neubergauthor=R.+D.+Wrightauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Characterization+of+AMN107%2C+a+selective+inhibitor+of+native+and+mutant+Bcr-Abl"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span></div><div class="casAuthors">Weisberg, Ellen; Manley, Paul W.; Breitenstein, Werner; Brueggen, Josef; Cowan-Jacob, Sandra W.; Ray, Arghya; Huntly, Brian; Fabbro, Doriano; Fendrich, Gabriele; Hall-Meyers, Elizabeth; Kung, Andrew L.; Mestan, Juergen; Daley, George Q.; Callahan, Linda; Catley, Laurie; Cavazza, Cara; Mohammed, Azam; Neuberg, Donna; Wright, Renee D.; Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-141</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-pos. (Ph+) acute lymphoblastic leukemia (ALL).  We describe a novel selective inhibitor of Bcr-Abl, AMN107 (IC50 < 30 nM), which is significantly more potent than imatinib, and active against a no. of imatinib-resistant Bcr-Abl mutants.  Crystallog. anal. of Abl-AMN107 complexes provides a structural explanation for the differential activity of AMN107 and imatinib against imatinib-resistant Bcr-Abl.  Consistent with its in vitro and pharmacokinetic profile, AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolonged survival in imatinib-resistant CML mouse models.  AMN107 is a promising new inhibitor for the therapy of CML and Ph+ ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow6QF3qX2uO7Vg90H21EOLACvtfcHk0li3NhV-5sURQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D&md5=d28e1a54b982951f8d3e6ef1d2d3b2eb</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DBreitenstein%26aufirst%3DW.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DHuntly%26aufirst%3DB.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DHall-Meyers%26aufirst%3DE.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DCallahan%26aufirst%3DL.%26aulast%3DCatley%26aufirst%3DL.%26aulast%3DCavazza%26aufirst%3DC.%26aulast%3DMohammed%26aufirst%3DA.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DWright%26aufirst%3DR.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DCharacterization%2520of%2520AMN107%252C%2520a%2520selective%2520inhibitor%2520of%2520native%2520and%2520mutant%2520Bcr-Abl%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D129%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Golemovic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verstovsek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manshouri, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alland, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arlinghaus, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beran, M.</span><span> </span><span class="NLM_article-title">AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">4941</span><span class="NLM_x">–</span> <span class="NLM_lpage">4947</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1158%2F1078-0432.CCR-04-2601" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2006&pages=4941-4947&author=M.+Golemovicauthor=S.+Verstovsekauthor=F.+Gilesauthor=J.+Cortesauthor=T.+Manshouriauthor=P.+W.+Manleyauthor=J.+Mestanauthor=M.+Duganauthor=L.+Allandauthor=J.+D.+Griffinauthor=R.+B.+Arlinghausauthor=T.+Sunauthor=H.+Kantarjianauthor=M.+Beran&title=AMN107%2C+a+novel+aminopyrimidine+inhibitor+of+Bcr-Abl%2C+has+in+vitro+activity+against+imatinib-resistant+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-2601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-2601%26sid%3Dliteratum%253Aachs%26aulast%3DGolemovic%26aufirst%3DM.%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DManshouri%26aufirst%3DT.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DDugan%26aufirst%3DM.%26aulast%3DAlland%26aufirst%3DL.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DArlinghaus%26aufirst%3DR.%2BB.%26aulast%3DSun%26aufirst%3DT.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DBeran%26aufirst%3DM.%26atitle%3DAMN107%252C%2520a%2520novel%2520aminopyrimidine%2520inhibitor%2520of%2520Bcr-Abl%252C%2520has%2520in%2520vitro%2520activity%2520against%2520imatinib-resistant%2520chronic%2520myeloid%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D11%26spage%3D4941%26epage%3D4947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span> </span><span class="NLM_article-title">Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Proteins Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1754</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1016%2Fj.bbapap.2005.07.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=16172030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlags7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1754&publication_year=2005&pages=3-13&author=P.+W.+Manleyauthor=S.+W.+Cowan-Jacobauthor=J.+Mestan&title=Advances+in+the+structural+biology%2C+design+and+clinical+development+of+Bcr-Abl+kinase+inhibitors+for+the+treatment+of+chronic+myeloid+leukaemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16cR"><div class="casContent"><span class="casTitleNuber">16c</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia</span></div><div class="casAuthors">Manley, Paul William; Cowan-Jacob, Sandra W.; Mestan, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1754</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">3-13</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The constitutively activated Abl tyrosine kinase domain of the chimeric Bcr-Abl oncoprotein is responsible for the transformation of hematopoietic stem cells and the symptoms of chronic myeloid leukemia (CML).  Imatinib targets the tyrosine kinase activity of Bcr-Abl and is a first-line therapy for this malignancy.  Although highly effective in chronic phase CML, patients who have progressed to the advanced phase of the disease frequently fail to respond to imatinib or develop resistance to therapy and relapse.  This is often due to the emergence of clones expressing mutant forms of Bcr-Abl, which exhibit a decreased sensitivity towards inhibition by imatinib.  Considerable progress has recently been made in understanding the structural biol. of Abl and the mol. basis for resistance, facilitating the discovery and development of second generation drugs designed to combat mutant forms of Bcr-Abl.  The first of these compds. to enter clin. development were BMS-354825 (BristolMyersSquibb) and AMN107 (Novartis Pharma) and, from Phase I results, both of these promise a breakthrough in the treatment of imatinib-resistant CML.  Recent advances with these and other promising classes of new CML drugs are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0fkeC4vxU_bVg90H21EOLACvtfcHk0li3NhV-5sURQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlags7fI&md5=b9d67d465f61804d2acd78605a4e9a75</span></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2005.07.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2005.07.040%26sid%3Dliteratum%253Aachs%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DMestan%26aufirst%3DJ.%26atitle%3DAdvances%2520in%2520the%2520structural%2520biology%252C%2520design%2520and%2520clinical%2520development%2520of%2520Bcr-Abl%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520chronic%2520myeloid%2520leukaemia%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2005%26volume%3D1754%26spage%3D3%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Horio, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naito, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayase, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niwa, T.</span><span> </span><span class="NLM_article-title">Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2712</span><span class="NLM_x">–</span> <span class="NLM_lpage">2717</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2712-2717&author=T.+Horioauthor=T.+Hamasakiauthor=T.+Inoueauthor=T.+Wakayamaauthor=S.+Itouauthor=H.+Naitoauthor=T.+Asakiauthor=H.+Hayaseauthor=T.+Niwa&title=Structural+factors+contributing+to+the+Abl%2FLyn+dual+inhibitory+activity+of+3-substituted+benzamide+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHorio%26aufirst%3DT.%26aulast%3DHamasaki%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DWakayama%26aufirst%3DT.%26aulast%3DItou%26aufirst%3DS.%26aulast%3DNaito%26aufirst%3DH.%26aulast%3DAsaki%26aufirst%3DT.%26aulast%3DHayase%26aufirst%3DH.%26aulast%3DNiwa%26aufirst%3DT.%26atitle%3DStructural%2520factors%2520contributing%2520to%2520the%2520Abl%252FLyn%2520dual%2520inhibitory%2520activity%2520of%25203-substituted%2520benzamide%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D2712%26epage%3D2717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Asaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higashioka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umehara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naito, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niwa, T.</span><span> </span><span class="NLM_article-title">Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1421</span><span class="NLM_x">–</span> <span class="NLM_lpage">1425</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=1421-1425&author=T.+Asakiauthor=Y.+Sugiyamaauthor=T.+Hamamotoauthor=M.+Higashiokaauthor=M.+Umeharaauthor=H.+Naitoauthor=T.+Niwa&title=Design+and+synthesis+of+3-substituted+benzamide+derivatives+as+Bcr-Abl+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAsaki%26aufirst%3DT.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DHamamoto%26aufirst%3DT.%26aulast%3DHigashioka%26aufirst%3DM.%26aulast%3DUmehara%26aufirst%3DM.%26aulast%3DNaito%26aufirst%3DH.%26aulast%3DNiwa%26aufirst%3DT.%26atitle%3DDesign%2520and%2520synthesis%2520of%25203-substituted%2520benzamide%2520derivatives%2520as%2520Bcr-Abl%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D1421%26epage%3D1425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kimura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naito, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuroda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuasa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokota, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamitsuji, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawata, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakaya, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naruoka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niwa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirabayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maekawa, T.</span><span> </span><span class="NLM_article-title">NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">3948</span><span class="NLM_x">–</span> <span class="NLM_lpage">3954</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=3948-3954&author=S.+Kimuraauthor=H.+Naitoauthor=H.+Segawaauthor=J.+Kurodaauthor=T.+Yuasaauthor=K.+Satoauthor=A.+Yokotaauthor=Y.+Kamitsujiauthor=E.+Kawataauthor=E.+Ashiharaauthor=Y.+Nakayaauthor=H.+Naruokaauthor=T.+Wakayamaauthor=K.+Nasuauthor=T.+Asakiauthor=T.+Niwaauthor=K.+Hirabayashiauthor=T.+Maekawa&title=NS-187%2C+a+potent+and+selective+dual+Bcr-Abl%2FLyn+tyrosine+kinase+inhibitor%2C+is+a+novel+agent+for+imatinib-resistant+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKimura%26aufirst%3DS.%26aulast%3DNaito%26aufirst%3DH.%26aulast%3DSegawa%26aufirst%3DH.%26aulast%3DKuroda%26aufirst%3DJ.%26aulast%3DYuasa%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DYokota%26aufirst%3DA.%26aulast%3DKamitsuji%26aufirst%3DY.%26aulast%3DKawata%26aufirst%3DE.%26aulast%3DAshihara%26aufirst%3DE.%26aulast%3DNakaya%26aufirst%3DY.%26aulast%3DNaruoka%26aufirst%3DH.%26aulast%3DWakayama%26aufirst%3DT.%26aulast%3DNasu%26aufirst%3DK.%26aulast%3DAsaki%26aufirst%3DT.%26aulast%3DNiwa%26aufirst%3DT.%26aulast%3DHirabayashi%26aufirst%3DK.%26aulast%3DMaekawa%26aufirst%3DT.%26atitle%3DNS-187%252C%2520a%2520potent%2520and%2520selective%2520dual%2520Bcr-Abl%252FLyn%2520tyrosine%2520kinase%2520inhibitor%252C%2520is%2520a%2520novel%2520agent%2520for%2520imatinib-resistant%2520leukemia%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D3948%26epage%3D3954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lowinger, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. A.</span><span> </span><span class="NLM_article-title">Design and discovery of small molecules targeting Raf-1 kinase</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2269</span><span class="NLM_x">–</span> <span class="NLM_lpage">2278</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.2174%2F1381612023393125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=12369855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD38XnvVGntrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=2269-2278&author=T.+B.+Lowingerauthor=B.+Riedlauthor=J.+Dumasauthor=R.+A.+Smith&title=Design+and+discovery+of+small+molecules+targeting+Raf-1+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">Design and discovery of small molecules targeting raf-1 kinase</span></div><div class="casAuthors">Lowinger, Timothy B.; Riedl, Bernd; Dumas, Jacques; Smith, Roger A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2269-2278</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review.  Raf kinase, an enzyme which acts downstream in the Ras signaling pathway, is involved in cancerous cell proliferation.  Thus, small mol. inhibitors of Raf kinase activity may be important agents for the treatment of cancer.  A novel class of Raf-1 inhibitors was discovered, using a combination of medicinal and combinatorial chem. approaches.  This effort culminated in the identification of the clin. candidate BAY 43-9006, currently undergoing Phase I clin. trials.  The present review summarizes the medicinal chem. development of ureas as highly potent inhibitors of Raf-1 kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqviNIBK_IYW7Vg90H21EOLACvtfcHk0li7NPY8OBN1cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnvVGntrk%253D&md5=a62445c3fb50083175ee4863ae84f6ce</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.2174%2F1381612023393125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612023393125%26sid%3Dliteratum%253Aachs%26aulast%3DLowinger%26aufirst%3DT.%2BB.%26aulast%3DRiedl%26aufirst%3DB.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26atitle%3DDesign%2520and%2520discovery%2520of%2520small%2520molecules%2520targeting%2520Raf-1%2520kinase%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2002%26volume%3D8%26spage%3D2269%26epage%3D2278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wan, P. T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barford, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">Mechanism of activation of the Raf-Erk signaling pathway by oncogenic mutations of B-Raf</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">855</span><span class="NLM_x">–</span> <span class="NLM_lpage">867</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1016%2FS0092-8674%2804%2900215-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=15035987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=855-867&author=P.+T.+C.+Wanauthor=M.+J.+Garnettauthor=S.+M.+Roeauthor=S.+Leeauthor=D.+Niculescu-Duvazauthor=V.+M.+Goodauthor=C.+M.+Jonesauthor=C.+J.+Marshallauthor=C.+J.+Springerauthor=D.+Barfordauthor=R.+Marais&title=Mechanism+of+activation+of+the+Raf-Erk+signaling+pathway+by+oncogenic+mutations+of+B-Raf"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span></div><div class="casAuthors">Wan, Paul T. C.; Garnett, Mathew J.; Roe, S. Mark; Lee, Sharlene; Niculescu-Duvaz, Dan; Good, Valerie M.; Project, Cancer Genome; Jones, C. Michael; Marshall, Christopher J.; Springer, Caroline J.; Barford, David; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">855-867</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Over 30 mutations of the B-RAF gene assocd. with human cancers have been identified, the majority of which are located within the kinase domain.  Here the authors show that of 22 B-RAF mutants analyzed, 18 have elevated kinase activity and signal to ERK in vivo.  Surprisingly, three mutants have reduced kinase activity towards MEK in vitro but, by activating C-RAF in vivo, signal to ERK in cells.  The structures of wild type and oncogenic V599EB-RAF kinase domains in complex with the RAF inhibitor BAY43-9006 show that the activation segment is held in an inactive conformation by assocn. with the P loop.  The clustering of most mutations to these two regions suggests that disruption of this interaction converts B-RAF into its active conformation.  The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYiQicwc1xVLVg90H21EOLACvtfcHk0li7NPY8OBN1cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D&md5=4cc020056c64e514286c000666da1972</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900215-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900215-6%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DP.%2BT.%2BC.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DGood%26aufirst%3DV.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BM.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DMechanism%2520of%2520activation%2520of%2520the%2520Raf-Erk%2520signaling%2520pathway%2520by%2520oncogenic%2520mutations%2520of%2520B-Raf%26jtitle%3DCell%26date%3D2004%26volume%3D116%26spage%3D855%26epage%3D867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Pargellis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Churchill, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirillo, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmore, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grob, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pav, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regan, J.</span><span> </span><span class="NLM_article-title">Inhibition of p38 Map kinase by utilizing a novel allosteric binding site</span> <span class="citation_source-journal">Nat. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">268</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1038%2Fnsb770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=11896401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=268-272&author=C.+Pargellisauthor=L.+Tongauthor=L.+Churchillauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=A.+G.+Grahamauthor=P.+M.+Grobauthor=E.+R.+Hickeyauthor=N.+Mossauthor=S.+Pavauthor=J.+Regan&title=Inhibition+of+p38+Map+kinase+by+utilizing+a+novel+allosteric+binding+site"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span></div><div class="casAuthors">Pargellis, Christopher; Tong, Liang; Churchill, Laurie; Cirillo, Pier F.; Gilmore, Thomas; Graham, Anne G.; Grob, Peter M.; Hickey, Eugene R.; Moss, Neil; Pav, Susan; Regan, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">268-272</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">The p38 MAP kinase plays a crucial role in regulating the prodn. of proinflammatory cytokines, such as tumor necrosis factor and interleukin-1.  Blocking this kinase may offer an effective therapy for treating many inflammatory diseases.  Here we report a new allosteric binding site for a diaryl urea class of highly potent and selective inhibitors against human p38 MAP kinase.  The formation of this binding site requires a large conformational change not obsd. previously for any of the protein Ser/Thr kinases.  This change is in the highly conserved Asp-Phe-Gly motif within the active site of the kinase.  Soln. studies demonstrate that this class of compds. has slow binding kinetics, consistent with the requirement for conformational change.  Improving interactions in this allosteric pocket, as well as establishing binding interactions in the ATP pocket, enhanced the affinity of the inhibitors by 12,000-fold.  One of the most potent compds. in this series, BIRB 796, has picomolar affinity for the kinase and low nanomolar inhibitory activity in cell culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT8_QT7_pbYrVg90H21EOLACvtfcHk0lhWgFtGXkZGAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D&md5=68850ecdbe08df4285ba38cfa2c93ea4</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnsb770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb770%26sid%3Dliteratum%253Aachs%26aulast%3DPargellis%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DChurchill%26aufirst%3DL.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DGrob%26aufirst%3DP.%2BM.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DMoss%26aufirst%3DN.%26aulast%3DPav%26aufirst%3DS.%26aulast%3DRegan%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520p38%2520Map%2520kinase%2520by%2520utilizing%2520a%2520novel%2520allosteric%2520binding%2520site%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2002%26volume%3D9%26spage%3D268%26epage%3D272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Dai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartandi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albert, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bousquet, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunha, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaser, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcotte, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moskey, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoll, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tapang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelides, M. R.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-(4-(3-amino-1<i>H</i>-indazol-4-yl)phenyl)-<i>N</i>'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1584</span><span class="NLM_x">–</span> <span class="NLM_lpage">1597</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm061280h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1584-1597&author=Y.+Daiauthor=K.+Hartandiauthor=Z.+Jiauthor=A.+A.+Ahmedauthor=D.+H.+Albertauthor=J.+L.+Bauchauthor=J.+J.+Bouskaauthor=P.+F.+Bousquetauthor=G.+A.+Cunhaauthor=K.+B.+Glaserauthor=C.+M.+Harrisauthor=D.+Hickmanauthor=J.+Guoauthor=J.+Liauthor=P.+A.+Marcotteauthor=K.+C.+Marshauthor=M.+D.+Moskeyauthor=R.+L.+Martinauthor=A.+M.+Olsonauthor=D.+J.+Osterlingauthor=L.+J.+Peaseauthor=N.+B.+Soniauthor=K.+D.+Stewartauthor=V.+S.+Stollauthor=P.+Tapangauthor=D.+R.+Reuterauthor=S.+K.+Davidsenauthor=M.+R.+Michaelides&title=Discovery+of+N-%284-%283-amino-1H-indazol-4-yl%29phenyl%29-N%27-%282-fluoro-5-methylphenyl%29urea+%28ABT-869%29%2C+a+3-aminoindazole-based+orally+active+multitargeted+receptor+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm061280h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061280h%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DY.%26aulast%3DHartandi%26aufirst%3DK.%26aulast%3DJi%26aufirst%3DZ.%26aulast%3DAhmed%26aufirst%3DA.%2BA.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DBauch%26aufirst%3DJ.%2BL.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DBousquet%26aufirst%3DP.%2BF.%26aulast%3DCunha%26aufirst%3DG.%2BA.%26aulast%3DGlaser%26aufirst%3DK.%2BB.%26aulast%3DHarris%26aufirst%3DC.%2BM.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMarcotte%26aufirst%3DP.%2BA.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DMoskey%26aufirst%3DM.%2BD.%26aulast%3DMartin%26aufirst%3DR.%2BL.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DPease%26aufirst%3DL.%2BJ.%26aulast%3DSoni%26aufirst%3DN.%2BB.%26aulast%3DStewart%26aufirst%3DK.%2BD.%26aulast%3DStoll%26aufirst%3DV.%2BS.%26aulast%3DTapang%26aufirst%3DP.%26aulast%3DReuter%26aufirst%3DD.%2BR.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26atitle%3DDiscovery%2520of%2520N-%25284-%25283-amino-1H-indazol-4-yl%2529phenyl%2529-N%2527-%25282-fluoro-5-methylphenyl%2529urea%2520%2528ABT-869%2529%252C%2520a%25203-aminoindazole-based%2520orally%2520active%2520multitargeted%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1584%26epage%3D1597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffregen, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdullah, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moseson, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohacek, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">2532</span><span class="NLM_x">–</span> <span class="NLM_lpage">2539</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2004&pages=2532-2539&author=T.+O%E2%80%99Hareauthor=R.+Pollockauthor=E.+P.+Stoffregenauthor=J.+A.+Keatsauthor=O.+M.+Abdullahauthor=E.+M.+Mosesonauthor=V.+M.+Riveraauthor=H.+Tangauthor=C.+A.+Metcalfauthor=R.+S.+Bohacekauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=W.+C.+Shakespeareauthor=D.+Dalgarnoauthor=T.+Clacksonauthor=T.+K.+Sawyerauthor=M.+W.+Deiningerauthor=B.+J.+Druker&title=Inhibition+of+wild-type+and+mutant+Bcr-Abl+by+AP23464%2C+a+potent+ATP-based+oncogenic+protein+kinase+inhibitor%3A+implications+for+CML"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DPollock%26aufirst%3DR.%26aulast%3DStoffregen%26aufirst%3DE.%2BP.%26aulast%3DKeats%26aufirst%3DJ.%2BA.%26aulast%3DAbdullah%26aufirst%3DO.%2BM.%26aulast%3DMoseson%26aufirst%3DE.%2BM.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DBohacek%26aufirst%3DR.%2BS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DInhibition%2520of%2520wild-type%2520and%2520mutant%2520Bcr-Abl%2520by%2520AP23464%252C%2520a%2520potent%2520ATP-based%2520oncogenic%2520protein%2520kinase%2520inhibitor%253A%2520implications%2520for%2520CML%26jtitle%3DBlood%26date%3D2004%26volume%3D104%26spage%3D2532%26epage%3D2539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohacek, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span> </span><span class="NLM_article-title">Activity of dual Src-Abl inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">9244</span><span class="NLM_x">–</span> <span class="NLM_lpage">9249</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=9244-9249&author=M.+Azamauthor=V.+Nardiauthor=W.+C.+Shakespeareauthor=C.+A.+Metcalfauthor=R.+S.+Bohacekauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=P.+Slizauthor=D.+R.+Veachauthor=W.+G.+Bornmannauthor=B.+Clarksonauthor=D.+C.+Dalgarnoauthor=T.+K.+Sawyerauthor=G.+Q.+Daley&title=Activity+of+dual+Src-Abl+inhibitors+highlights+the+role+of+BCR%2FABL+kinase+dynamics+in+drug+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DNardi%26aufirst%3DV.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DBohacek%26aufirst%3DR.%2BS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DSliz%26aufirst%3DP.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26atitle%3DActivity%2520of%2520dual%2520Src-Abl%2520inhibitors%2520highlights%2520the%2520role%2520of%2520BCR%252FABL%2520kinase%2520dynamics%2520in%2520drug%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D9244%26epage%3D9249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lentini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broudy, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russian, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span> </span><span class="NLM_article-title">Novel <i>N</i><sup>9</sup>-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4907</span><span class="NLM_x">–</span> <span class="NLM_lpage">4912</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4907-4912&author=Y.+Wangauthor=W.+C.+Shakespeareauthor=W.-S.+Huangauthor=R.+Sundaramoorthiauthor=S.+Lentiniauthor=S.+Dasauthor=S.+Liuauthor=G.+Bandaauthor=D.+Wenauthor=X.+Zhuauthor=Q.+Xuauthor=J.+Keatsauthor=F.+Wangauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+T.+Snodgrassauthor=M.+I.+Broudyauthor=K.+Russianauthor=D.+Dalgarnoauthor=T.+Clacksonauthor=T.+K.+Sawyer&title=Novel+N9-arenethenyl+purines+as+potent+dual+Src%2FAbl+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DLentini%26aufirst%3DS.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DBanda%26aufirst%3DG.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSnodgrass%26aufirst%3DJ.%2BT.%26aulast%3DBroudy%26aufirst%3DM.%2BI.%26aulast%3DRussian%26aufirst%3DK.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26atitle%3DNovel%2520N9-arenethenyl%2520purines%2520as%2520potent%2520dual%2520Src%252FAbl%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4907%26epage%3D4912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Rational design of inhibitors that bind to inactive kinase conformations</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1038%2Fnchembio799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=16783341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=358-364&author=Y.+Liuauthor=N.+S.+Gray&title=Rational+design+of+inhibitors+that+bind+to+inactive+kinase+conformations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23aR"><div class="casContent"><span class="casTitleNuber">23a</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of inhibitors that bind to inactive kinase conformations</span></div><div class="casAuthors">Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">358-364</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The majority of kinase inhibitors, known as type I inhibitors that have been developed so far target the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated.  Recently, crystal structures of inhibitors such as imatinib, BIRB796, and sorafenib (BAY43-9006), known as type II inhibitors, have revealed a new binding mode that exploits an addnl. binding site immediately adjacent to the region occupied by ATP.  This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation.  The examn. of binding features of known type II inhibitors is discussed and a pharmacophore model currently used in the design of a new generation of structurally diverse type II inhibitors is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxahsMPlhgDbVg90H21EOLACvtfcHk0lhzDMySK-ComQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D&md5=4a9347a44a2cf4a412c9741fdcc5696b</span></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=10.1038%2Fnchembio799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio799%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DRational%2520design%2520of%2520inhibitors%2520that%2520bind%2520to%2520inactive%2520kinase%2520conformations%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26spage%3D358%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Okram, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagle, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spraggon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">A general strategy for creating “inactive-conformation” Abl inhibitors</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">779</span><span class="NLM_x">–</span> <span class="NLM_lpage">786</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1016%2Fj.chembiol.2006.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=16873026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD28XntlGisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=779-786&author=B.+Okramauthor=A.+Nagleauthor=F.+J.+Adrianauthor=C.+Leeauthor=P.+Renauthor=X.+Wangauthor=T.+Simauthor=Y.+Xieauthor=X.+Wangauthor=G.+Xiaauthor=G.+Spraggonauthor=M.+Warmuthauthor=Y.+Liuauthor=N.+S.+Gray&title=A+general+strategy+for+creating+%E2%80%9Cinactive-conformation%E2%80%9D+Abl+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23bR"><div class="casContent"><span class="casTitleNuber">23b</span><div class="casTitle"><span class="NLM_cas:atitle">A General Strategy for Creating "Inactive-Conformation" Abl Inhibitors</span></div><div class="casAuthors">Okram, Barun; Nagle, Advait; Adrian, Francisco J.; Lee, Christian; Ren, Pingda; Wang, Xia; Sim, Taebo; Xie, Yongping; Wang, Xing; Xia, Gang; Spraggon, Glen; Warmuth, Markus; Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">779-786</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Kinase inhibitors that bind to the ATP cleft can be broadly classified into two groups: Those that bind exclusively to the ATP site with the kinase assuming a conformation otherwise conducive to phosphotransfer (type I), and those that exploit a hydrophobic site immediately adjacent to the ATP pocket made accessible by a conformational rearrangement of the activation loop (type II).  To date, all type II inhibitors were discovered by using structure-activity-guided optimization strategies.  Here, we describe a general pharmacophore model of type II inhibition that enables a rational "hybrid-design" approach whereby a 3-trifluoromethylbenzamide functionality is appended to four distinct type I scaffolds in order to convert them into their corresponding type II counterparts.  We demonstrate that the designed compds. function as type II inhibitors by using biochem. and cellular kinase assays and by cocrystallog. with Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEmN-Rh-LxOLVg90H21EOLACvtfcHk0lhzDMySK-ComQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntlGisL0%253D&md5=84514353c00e20f85225f62d00dc2529</span></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2006.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2006.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DOkram%26aufirst%3DB.%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DAdrian%26aufirst%3DF.%2BJ.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DSpraggon%26aufirst%3DG.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DA%2520general%2520strategy%2520for%2520creating%2520%25E2%2580%259Cinactive-conformation%25E2%2580%259D%2520Abl%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2006%26volume%3D13%26spage%3D779%26epage%3D786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Sherman, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friesner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farid, R.</span><span> </span><span class="NLM_article-title">Novel procedure for modeling ligand/receptor induced fit effects</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">534</span><span class="NLM_x">–</span> <span class="NLM_lpage">553</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050540c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlCgsr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=534-553&author=W.+Shermanauthor=T.+Dayauthor=M.+P.+Jacobsonauthor=R.+A.+Friesnerauthor=R.+Farid&title=Novel+procedure+for+modeling+ligand%2Freceptor+induced+fit+effects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Procedure for Modeling Ligand/Receptor Induced Fit Effects</span></div><div class="casAuthors">Sherman, Woody; Day, Tyler; Jacobson, Matthew P.; Friesner, Richard A.; Farid, Ramy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">534-553</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present a novel protein-ligand docking method that accurately accounts for both ligand and receptor flexibility by iteratively combining rigid receptor docking (Glide) with protein structure prediction (Prime) techniques.  While traditional rigid-receptor docking methods are useful when the receptor structure does not change substantially upon ligand binding, success is limited when the protein must be "induced" into the correct binding conformation for a given ligand.  We provide an in-depth description of our novel methodol. and present results for 21 pharmaceutically relevant examples.  Traditional rigid-receptor docking for these 21 cases yields an av. RMSD of 5.5 Å.  The av. ligand RMSD for docking to a flexible receptor for the 21 pairs is 1.4 Å; the RMSD is ≤1.8 Å for 18 of the cases.  For the three cases with RMSDs greater than 1.8 Å, the core of the ligand is properly docked and all key protein/ligand interactions are captured.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm3E6ctnPGSrVg90H21EOLACvtfcHk0ljk3elgMusWEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlCgsr7I&md5=388811ead5cee1fd460951263de486cb</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm050540c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050540c%26sid%3Dliteratum%253Aachs%26aulast%3DSherman%26aufirst%3DW.%26aulast%3DDay%26aufirst%3DT.%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DFarid%26aufirst%3DR.%26atitle%3DNovel%2520procedure%2520for%2520modeling%2520ligand%252Freceptor%2520induced%2520fit%2520effects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D534%26epage%3D553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stehle, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schelling, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Schravendijk, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrade, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grossman, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacNeil, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keenan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohacek, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weigele, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T.</span><span> </span><span class="NLM_article-title">Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">46</span><span class="NLM_x">–</span> <span class="NLM_lpage">57</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1111%2Fj.1747-0285.2005.00316.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=16492148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsVSjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2006&pages=46-57&author=D.+Dalgarnoauthor=T.+Stehleauthor=S.+Narulaauthor=P.+Schellingauthor=M.+R.+van+Schravendijkauthor=S.+Adamsauthor=L.+Andradeauthor=J.+Keatsauthor=M.+Ramauthor=L.+Jinauthor=T.+Grossmanauthor=I.+MacNeilauthor=C.+Metcalfauthor=W.+Shakespeareauthor=Y.+Wangauthor=T.+Keenanauthor=R.+Sundaramoorthiauthor=R.+Bohacekauthor=M.+Weigeleauthor=T.+Sawyer&title=Structural+basis+of+Src+tyrosine+kinase+inhibition+with+a+new+class+of+potent+and+selective+trisubstituted+purine-based+compounds"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds</span></div><div class="casAuthors">Dalgarno, David; Stehle, Thilo; Narula, Surinder; Schelling, Pierre; van Schravendijk, Marie Rose; Adams, Susan; Andrade, Lawrence; Keats, Jeff; Ram, Mary; Jin, Lei; Grossman, Trudy; MacNeil, Ian; Metcalf, Chester, III; Shakespeare, William; Wang, Yihan; Keenan, Terry; Sundaramoorthi, Raji; Bohacek, Regine; Weigele, Manfred; Sawyer, Tomi</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-57</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The tyrosine kinase pp60src (Src) is the prototypical member of a family of proteins that participate in a broad array of cellular signal transduction processes, including cell growth, differentiation, survival, adhesion, and migration.  Abnormal Src family kinase (SFK) signaling has been linked to several disease states, including osteoporosis and cancer metastases.  Src has thus emerged as a mol. target for the discovery of small-mol. inhibitors that regulate Src kinase activity by binding to the ATP pocket within the catalytic domain.  Here, we present crystal structures of the kinase domain of Src in complex with two purine-based inhibitors: AP23451, a small-mol. inhibitor designed to inhibit Src-dependent bone resorption, and AP23464, a small-mol. inhibitor designed to inhibit the Src-dependent metastatic spread of cancer.  In each case, a trisubstituted purine template core was elaborated using structure-based drug design to yield a potent Src kinase inhibitor.  These structures represent early examples of high affinity purine-based Src family kinase-inhibitor complexes, and they provide a detailed view of the specific protein-ligand interactions that lead to potent inhibition of Src.  In particular, the 3-hydroxyphenethyl N9 substituent of AP23464 forms unique interactions with the protein that are crit. to the picomolar affinity of this compd. for Src.  The comparison of these new structures with two relevant kinase-inhibitor complexes provides a structural basis for the obsd. kinase inhibitory selectivity.  Further comparisons reveal a concerted induced-fit movement between the N- and C-terminal lobes of the kinase that correlates with the affinity of the ligand.  Binding of the most potent inhibitor, AP23464, results in the largest induced-fit movement, which can be directly linked to interactions of the hydrophenethyl N9 substituent with a region at the interface between the two lobes.  A less pronounced induced-fit movement is also obsd. in the Src-AP23451 complex.  These new structures illustrate how the combination of structural, computational, and medicinal chem. can be used to rationalize the process of developing high affinity, selective tyrosine kinase inhibitors as potential therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqAcWZyLy8JrVg90H21EOLACvtfcHk0ljk3elgMusWEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsVSjt7Y%253D&md5=5a89de976e29e65aec0553c84e2e0b92</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2005.00316.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2005.00316.x%26sid%3Dliteratum%253Aachs%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DStehle%26aufirst%3DT.%26aulast%3DNarula%26aufirst%3DS.%26aulast%3DSchelling%26aufirst%3DP.%26aulast%3Dvan%2BSchravendijk%26aufirst%3DM.%2BR.%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DAndrade%26aufirst%3DL.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DRam%26aufirst%3DM.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DGrossman%26aufirst%3DT.%26aulast%3DMacNeil%26aufirst%3DI.%26aulast%3DMetcalf%26aufirst%3DC.%26aulast%3DShakespeare%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKeenan%26aufirst%3DT.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DBohacek%26aufirst%3DR.%26aulast%3DWeigele%26aufirst%3DM.%26aulast%3DSawyer%26aufirst%3DT.%26atitle%3DStructural%2520basis%2520of%2520Src%2520tyrosine%2520kinase%2520inhibition%2520with%2520a%2520new%2520class%2520of%2520potent%2520and%2520selective%2520trisubstituted%2520purine-based%2520compounds%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2006%26volume%3D67%26spage%3D46%26epage%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Boesen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madsen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henriksen, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahl, O.</span><span> </span><span class="NLM_article-title">Preparation of <i>N</i>-(alk-1-enyl) nucleobase compounds by Horner and Horner−Wadsworth−Emmons reactions</span> <span class="citation_source-journal">J. Chem. Soc., Perkin Trans. 1</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_fpage">2015</span><span class="NLM_x">–</span> <span class="NLM_lpage">2021</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&pages=2015-2021&author=T.+Boesenauthor=C.+Madsenauthor=U.+Henriksenauthor=O.+Dahl&title=Preparation+of+N-%28alk-1-enyl%29+nucleobase+compounds+by+Horner+and+Horner%E2%88%92Wadsworth%E2%88%92Emmons+reactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoesen%26aufirst%3DT.%26aulast%3DMadsen%26aufirst%3DC.%26aulast%3DHenriksen%26aufirst%3DU.%26aulast%3DDahl%26aufirst%3DO.%26atitle%3DPreparation%2520of%2520N-%2528alk-1-enyl%2529%2520nucleobase%2520compounds%2520by%2520Horner%2520and%2520Horner%25E2%2588%2592Wadsworth%25E2%2588%2592Emmons%2520reactions%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%26date%3D2000%26spage%3D2015%26epage%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Huang, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lentini, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span> </span><span class="NLM_article-title">Facile synthesis of 9-(arenethenyl)purines via Heck reaction of 9-vinylpurines and aryl halides</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">7388</span><span class="NLM_x">–</span> <span class="NLM_lpage">7391</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=7388-7391&author=W.-S.+Huangauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=R.+M.+Thomasauthor=D.+Wenauthor=S.+Liuauthor=S.+P.+Lentiniauthor=S.+Dasauthor=G.+Bandaauthor=T.+K.+Sawyerauthor=W.+C.+Shakespeare&title=Facile+synthesis+of+9-%28arenethenyl%29purines+via+Heck+reaction+of+9-vinylpurines+and+aryl+halides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DR.%2BM.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLentini%26aufirst%3DS.%2BP.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DBanda%26aufirst%3DG.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DFacile%2520synthesis%2520of%25209-%2528arenethenyl%2529purines%2520via%2520Heck%2520reaction%2520of%25209-vinylpurines%2520and%2520aryl%2520halides%26jtitle%3DTetrahedron%2520Lett.%26date%3D2007%26volume%3D48%26spage%3D7388%26epage%3D7391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Pitha, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ts’o, P. O. P.</span><span> </span><span class="NLM_article-title"><i>N</i>-Vinyl derivatives of substituted pyrimidines and purines</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1968</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1341</span><span class="NLM_x">–</span> <span class="NLM_lpage">1344</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo01268a006" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1968&pages=1341-1344&author=J.+Pithaauthor=P.+O.+P.+Ts%E2%80%99o&title=N-Vinyl+derivatives+of+substituted+pyrimidines+and+purines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjo01268a006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo01268a006%26sid%3Dliteratum%253Aachs%26aulast%3DPitha%26aufirst%3DJ.%26aulast%3DTs%25E2%2580%2599o%26aufirst%3DP.%2BO.%2BP.%26atitle%3DN-Vinyl%2520derivatives%2520of%2520substituted%2520pyrimidines%2520and%2520purines%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1968%26volume%3D33%26spage%3D1341%26epage%3D1344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Huang, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span> </span><span class="NLM_article-title">An efficient synthesis of nilotinib (AMN107)</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_fpage">2121</span><span class="NLM_x">–</span> <span class="NLM_lpage">2124</span><div class="note"><p class="first last"> and references cited therein</p></div></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1055%2Fs-2007-983754" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpslCjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&pages=2121-2124&author=W.-S.+Huangauthor=W.+C.+Shakespeare&title=An+efficient+synthesis+of+nilotinib+%28AMN107%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">An efficient synthesis of nilotinib (AMN107)</span></div><div class="casAuthors">Huang, Wei-Sheng; Shakespeare, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2121-2124</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">A concise synthesis of AMN107, a compd. currently undergoing several phase II/III clin. trials for chronic myelogenous leukemia, is described.  The new procedure reduces the no. of synthetic steps from eight to four, with an overall yield of 65%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVk1pQeYvBWbVg90H21EOLACvtfcHk0lhJb6oClihZ6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpslCjtbY%253D&md5=4ca31907c33acd3510b7dcfa4e70374c</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1055%2Fs-2007-983754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2007-983754%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DAn%2520efficient%2520synthesis%2520of%2520nilotinib%2520%2528AMN107%2529%26jtitle%3DSynthesis%26date%3D2007%26spage%3D2121%26epage%3D2124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Pierce, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ter Haar, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binch, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, P.</span><span> </span><span class="NLM_article-title">CH···O and CH···N hydrogen bonds in ligand design: A novel quinazolin-4-ylthiazol-2-ylamine protein kinase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1278</span><span class="NLM_x">–</span> <span class="NLM_lpage">1281</span><div class="note"><p class="first last">and references cited therein</p></div></span><div class="citationLinks">[<a href="/doi/10.1021/jm0492249" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1278-1281&author=A.+C.+Pierceauthor=E.+ter+Haarauthor=H.+M.+Binchauthor=D.+P.+Kayauthor=S.+R.+Patelauthor=P.+Li&title=CH%C2%B7%C2%B7%C2%B7O+and+CH%C2%B7%C2%B7%C2%B7N+hydrogen+bonds+in+ligand+design%3A+A+novel+quinazolin-4-ylthiazol-2-ylamine+protein+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm0492249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0492249%26sid%3Dliteratum%253Aachs%26aulast%3DPierce%26aufirst%3DA.%2BC.%26aulast%3Dter%2BHaar%26aufirst%3DE.%26aulast%3DBinch%26aufirst%3DH.%2BM.%26aulast%3DKay%26aufirst%3DD.%2BP.%26aulast%3DPatel%26aufirst%3DS.%2BR.%26aulast%3DLi%26aufirst%3DP.%26atitle%3DCH%25C2%25B7%25C2%25B7%25C2%25B7O%2520and%2520CH%25C2%25B7%25C2%25B7%25C2%25B7N%2520hydrogen%2520bonds%2520in%2520ligand%2520design%253A%2520A%2520novel%2520quinazolin-4-ylthiazol-2-ylamine%2520protein%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1278%26epage%3D1281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Daylight Chemical Information System, Inc.</span><a href="http://www.daylight.com" class="extLink">http://www.daylight.com</a>, accessed March 2005.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Daylight+Chemical+Information+System%2C+Inc.http%3A%2F%2Fwww.daylight.com%2C+accessed+March+2005."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Seeliger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">299</span><span class="NLM_x">–</span> <span class="NLM_lpage">311</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1016%2Fj.str.2007.01.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=17355866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisleisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=299-311&author=M.+A.+Seeligerauthor=B.+Nagarauthor=F.+Frankauthor=X.+Caoauthor=M.+N.+Hendersonauthor=J.+Kuriyan&title=c-Src+binds+to+the+cancer+drug+imatinib+with+an+inactive+Abl%2Fc-Kit+conformation+and+a+distributed+thermodynamic+penalty"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32aR"><div class="casContent"><span class="casTitleNuber">32a</span><div class="casTitle"><span class="NLM_cas:atitle">c-Src Binds to the Cancer Drug Imatinib with an Inactive Abl/c-Kit Conformation and a Distributed Thermodynamic Penalty</span></div><div class="casAuthors">Seeliger, Markus A.; Nagar, Bhushan; Frank, Filipp; Cao, Xiaoxian; Henderson, M. Nidanie; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">299-311</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The cancer drug imatinib inhibits the tyrosine kinases c-Abl, c-Kit, and the PDGF receptor.  Imatinib is less effective against c-Src, which is difficult to understand because residues interacting with imatinib in crystal structures of Abl and c-Kit are conserved in c-Src.  The crystal structure of the c-Src kinase domain in complex with imatinib closely resembles that of Abl•imatinib and c-Kit•imatinib, and differs significantly from the inactive "Src/CDK" conformation of the Src family kinases.  Attempts to increase the affinity of c-Src for imatinib by swapping residues with the corresponding residues in Abl have not been successful, suggesting that the thermodn. penalty for adoption of the imatinib-binding conformation by c-Src is distributed over a broad region of the structure.  Two mutations that are expected to destabilize the inactive Src/CDK conformation increase drug sensitivity 15-fold, suggesting that the free-energy balance between different inactive states is a key to imatinib binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2SQGjjXdg1LVg90H21EOLACvtfcHk0lhJb6oClihZ6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisleisbY%253D&md5=ddfbcf06d91b408ca5fb25af9774c334</span></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2007.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2007.01.015%26sid%3Dliteratum%253Aachs%26aulast%3DSeeliger%26aufirst%3DM.%2BA.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DFrank%26aufirst%3DF.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DHenderson%26aufirst%3DM.%2BN.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3Dc-Src%2520binds%2520to%2520the%2520cancer%2520drug%2520imatinib%2520with%2520an%2520inactive%2520Abl%252Fc-Kit%2520conformation%2520and%2520a%2520distributed%2520thermodynamic%2520penalty%26jtitle%3DStructure%26date%3D2007%26volume%3D15%26spage%3D299%26epage%3D311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Levinson, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuchment, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koldobskiy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karplus, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J. A</span><span> </span><span class="NLM_article-title">Src-like inactive conformation in the Abl tyrosine kinase domain</span> <span class="citation_source-journal">PLoS Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">753</span><span class="NLM_x">–</span> <span class="NLM_lpage">767</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2006&pages=753-767&author=N.+M.+Levinsonauthor=O.+Kuchmentauthor=K.+Shenauthor=M.+A.+Youngauthor=M.+Koldobskiyauthor=M.+Karplusauthor=P.+A.+Coleauthor=J.+A+Kuriyan&title=Src-like+inactive+conformation+in+the+Abl+tyrosine+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLevinson%26aufirst%3DN.%2BM.%26aulast%3DKuchment%26aufirst%3DO.%26aulast%3DShen%26aufirst%3DK.%26aulast%3DYoung%26aufirst%3DM.%2BA.%26aulast%3DKoldobskiy%26aufirst%3DM.%26aulast%3DKarplus%26aufirst%3DM.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DKuriyan%26aufirst%3DJ.%2BA%26atitle%3DSrc-like%2520inactive%2520conformation%2520in%2520the%2520Abl%2520tyrosine%2520kinase%2520domain%26jtitle%3DPLoS%2520Biol.%26date%3D2006%26volume%3D4%26spage%3D753%26epage%3D767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">4236</span><span class="NLM_x">–</span> <span class="NLM_lpage">4243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=12154025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4236-4243&author=B.+Nagarauthor=W.+G.+Bornmannauthor=P.+Pellicenaauthor=T.+Schindlerauthor=D.+R.+Veachauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Crystal+structures+of+the+kinase+domain+of+c-Abl+in+complex+with+the+small+molecule+inhibitors+PD173955+and+imatinib+%28STI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32cR"><div class="casContent"><span class="casTitleNuber">32c</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span></div><div class="casAuthors">Nagar, Bhushan; Bornmann, William G.; Pellicena, Patricia; Schindler, Thomas; Veach, Darren R.; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4236-4243</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia.  Small mol. inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia.  We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).  Both compds. bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways.  As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate.  In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase.  The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex.  In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571.  The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5qYZHMOZCrVg90H21EOLACvtfcHk0lgHJt0TgO5oWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D&md5=843213cd6038ed82a0e43dce56e81a91</span></div><a href="/servlet/linkout?suffix=cit32c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structures%2520of%2520the%2520kinase%2520domain%2520of%2520c-Abl%2520in%2520complex%2520with%2520the%2520small%2520molecule%2520inhibitors%2520PD173955%2520and%2520imatinib%2520%2528STI-571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D4236%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jahnke, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liebetanz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span> </span><span class="NLM_article-title">The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">861</span><span class="NLM_x">–</span> <span class="NLM_lpage">871</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32d&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1016%2Fj.str.2005.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32d&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=15939018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32d&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltFCksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=861-871&author=S.+W.+Cowan-Jacobauthor=G.+Fendrichauthor=P.+W.+Manleyauthor=W.+Jahnkeauthor=D.+Fabbroauthor=J.+Liebetanzauthor=T.+Meyer&title=The+crystal+structure+of+a+c-Src+complex+in+an+active+conformation+suggests+possible+steps+in+c-Src+activation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32dR"><div class="casContent"><span class="casTitleNuber">32d</span><div class="casTitle"><span class="NLM_cas:atitle">The Crystal Structure of a c-Src Complex in an Active Conformation Suggests Possible Steps in c-Src Activation</span></div><div class="casAuthors">Cowan-Jacob, Sandra W.; Fendrich, Gabriele; Manley, Paul W.; Jahnke, Wolfgang; Fabbro, Doriano; Liebetanz, Janis; Meyer, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">861-871</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The regulation of the activity of Abl and Src family tyrosine kinases is mediated by intramol. interactions between the SH3, SH2, and kinase (SH1) domains.  We have detd. the crystal structure of an unphosphorylated form of c-Src in which the SH2 domain is not bound to the C-terminal tail.  This results in an open structure where the kinase domain adopts an active conformation and the C terminus binds within a hydrophobic pocket in the C-terminal lobe.  NMR binding studies support the hypothesis that an N-terminal myristate could bind in this pocket, as obsd. for Abl, suggesting that c-Src may also be regulated by myristate binding.  In addn., the structure contains a des-Me analog of the antileukemia drug imatinib (STI571; Gleevec).  This structure reveals why the drug shows a low affinity for active kinase conformations, contributing to its excellent kinase selectivity profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpipzhBFIZrQ7Vg90H21EOLACvtfcHk0lgHJt0TgO5oWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltFCksLk%253D&md5=f0de83e5bca45fe96795e5327e6d1369</span></div><a href="/servlet/linkout?suffix=cit32d&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2005.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2005.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DLiebetanz%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DT.%26atitle%3DThe%2520crystal%2520structure%2520of%2520a%2520c-Src%2520complex%2520in%2520an%2520active%2520conformation%2520suggests%2520possible%2520steps%2520in%2520c-Src%2520activation%26jtitle%3DStructure%26date%3D2005%26volume%3D13%26spage%3D861%26epage%3D871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Dar, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Small molecule recognition of c-Src via the Imatinib-binding conformation</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1015</span><span class="NLM_x">–</span> <span class="NLM_lpage">1022</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm900166t&amp;key=10.1016%2Fj.chembiol.2008.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm900166t&amp;key=18940662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1KmsrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=1015-1022&author=A.+C.+Darauthor=M.+S.+Lopezauthor=K.+M.+Shokat&title=Small+molecule+recognition+of+c-Src+via+the+Imatinib-binding+conformation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Recognition of c-Src via the Imatinib-Binding Conformation</span></div><div class="casAuthors">Dar, Arvin C.; Lopez, Michael S.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1015-1022</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The cancer drug, Imatinib, is a selective Abl kinase inhibitor that does not inhibit the closely related kinase c-Src.  This one drug and its ability to selectively inhibit Abl over c-Src has been a guiding principle in virtually all kinase drug discovery efforts in the last 15 years.  A prominent hypothesis explaining the selectivity of Imatinib is that Abl has an intrinsic ability to adopt an inactive conformation (termed DFG-out), whereas c-Src appears to pay a high intrinsic energetic penalty for adopting this conformation, effectively excluding Imatinib from its ATP pocket.  This explanation of the difference in binding affinity of Imatinib for Abl vs. c-Src makes the striking prediction that it would not be possible to design an inhibitor that binds to the DFG-out conformation of c-Src with high affinity.  The authors report the discovery of a series of such inhibitors.  The authors use structure-activity relationships and x-ray crystallog. to confirm the authors' findings.  These studies suggest that small mols. are capable of inducing the generally unfavorable DFG-out conformation in c-Src.  Structural comparison between c-Src in complex with these inhibitors allows the authors to speculate on the differential selectivity of Imatinib for c-Src and Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgbxnfmxtR-LVg90H21EOLACvtfcHk0lgHJt0TgO5oWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1KmsrfP&md5=f1047f4a56359511939164a3c2604cb6</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2008.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2008.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DDar%26aufirst%3DA.%2BC.%26aulast%3DLopez%26aufirst%3DM.%2BS.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DSmall%2520molecule%2520recognition%2520of%2520c-Src%2520via%2520the%2520Imatinib-binding%2520conformation%26jtitle%3DChem.%2520Biol.%26date%3D2008%26volume%3D15%26spage%3D1015%26epage%3D1022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">DiMauro, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newcomb, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nunes, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bemis, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boucher, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchanan, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckner, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cee, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deak, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epstein, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faust, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geuns-Meyer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henkle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodous, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masse, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGowan, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgenstern, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliveira, dos Santos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powers, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlinson, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tudor, Y.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turci, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welcher, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span> </span><span class="NLM_article-title">Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: Synthesis, SAR, and in vivo anti-inflammatory activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">5671</span><span class="NLM_x">–</span> <span class="NLM_lpage">5686</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0605482" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm900166t&amp;key=1%3ACAS%3A528%3ADC%252BD28XosVChsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5671-5686&author=E.+F.+DiMauroauthor=J.+Newcombauthor=J.+J.+Nunesauthor=J.+E.+Bemisauthor=C.+Boucherauthor=J.+L.+Buchananauthor=W.+H.+Bucknerauthor=V.+J.+Ceeauthor=L.+Chaiauthor=H.+L.+Deakauthor=L.+Epsteinauthor=T.+Faustauthor=P.+Gallantauthor=S.+D.+Geuns-Meyerauthor=A.+Goreauthor=Y.+Guauthor=B.+Henkleauthor=B.+L.+Hodousauthor=F.+Hsiehauthor=X.+Huangauthor=J.+L.+Kimauthor=J.+Leeauthor=M.+W.+Martinauthor=C.+E.+Masseauthor=D.+C.+McGowanauthor=D.+Metzauthor=D.+Mohnauthor=K.+A.+Morgensternauthor=A.+Oliveira%2C+dos+Santosauthor=V.+F.+Patelauthor=D.+Powersauthor=P.+E.+Roseauthor=S.+Schneiderauthor=S.+A.+Tomlinsonauthor=Y.-Y.+Tudorauthor=S.+M.+Turciauthor=A.+A.+Welcherauthor=R.+D.+Whiteauthor=H.+Zhaoauthor=L.+Zhuauthor=X.+Zhu&title=Discovery+of+aminoquinazolines+as+potent%2C+orally+bioavailable+inhibitors+of+Lck%3A+Synthesis%2C+SAR%2C+and+in+vivo+anti-inflammatory+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Aminoquinazolines as Potent, Orally Bioavailable Inhibitors of Lck: Synthesis, SAR, and in Vivo Anti-Inflammatory Activity</span></div><div class="casAuthors">DiMauro, Erin F.; Newcomb, John; Nunes, Joseph J.; Bemis, Jean E.; Boucher, Christina; Buchanan, John L.; Buckner, William H.; Cee, Victor J.; Chai, Lilly; Deak, Holly L.; Epstein, Linda F.; Faust, Ted; Gallant, Paul; Geuns-Meyer, Stephanie D.; Gore, Anu; Gu, Yan; Henkle, Brad; Hodous, Brian L.; Hsieh, Faye; Huang, Xin; Kim, Joseph L.; Lee, Josie H.; Martin, Matthew W.; Masse, Craig E.; McGowan, David C.; Metz, Daniela; Mohn, Deanna; Morgenstern, Kurt A.; Oliveira-dos-Santos, Antonio; Patel, Vinod F.; Powers, David; Rose, Paul E.; Schneider, Stephen; Tomlinson, Susan A.; Tudor, Yan-Yan; Turci, Susan M.; Welcher, Andrew A.; White, Ryan D.; Zhao, Huilin; Zhu, Li; Zhu, Xiaotian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5671-5686</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The lymphocyte-specific kinase (Lck) is a cytoplasmic tyrosine kinase of the Src family expressed in T cells and natural killer (NK) cells.  Genetic evidence in both mice and humans demonstrates that Lck kinase activity is crit. for signaling mediated by the T cell receptor (TCR), which leads to normal T cell development and activation.  Selective inhibition of Lck is expected to offer a new therapy for the treatment of T-cell-mediated autoimmune and inflammatory disease.  Screening of our kinase-preferred collection identified aminoquinazoline I as a potent, nonselective inhibitor of Lck and T cell proliferation.  In this report, we describe the synthesis and structure-activity relationships of a series of novel aminoquinazolines possessing in vitro mechanism-based potency.  Two optimized, orally bioavailable compds. exhibit antiinflammatory activity (ED50 of 22 and 11 mg/kg, resp.) in the anti-CD3-induced prodn. of interleukin-2 (IL-2) in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm7qaZo8QJ6bVg90H21EOLACvtfcHk0lgzlmfk4QrQEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XosVChsLk%253D&md5=3ed1152bf34749755fdd9c2f8f25950c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm0605482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0605482%26sid%3Dliteratum%253Aachs%26aulast%3DDiMauro%26aufirst%3DE.%2BF.%26aulast%3DNewcomb%26aufirst%3DJ.%26aulast%3DNunes%26aufirst%3DJ.%2BJ.%26aulast%3DBemis%26aufirst%3DJ.%2BE.%26aulast%3DBoucher%26aufirst%3DC.%26aulast%3DBuchanan%26aufirst%3DJ.%2BL.%26aulast%3DBuckner%26aufirst%3DW.%2BH.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DChai%26aufirst%3DL.%26aulast%3DDeak%26aufirst%3DH.%2BL.%26aulast%3DEpstein%26aufirst%3DL.%26aulast%3DFaust%26aufirst%3DT.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DGeuns-Meyer%26aufirst%3DS.%2BD.%26aulast%3DGore%26aufirst%3DA.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DHenkle%26aufirst%3DB.%26aulast%3DHodous%26aufirst%3DB.%2BL.%26aulast%3DHsieh%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DM.%2BW.%26aulast%3DMasse%26aufirst%3DC.%2BE.%26aulast%3DMcGowan%26aufirst%3DD.%2BC.%26aulast%3DMetz%26aufirst%3DD.%26aulast%3DMohn%26aufirst%3DD.%26aulast%3DMorgenstern%26aufirst%3DK.%2BA.%26aulast%3DOliveira%252C%2Bdos%2BSantos%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DPowers%26aufirst%3DD.%26aulast%3DRose%26aufirst%3DP.%2BE.%26aulast%3DSchneider%26aufirst%3DS.%26aulast%3DTomlinson%26aufirst%3DS.%2BA.%26aulast%3DTudor%26aufirst%3DY.-Y.%26aulast%3DTurci%26aufirst%3DS.%2BM.%26aulast%3DWelcher%26aufirst%3DA.%2BA.%26aulast%3DWhite%26aufirst%3DR.%2BD.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520aminoquinazolines%2520as%2520potent%252C%2520orally%2520bioavailable%2520inhibitors%2520of%2520Lck%253A%2520Synthesis%252C%2520SAR%252C%2520and%2520in%2520vivo%2520anti-inflammatory%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5671%26epage%3D5686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_etal"></span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Azam%2C+M.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DAzam%26aufirst%3DM." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Wang, Y.; Huang, W.-S.; Sundaramoorthi, R.; Zhu, X.; Thomas, R. M.; Shakespeare, W. C.; Dalgarno, D. C.; Sawyer, T. K.</span><span> </span><span class="NLM_article-title">Preparation of purine heterocyclic derivatives as kinase inhibitors for therapeutic use as anticancer agents</span>. PCT Int. Appl. WO 2007021937,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=Y.+Wang&author=W.-S.+Huang&author=R.+Sundaramoorthi&author=X.+Zhu&author=R.+M.+Thomas&author=W.+C.+Shakespeare&author=D.+C.+Dalgarno&author=T.+K.+Sawyer&title=Preparation+of+purine+heterocyclic+derivatives+as+kinase+inhibitors+for+therapeutic+use+as+anticancer+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26atitle%3DPreparation%2520of%2520purine%2520heterocyclic%2520derivatives%2520as%2520kinase%2520inhibitors%2520for%2520therapeutic%2520use%2520as%2520anticancer%2520agents%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1iep" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1iep','PDB','1iep'); return false;">PDB: 1iep</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2og8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2og8','PDB','2og8'); return false;">PDB: 2og8</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3el7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3el7','PDB','3el7'); return false;">PDB: 3el7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3el8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3el8','PDB','3el8'); return false;">PDB: 3el8</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1fpu" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1fpu','PDB','1fpu'); return false;">PDB: 1fpu</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-si1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i69"><a href="/doi/suppl/10.1021/jm900166t">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_58785"></div></div></div></div></div><hr /></hr><p class="last">Combustion analysis of certain tested compounds. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm900166t/suppl_file/jm900166t_si_001.pdf">jm900166t_si_001.pdf (19.58 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm900166t&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm900166t%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2009.52.issue-15%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm900166t" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677af48efcc13d0c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
